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Summary 
Since the introduction of antibiotics into clinical use, bacteria have continued to evolve 
and acquire mechanisms of resistance. In a relatively short time period, this has rapidly 
escalated into a serious health crisis recognised by major governing/scientific bodies 
worldwide. The rate at which antibiotic resistance spreads now outpaces our current 
ability to discover and manufacture new antibiotics. 
 
Steps taken to combat antibiotic resistance have had little impact in preventing the spread 
of relevant pathogens, especially within hospital settings. The current state of antibiotic 
development has only exacerbated these issues by severely limiting the arsenal of 
therapeutics available to treat problematic infections. Without sufficient incentives, large 
pharmaceutical companies have focused on developing financially ‘safe’ drugs to treat 
non-infectious related conditions, leaving the bulk of antibiotic research to smaller 
biotechnology companies and academia, often in collaboration together.  
 
In this study, we have examined the clinical utility and mechanism of action (MoA) of 
BDM-I, which is a small synthetic molecule currently being developed by the Australian 
biotechnology company Opal Biosciences Limited. Importantly, BDM-I (3,4-
methylenedioxy-β-nitropropene) appears to be a novel antimicrobial compound and has 
shown promising activity in vitro against clinically relevant pathogens, such as MRSA 
and VRE. In this regard, previous studies have shown that BDM-I does not inhibit 
common antimicrobial targets, and proposed that it binds to bacterial tyrosine 
phosphatases. While an antibiotic inhibiting a novel cellular target(s) is desirable, in this 
case the specific MoA (of BDM-I) and its physiological effect on bacterial cells is not 
known, thus limiting the potential for further development. 
 
 
xvii 
 
Therefore, due to this knowledge gap, we attempted to gain insight into the BDM-I MoA 
(including its binding partner) using an omics approach (i.e. whole genome sequencing 
and proteomics). Additionally, we also aimed to study the activity of BDM-I against the 
clinically relevant ESKAPE pathogens. 
 
To study the activity of BDM-I, extensive MIC testing was completed using clinical 
isolates with varying degrees of multi-drug resistance. Initial tests using gram-negative 
isolates (K. pneumoniae, P. aeruginosa and E. coli) did not identify any antimicrobial 
activity at concentrations £128 µg/mL. However, studies using the gram-positive 
pathogens S. aureus and E. faecium revealed that BDM-I displayed good (and potentially 
clinically relevant) activity, particularly against S. aureus. Additional MIC testing was 
then completed using a large number of clinical MRSA and VRE isolates with varying 
degrees of vancomycin susceptibility. Interestingly, we identified that BDM-I is highly 
effective against vancomycin intermediate S. aureus (VISA) isolates, which prompted 
further investigation into possible synergy between BDM-I and vancomycin. Results 
from these studies identified that BDM-I exerts an additive/synergistic effect on 
vancomycin in the case of hVISA and VISA isolates, as well as vanB VRE isolates.  
 
Induction experiments were then conducted using MRSA and VRE, in order to generate 
mutants with increased resistance to BDM-I. In this regard, MRSA was (in most cases) 
unable to develop increased resistance. However, in the case of VRE, significant MIC 
increases were observed within 10 days of BDM-I exposure, which continued steadily 
until the experiment was terminated. Importantly, the generation of mutant isolates 
 
 
xviii 
enabled us to utilise whole genome sequencing in an attempt to identify mutations driving 
the increased resistance and elucidate the BDM-I MoA. 
 
Subsequently, analysis of the sequencing data revealed mutations within different genes 
of the ATP synthase operon for all sequenced VRE mutants, indicating that BDM-I may 
affect ATP synthesis. In comparison, analysis of the MRSA mutant data revealed 
mutations within the walK gene, which is part of the WalKR two component regulatory 
system (associated with cell wall homeostasis). Following whole genome sequencing, we 
then conducted proteomic analysis of proteins extracted from BDM-I treated MRSA and 
VRE cells, in order to identify global changes in expression levels. Interestingly, and 
consistent with the above observations, we identified the downregulation of ATP synthase 
subunits within both VRE and MRSA by ³2-fold, as well as the downregulation of WalK 
within MRSA by ³9-fold. Additionally, we also identified that proteins involved in lactic 
acid fermentation were upregulated within VRE, while proteins involved in UMP 
biosynthesis (pyrimidine metabolism) were significantly downregulated within both 
isolates. 
 
In combination, whole genome sequencing and proteomic analysis revealed that ATP 
synthase is likely (negatively) affected as a result of the BDM-I MoA. Therefore, we 
utilised ATP assays to examine whether ATP synthesis was inhibited upon exposure to 
BDM-I. Subsequently, results identified significant reductions in intracellular ATP 
concentrations, suggesting that BDM-I does in fact affect the activity of ATP synthase. 
Additionally, we also examined the relationship between BDM-I and WalK by imaging 
(via transmission electron microscopy) BDM-I MRSA mutants, in order to identify 
changes in the cell wall phenotype. Interestingly, this revealed significant reductions in 
 
 
xix 
cell wall thickness, which correlated with increased resistance to BDM-I and increased 
susceptibility to vancomycin and daptomycin.  
 
Finally, we attempted to identify the BDM-I binding partner using novel methods, 
including the drug affinity response sensitivity assay (DARTS) and thermal proteome 
proteomics (TPP). Unfortunately, we were unable to identify a potential binding partner 
using DARTS, likely due to the limited sensitivity of the protocol and its reliance on gel-
based separation techniques. However, preliminary results from TPP analysis identified 
several proteins that were thermostabilised following BDM-I treatment, one of which 
(adenylate cyclase) may be linked to the apparent MoA of BDM-I (i.e., negatively 
affecting ATP synthesis).  
 
By completing this study, we were able to identify that BDM-I displays significant 
activity against MRSA and VRE isolates. Furthermore, we were able to identify a 
synergistic relationship between BDM-I and vancomycin, which highlights the potential 
use of both antibiotics in combination to treat complicated infections. Regarding the 
BDM-I MoA, we identified through whole genome sequencing, proteomics and ATP 
assays, that BDM-I affects ATP synthesis (via the oxidative phosphorylation pathway). 
In this regard, E. faecium has the ability to adapt to BDM-I (at least to some extent) by 
potentially switching to substrate level ATP synthesis via lactic acid fermentation, while 
S. aureus adapts to BDM-I by regulating cellular pathways/processes (such as cell wall 
synthesis) that require large quantities of ATP, and this is likely due to the essentiality of 
ATP synthase in S. aureus. 
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Introduction 
 
1.1 Antibiotic Discovery 
 
The term antibiotic was initially used by Waksman et al. (1942) to describe any substance 
produced by a microorganism that was antagonistic to the growth of another in high 
dilution. However, it is now used to more broadly describe antibacterial compounds, 
including those that are semi-synthetic and synthetic, such as sulphonamides. In any case, 
following the discovery of penicillin in 1928 by Alexander Fleming, there was a 
substantial increase into the research and development of antimicrobial compounds. In 
the following decades numerous antibiotics were discovered and implemented into 
clinical use. However, since the 1960s, the discovery rate of novel antimicrobials has 
dropped significantly, with only two new antibiotic classes being discovered and 
deployed clinically (i.e, oxazolidinones and lipopeptides, such as linezolid and 
daptomycin, respectively) (Fischbach and Walsh, 2009). Worryingly, the majority of 
antibiotics in clinical use today are derivatives of compounds which were discovered 
between the 1940s and 1960s. This trend in reduced antibiotic development/deployment 
now coincides with the continual emergence and spread of antibiotic resistant bacteria 
(Figure 1.1) (Lewis, 2013).    
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Flemming’s accidental discovery in 1928 was the catalyst that began the golden age of 
antibiotic discovery. His work, as well as that of Selman Waksman in the 1940s 
(developed the first method of high throughput screening of soil Streptomycetes) drove 
the discovery of antibiotics such as streptomycin, which was pivotal in treating once 
incurable diseases such as tuberculosis (Lewis, 2016). Over the next 20 years, using the 
“Waksman platform”, most of the major classes of antibiotics that are currently used 
clinically were discovered and utilized with great effect to treat bacterial infections. 
However, in the 1960s the “Waksman platform” became obsolete, with no novel 
antimicrobials being discovered. This shifted antibiotic development towards synthetic 
compounds and the modification of existing natural compounds. Again, these 
methodologies were effective, with the development of the widely successful 
fluoroquinolones, as well as the production of analogues of naturally occurring 
Figure 1.1: Timeline illustrating the date antibiotics were deployed (into clinical use) as 
well as the date resistance was first observed. Image adapted from Clatworthy et al. 
(Clatworthy et al., 2007) 
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compounds (Lewis, 2016). Additionally, during this time pharmaceutical companies 
began moving away from antibiotic development due to the belief that infectious diseases 
were no longer a major concern. In the 1990s however, it became clear that this was not 
the case as the spread of resistance began to outpace the development of antimicrobials.  
 
Modern methods of antibiotic discovery have been driven by advances in technology, 
particularly in genomics and computing which have enabled a ‘genes-to-drugs’ approach 
as the standard for therapeutic drug development (Brown and Wright, 2016). Whole 
genome sequencing coupled with high-throughput DNA manipulation techniques have 
driven the search for novel antibiotic targets (based on gene essentiality), that are 
insusceptible to known mechanisms of resistance. While these methods have been 
successful in identifying potential drug targets, screening methods have been unable to 
identify suitable compounds with the necessary pharmacodynamic profiles (Brown and 
Wright, 2016). Chemical screening of whole cells for growth inhibition has also been 
used in modern antimicrobial discovery, although this methodology is associated with its 
own drawbacks including the generation of extremely large datasets of active compounds, 
which are difficult to pursue due to a lack of prioritization tools (Brown and Wright, 
2016). 
 
Unfortunately, these modern approaches to drug discovery have been largely 
unsuccessful in identifying novel antimicrobial compounds to combat the increasing 
prevalence of antibiotic resistance, as only two new classes of antibiotics have been 
discovered since the 1960s (i.e, oxazolidinones and lipopeptides) (Fischbach and Walsh, 
2009).  
 
 
 
4 
1.2 Major Antibiotic Classes 
 
Antibiotics selectively inhibit essential cellular processes within prokaryotic organisms, 
and act to either kill (bactericidal) or inhibit their growth (bacteriostatic). The majority of 
antimicrobials currently used clinically target one of three main processes within a 
bacterial cell (Figure 1.2); cell wall synthesis, protein synthesis,  and nucleic acid 
synthesis (Kohanski et al., 2010, Walsh, 2000). 
 
  
Figure 1.2: Cellular Targets of Antibiotics. Broadly speaking, antibiotics target one of three 
key cellular processes including cell wall synthesis, nucleic acid synthesis and protein 
synthesis. Image sourced online from https://www.orthobullets.com/basic-
science/9059/antibiotic-classification-and-mechanism  
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1.2.1 Inhibitors of Cell Wall Synthesis 
Most bacteria possess a cell wall making it an ideal target for antimicrobial compounds, 
due to its absence in mammalian cells, as well as its variation between different bacterial 
genera. The key component of the cell wall is a mucopolysaccharide called 
peptidoglycan, whose composition and location within the cell envelope differs between 
gram-positive and gram-negative bacteria. Peptidoglycan synthesis is a multi-step process 
with four key stages: the synthesis of peptidoglycan precursors in the cytoplasm; the 
transport of the newly formed lipid-anchored disaccharide-pentapeptide monomer 
subunit (lipid II) across the membrane; the insertion of glycan chains into the cell wall, 
and; transpeptidation linking and overall maturation (McDermott et al., 2003, Typas et 
al., 2011).  
 
β-lactams (penicillins, carbapenems, cephalosporins) are the most widely used antibiotics 
possessing a broad spectrum of activity. They target the third stage of peptidoglycan 
synthesis by inhibiting the formation of peptide bonds which are catalysed by penicillin-
binding proteins (PBPs). β-lactams contain a cyclic amide ring that competitively binds 
to the PBP binding site, which disables the enzyme and effectively blocks the PBP 
peptidoglycan cross-linking activity, resulting in the induction of cell stress responses and 
cell lysis (Kohanski et al., 2010). Another group of antibiotics targeting cell wall synthesis 
are the Glycopeptides (vancomycin, teicoplanin), which are large hetero-cyclic molecules 
with specific activity against gram-positive species. Unlike the β-lactams, glycopeptides 
bind to the cell wall directly instead of anabolic enzymes (PBPs). They function by 
binding to the D-Ala-D-Ala dipeptide terminus of peptidoglycan pentapeptide side chains 
and thus inhibit transglycosylase and PBP activity. As a consequence, this prevents the 
addition of new subunits to peptidoglycan which inhibits cell wall maturation and reduces 
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the overall mechanical strength of the cell (Kohanski et al., 2010, McDermott et al., 
2003).  
 
Additional antibiotics are available that inhibit peptidoglycan synthesis, such as 
fosfomycin and bacitracin, which inhibit the synthesis and transport of individual 
peptidoglycan units, respectively. Furthermore, cationic antimicrobial peptides (such as 
polymyxin B) and lipopeptide antibiotics such as daptomycin are also currently in use to 
treat infections caused by gram-positive organisms, although they target the cell 
membrane rather than peptidoglycan synthesis, and function by aggregating within the 
cell membrane and inducing rapid membrane depolarization resulting in cell death 
(Kohanski et al., 2010). 
 
1.2.2 Inhibitors of Protein Synthesis 
Protein synthesis is a complex process that is divided into three primary phases, initiation, 
elongation and termination. Synthesis is carried out within the ribosome, which is 
composed of two subunits (termed 50S and 30S), that complex with an mRNA transcript 
(tRNA) and initiation factors to translate linear protein from mRNA. Given the significant 
differences between prokaryotic and eukaryotic ribosomes and their essentiality in 
cellular metabolism, they present an ideal target for antibiotics. 
 
Broadly speaking, protein synthesis inhibitors target either the 30S or 50S ribosomal 
subunits. Antibiotics that target the former include the tetracyclines, which block access 
of tRNA to the ribosome, and the aminocyclitols (spectinomycin, aminoglycosides). 
Spectinomycin and aminoglycoside antibiotics target the 16S rRNA segment of the 30S 
subunit, although they inhibit protein synthesis at this site using different mechanisms. 
Spectinomycin inhibits the elongation factor-catalysed translocation of peptidyl tRNA to 
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the ribosome, which reduces the binding stability of tRNA. In comparison, the 
aminoglycosides promote protein mistranslation by altering the complex formed between 
an mRNA codon and tRNA at the ribosome, promoting the addition of incorrect amino 
acids (Kohanski et al., 2010). 
 
Antibiotics that target the 50S ribosomal subunit include the macrolides, lincosamides, 
streptogramins, amphenicols and oxazolidinones. The majority of these 50S ribosome 
inhibitors function by physically inhibiting the translocation of peptidyl tRNAs. In doing 
so, amino acids cannot be added to a growing peptide chain within the ribosome. An 
exception to this are the oxazolidinones, as they block the initiation of protein translation 
(Kohanski et al., 2010).  
 
1.2.3 Inhibitors of Nucleic Acid Metabolism 
Synthetic compounds including the quinolones (fluoroquinolones), sulphonamides and 
rifamycins are commonly used broad-spectrum antibiotics that target nucleotide synthesis 
(McDermott et al., 2003).  
 
Sulphonamides such as trimethoprim are the oldest class of antimicrobials, and were the 
first to be introduced clinically in the 1930s. They are structurally similar to p-
aminobenzoic acid (PABA), which is involved in the synthesis of purine and pyrimidine 
nucleotides, and function by competitively binding to the active site of the enzyme 
dihydropteroate synthetase and blocking the formation of nucleotide precursors 
(McDermott et al., 2003). 
 
Quinolones inhibit the activity of topoisomerase enzymes which catalyze the supercoiling 
of DNA strands during cell division. Two enzymes can be targeted by quinolone 
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antibiotics depending on the gram-reaction of the target bacteria. Within gram-negatives, 
quinolone antibiotics will primarily target topoisomerase IV, while in gram-positives they 
will primarily target topoisomerase II (DNA Gyrase) (Kohanski et al., 2010, McDermott 
et al., 2003). The effect of quinolone binding to topoisomerase enzymes results in cell 
death due to the introduction of double-stranded DNA breaks, which are bound to and 
blocked by the topoisomerase-quinolone complex. This blockage inhibits DNA-
replication machinery and stalls DNA synthesis, leading to bacteriostasis and eventually 
cell death (Kohanski et al., 2010).  
 
The rifamycins are another class of antibiotics inhibiting nucleic acid synthesis and are 
used routinely to treat infections caused by M. tuberculosis. Rifamycin antibiotics such 
as rifampin target the β-subunit of an actively transcribing RNA polymerase, effectively 
inhibiting the initiation of bacterial transcription. This mechanism is bactericidal in gram-
positive species and bacteriostatic in gram-negative species, which is attributed to 
differences in drug uptake associated with the physiologies of each cell type (Kohanski 
et al., 2010, McDermott et al., 2003).  
 
1.3 Antibiotic Resistance 
 
Antibiotic-like compounds have existed within nature long before their implementation 
into clinical settings. It is estimated that antibiotics and antibiotic resistance genes have 
existed for millions of years, dating back to the Cambrian period (Allen et al., 2010). The 
role of antibiotic-like compounds in microbial communities is not fully understood, with 
evidence suggesting they play a role in microbial signalling networks, in addition to cell 
inhibition. In this regard, it is believed that such compounds play essential roles in various 
aspects of microbial life, including; pathogenesis, community structure and biofilm 
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formation (Allen et al., 2010, Hall and Barlow, 2004, Ryan and Dow, 2008). Similarly, 
antibiotic resistance genes also appear to play important roles in microbial interactions, 
possibly functioning in the regulation of biosynthetic pathways (Allen et al., 2010). 
 
While it is established that antibiotics predate their clinical implementation, it is due to 
heavy selective pressures associated with both clinical and industrial uses of antibiotics, 
that we are seeing an alarming increase in the generation of antibiotic resistant organisms. 
Arguably, the greatest misuse of antibiotics is seen within the agricultural industry. 
Antibiotics have been used in agriculture and aquaculture extensively since their 
discovery in the mid-1900s to treat disease, promote growth and enhance feed 
proficiency. The large-scale use of antibiotics in feed and water creates an ideal 
environment for the increased prevalence of antibiotic resistant organisms associated with 
farm animals, which can then be disseminated into the environment risking potential 
exposure to humans. For example, the emergence of vancomycin-resistant enterococci 
(VRE) in Europe in 1996 was attributed to the use of the related antibiotic avoparcin in 
animal feed, which eventually led to the ban of the compound from animal husbandry 
(Arias and Murray, 2012, Dantas and Sommer, 2014, Levy and Marshall, 2004, 
Silbergeld et al., 2008). 
 
The misuse (or simply use) of antibiotics within a clinical setting is the second greatest 
contributor to the development of antibiotic resistance, especially within healthcare 
environments. Antibiotics are often prescribed for non-bacterial infections to demanding 
patients, who will often choose not to finish a course of antibiotics once their health 
improves. These practices facilitate the selection and proliferation of resistant strains 
which can potentially be spread within the community (Bush et al., 2011). Major concerns 
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surrounding the misuse of antibiotics are within the developing world, where antibiotics 
are available over the counter without prescriptions, which, when coupled with poor 
hygiene, results in a reservoir for the generation of multi-resistant superbugs.   
 
1.3.1 Mechanisms of Resistance 
Antibiotics can be classified by their primary cellular targets, as well as whether they are 
bacteriostatic or bactericidal. As stated previously, most antimicrobial compounds target 
one of three primary targets; nucleic acid synthesis, protein synthesis, or cell wall 
synthesis (Kohanski et al., 2010, Walsh, 2000). Similarly, there are three primary 
resistance mechanisms employed by bacteria to circumvent the inhibitory actions of 
antimicrobials. These methods include; the enzymatic inactivation of an antibiotic, the 
removal of the antibiotic from the cell and the modification of the antibiotic’s target, as 
illustrated in Figure 1.3. 
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Figure 1.3: Bacterial Mechanisms of Antibiotic Resistance including; (a and b) modification 
of drug target through mutation, (c) enzymatic inactivation of the drug molecule and (d) the 
removal of the antibiotic by efflux pumps. Image adapted from Dantas and Sommer (Dantas 
and Sommer, 2014). 
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Antibiotic resistance in bacteria is either intrinsic, arises via genetic mutation, or is 
acquired through horizontal gene transfer (of resistance determinants), or a combination 
thereof. Intrinsic resistance is often genera specific and describes resistance against 
antibiotics which is due to the innate physiology of a specific bacterial species (Cox and 
Wright, 2013). It is most often associated with gram-negative bacteria due to the presence 
of an outer membrane that surrounds a relatively thin layer of peptidoglycan. The outer 
membrane is composed of lipid molecules bound to polysaccharide units, which, due to 
the tightly packed nature of the hydrocarbon chains and the large number of linked fatty 
acid chains, significantly reduce its permeability and thus the ability of antibiotics to cross 
into the cell (Arzanlou et al., 2017, Cox and Wright, 2013). To compensate for this 
reduced permeability, gram-negative species possess porins within the membrane that 
allow for the diffusion of molecules into the cell. However, porins also inhibit the entry 
of antibiotics into the cell via several mechanisms, including size limitation and charge 
repulsion (Cox and Wright, 2013).  
 
Intrinsic resistance is also driven by multi-drug resistance efflux pumps (Figure 1.3d), 
which are present within both gram-positive and gram-negative bacterial species. Efflux 
pumps can be either substrate specific or target a broad range of molecules (such as 
classes of antibiotics), and function by actively exporting drug molecules out of a cell at 
a faster rate than they can enter by diffusion (Cox and Wright, 2013, Walsh, 2000). There 
are five main classes of efflux pumps within prokaryotes, the ATP binding cassette 
(ABC), the major facilitator (MF), the multidrug and toxic compound efflux (MATE), 
the small multidrug resistance (SMR) and the resistance-nodulation-division family 
(RND). The RND family are the main drivers of intrinsic resistance in gram-negative 
bacteria and have been identified in multiple species, including P. aeruginosa (MexAB-
 
 
13 
OprM RND system) and E. coli (AcrAB-TolC RND system), and drive resistance against 
multiple antibiotics including β-lactams, fluoroquinolones, tetracycline and macrolides. 
While efflux pumps alone are not sufficient to produce high level resistance, it is due to 
a combination of both the outer membrane and constitutively expressed efflux pumps that 
some gram-negative species are intrinsically resistant to certain antibacterial compounds 
(Cox and Wright, 2013). 
 
In addition to intrinsic resistance, bacteria are also capable of acquiring resistance to 
antibiotics through the horizontal gene transfer of resistance determinants (carried by 
plasmids, for example). Such determinants typically encode proteins involved in the 
enzymatic inactivation of a drug, the modification of a drug target, or even drug efflux as 
discussed above (Munita and Arias, 2016). 
 
Of these, a common mechanism is the enzymatic alteration or complete degradation of 
an antibiotic (Figure 1.3c), which was first discovered in the 1950s for penicillin resistant 
bacteria. The chemical alteration of antibiotic compounds is common in both gram-
positive and gram-negative bacteria, and typically occurs through the acetylation, 
phosphorylation or adenylation of a compound. These reactions result in steric hindrance 
and a significant decrease in a drugs affinity for its target (Munita and Arias, 2016, Walsh, 
2000). Resistance driven by drug modification has been documented extensively in the 
case of aminoglycoside resistance. Multiple aminoglycoside modifying enzymes (AMEs) 
have been described and are the main contributors to aminoglycoside resistance 
worldwide. Genes encoding for AMEs are typically found on mobile genetic elements 
(MGEs) and covalently alter the hydroxyl or amino groups of aminoglycoside molecules. 
The AMEs present within bacterial populations tend to vary widely based on geographical 
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distribution. For example, the phosphotransferase family of enzymes is widely distributed 
amongst gram-negative and gram-positive bacteria and provides resistance against 
kanamycin and streptomycin, while the acetyltransferase family of enzymes is found 
predominantly in gram-negative species affecting most aminoglycoside antibiotics 
(Munita and Arias, 2016).  
 
Alternatively, antibiotics may be enzymatically destroyed before they are able to reach 
their targets within the cell. In the context of penicillin resistance which has been observed 
since the 1950s, was the discovery of the β-lactamase enzymes which destroy β-lactam 
antibiotics by removing the amide of the β-lactam ring.  To date, over 1000 β-lactamases 
have been discovered which illuminates a “prime example of antibiotic-driven bacterial 
evolution” (Munita and Arias, 2016). Multiple β-lactamases have been identified and are 
generally characterized into one of four groups based on their substrate specificity.  
 
Group A β-lactamases contain a serine residue in their catalytic site and include a variety 
of different proteins with differing activities, including the penicillinases, extended 
spectrum β-lactamases (ESBLs) and carbapenemases. Unique to group A proteins is their 
sensitivity to clavulanic acid (β-lactamases inhibitor) and their activity against the 
monobactams, but not the cephamycins (Bush, 2013).  
 
Group B β-lactamases are known as the metallo-β-lactamases due to the fact they utilize 
a metal ion as a cofactor when binding to the β-lactam ring. Originally, the genes encoding 
these enzymes were known to be located only on the chromosome, however in the 1990s 
a large number of gram-negative hospital pathogens were reported to carry genes 
encoding these enzymes, indicating that they were now being spread via horizontal gene 
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transfer (Munita and Arias, 2016, Queenan and Bush, 2007). A prominent member of the 
group B β-lactamases is the New Delhi Metallo β-lactamase (NDM-1), which was first 
isolated in 2008 from a Swedish patient who had been hospitalized in India. The blaNDM 
gene is of particular concern due to its high rate of transmission between different gram-
negative species, which has allowed for its rapid dissemination within several countries 
(Bush and Jacoby, 2010).  
 
Group C β-lactamases are active against all penicillins and cephalosporins currently 
available. In terms of clinical importance, the group C enzyme AmpC remains the major 
facilitator of β-lactam resistance in several gram-negative species, most often located on 
the chromosome (although it has been identified on plasmids) of several bacteria 
including E. aerogenes, M. morganii and P. aeruginosa, among others (Jacoby, 2009). 
 
The final class of β-lactamass (group D) are commonly known as the OXA class of 
enzymes and are characterized by their ability to degrade third generation cephalosporins 
and carbapenems. Many OXA enzymes have been described and are typically carried on 
a range of mobile genetic elements, most of which are capable of interspecies 
transmission. For example, OXA-48 is a common group D β-lactamase which is wide 
spread in K. pneumoniae and other Enterobacteriaceae (Bush and Jacoby, 2010, Evans 
and Amyes, 2014, Munita and Arias, 2016). 
 
Another mechanism of acquired resistance involves the modification of a drug target to 
reduce its affinity for an antibiotic (Figure 1.3a-b). This mechanism typically occurs by 
either protecting the target site, or completely modifying the target site. A well-studied 
example of target protection is tetracycline resistance in Streptococcus spp, which is 
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mediated by the plasmid bound Tet(M) protein. Tet(M) acts as a homologue of elongation 
factors used in translation, and acts by releasing tetracycline which has bound to the 
ribosome. When releasing tetracycline, it also causes a conformational change within the 
ribosome which prevents tetracycline from rebinding to its target site (Munita and Arias, 
2016). 
 
Alternatively, bacteria may modify the target site of antibiotics either via the acquisition 
of mutations within the site, or via the activity of specialized enzymes. Numerous target 
site mutations have been identified which confer resistance to a variety of antibiotics, 
with one of the most well characterized being rifampin resistance. Rifampin acts by 
inhibiting the DNA-dependent RNA polymerase (rpoB) which blocks bacterial 
transcription. High level resistance to rifampin can arise due to single nucleotide 
polymorphisms (SNPs) within rpoB that cause an amino acid substitution. This alteration 
significantly reduces the affinity of rifampin to its target site. Other examples of 
mutational resistance include fluoroquinolone and oxazolidinone resistance, due to 
chromosomal mutations in genes encoding the target sites (Dantas and Sommer, 2014, 
Munita and Arias, 2016). 
 
Bacteria can also develop resistance by enzymatically altering the target site. This 
mechanism has been observed within vancomycin resistant Enterococci (VRE), as well 
as within S. aureus strains resistant to erythromycin. Vancomycin resistance in 
Enterococci is mediated by the vanHAX genes, which encode several enzymes which 
produce peptidoglycan terminating with D-Ala-D-Lac rather than D-Ala-D-Ala, which 
has a 1000-fold decreased affinity to vancomycin (discussed further in section 1.4) 
(Walsh, 2000). Erythromycin resistance in S. aureus can be facilitated using a similar 
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strategy, involving the modification of the 23S RNA component of the ribosome by the 
enzyme Erm (a methyl transferase) (Walsh, 2000).  
 
1.3.2 Spread of Resistance 
In most cases, it is not long after an antibiotic is introduced clinically that significant 
resistance emerges (see Figure 1.1); which can occur on a timescale of months to years 
(Walsh, 2000). The ability of bacteria to rapidly acquire, and in turn disseminate genetic 
material conferring resistance, is an evolutionary mechanism that often outpaces our 
(current) ability to develop effective novel treatments. The mechanisms that facilitate the 
transfer of DNA between bacteria have been studied extensively, and typically occur in 
one of two ways (Figure 1.4); vertical transfer (de novo mutations that occur during 
replication are passed on to subsequent generations), or more importantly, horizontal gene 
transfer (Andersson and Hughes, 2010, Dantas and Sommer, 2014).  
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Figure 1.4: Mechanisms of spreading antibiotic resistance. Resistance spreads 
commonly through horizontal gene transfer, including conjugation (direct transfer of 
plasmid DNA from a donor to recipient cell), transformation (uptake of DNA from the 
environment by competent cells) and transduction (transfer of resistance genes via a 
bacteriophage vector). Also illustrated are de novo mutations which are passed to 
daughter cells following replication. Image adapted from Andersson et al (Andersson 
and Hughes, 2010).  
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The most common mechanism by which resistance genes spread throughout a bacterial 
population is via horizontal gene transfer, which involves the transfer of mobile genetic 
elements (MGEs), such as plasmids, transposons and insertion sequences between 
bacterial cells (Normark and Normark, 2002). Horizontal gene transfer can occur through 
three primary mechanisms known as transformation, conjugation, and transduction.  
 
Transformation refers to the uptake, integration, and expression of extracellular DNA 
under natural growth conditions by physiologically competent bacteria. Transformation 
was first identified as a mechanism that can facilitate the spread of antibiotic resistance 
genes in 1951. In this case, penicillin and streptomycin resistance determinants were 
introduced into previously sensitive strains of S. pneumoniae, by exposing them to 
extracellular DNA derived from resistant strains (von Wintersdorff et al., 2016). In 
general, for transformation to take place a number of conditions must be met, including; 
extracellular DNA must be present within the environment, the recipient bacteria must be 
competent, and the transformed DNA must be stabilized either through genome 
integration or recircularization. Some bacterial genera, such as Neisseria are 
constitutively competent, while others need to be induced into a competent state, which 
is often mitigated by environmental stressor conditions. Interestingly, studies have shown 
that antibiotics can also induce competence in certain species, highlighting the issue of 
antibiotic use prompting the spread of resistance (von Wintersdorff et al., 2016). Despite 
this, transformation is not considered the main mechanism driving the spread of antibiotic 
resistance, but has been observed in the case of penicillin resistance within the important 
pathogen Streptococcus pneumoniae, as well as resistance to fluoroquinolones and β-
lactams within Neisseria gonorrhoeae (Barlow, 2009).  
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Transduction is another mechanism of horizontal gene transfer which involves the 
transfer of genetic material between cells via a bacteriophage vector. DNA that can be 
transferred via transduction includes chromosomal DNA and MGEs such as plasmids and 
transposons. Transduction has been associated with the transmission of antibiotic 
resistance genes within/between multiple species; including erythromycin and 
tetracycline resistance in S. pyogenes, β-lactam resistance in E. coli, and the spread of 
resistance plasmids in MRSA (von Wintersdorff et al., 2016). The role of transduction in 
the dissemination of antibiotic resistance is significant, with recent research finding that 
bacteriophages isolated from different environments (wastewater, animal and human 
faecal samples, meat) often carry multiple resistance genes, elucidating their roles as 
significant reservoirs of antibiotic resistance (Colomer-Lluch et al., 2014, Colomer-Lluch 
et al., 2011, Shousha et al., 2015). 
 
In comparison to the others, conjugation is probably the most important horizontal gene 
transfer mechanism driving the spread of antibiotic resistance. Conjugation is a multi-
step process involving the direct transfer of genetic material from a donor cell to a 
recipient cell via surface pili or adhesins (Thomas and Nielsen, 2005, von Wintersdorff 
et al., 2016). Genes that encode conjugation systems are generally located on plasmids or 
within the chromosome on integrative conjugative elements (Cabezón et al., 2015).    
 
Plasmids (small, circular DNA molecules which are extrachromosomal in nature and 
capable of independent replication) represent the most commonly transferred MGE via 
conjugation and are often capable of carrying other MGEs in addition to resistance genes. 
Plasmids may be conjugative (self-transmissable), or non-conjugative (not self-
transmissible) but mobilizable; a plasmid may lack all of the gene/sequences required for 
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self-transfer and thus rely on ‘helper’ conjugative plasmids. In any case, plasmids play a 
major role in the rapid dissemination of antibiotic resistance (and other important 
phenotypes) within healthcare settings and of particular concern, a single plasmid may 
confer resistance to multiple, distinct antibiotic classes. Once multiple resistance genes 
have accumulated on a plasmid, resistance can then be rapidly spread between different 
strains, species or genera, and this has been documented in healthcare settings (von 
Wintersdorff et al., 2016). For example, the wide dissemination of the blaCTX-M ESBL 
genes between genera of the Enterobacteriaceae has been attributed to various broad and 
narrow host range plasmids.   
 
In addition to plasmids, several other MGEs, such as transposons, insertion sequences 
and integrons, also play a major role in the transmission of resistance genes between 
bacteria. Transposons and insertion sequences (IS) are DNA elements that can excise 
themselves and associated DNA from one genome location (on a plasmid or 
chromosome) and randomly integrate at another. Alternatively, integrons use site-specific 
recombination to move genes between locations, however these MGEs can often be co-
located and transferred in a single event via conjugation into a recipient cells genome 
(Partridge et al., 2018). For example, integrons are often located on transposons, which 
in turn are often located on plasmids (Partridge et al., 2018). This cooperative framework 
enables bacteria to rapidly evolve through the accretion of antibiotic resistance genes 
within a particular cell. 
 
1.4 ESKAPE Pathogens 
 
Although antibiotic resistance is common across a wide variety of bacterial species, there 
are six species that are of particular concern in healthcare settings: Enterococcus faecium; 
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Staphylococcus aureus; Klebsiella pneumoniae; Acinetobacter baumanii; Pseudomonas 
aeruginosa, and; Enterobacter species (Boucher et al., 2009). They are collectively 
known by the acronym ‘ESKAPE’, indicating that these important hospital pathogens are 
readily capable of “escaping” the inhibitory effects of antimicrobials through the 
development of resistance mechanisms. 
 
1.4.1 Enterococcus faecium 
Enterococci are gram-positive cocci that are resident within the bowels of humans and 
other animals, often making up a small proportion of the gut microbial population 
(Moellering, 1992). Under the right conditions however, enterococci are capable of 
causing infection, often as a result of broad spectrum antibiotic use which reduces 
microbial competition in the gastrointestinal tract (Arias and Murray, 2012). Most 
enterococcal infections are nosocomial in origin, with certain pathogenic strains of E. 
faecalis and E. faecium being able to spread in hospital settings due to their durability in 
hostile environments.  
 
A study completed in 2004 by Wisplinghoff et al., identified Enterococcus species as 
being the third most common cause of bacteraemia in the United States (Wisplinghoff et 
al., 2004), while another study conducted in 2008 on antibiotic-resistant pathogens 
associated with healthcare-acquired infections, identified Enterococcus species as being 
the second greatest cause of central line-associated bloodstream infections (Hidron et al., 
2008). As such, it is apparent that Enterococcus species are a major contributor to the 
incidence of hospital acquired infections in the United States and, of particular concern, 
the mortality rate associated with these infections is high (33.9%) (Wisplinghoff et al., 
2004). In an Australian context, a study in 2013 identified that one third of enterococcal 
bacteraemias were caused by E. faecium; of these, 90% were ampicillin resistant and 
 
 
23 
36.5% were vancomycin non-susceptible, with the majority of infections being hospital-
associated (Coombs et al., 2014).  
 
Enterococci are intrinsically resistant to a number of antibiotic classes and retain the 
ability to acquire additional resistance, either via mutation or through the process of 
horizontal gene transfer (Arias and Murray, 2012). β-lactam antibiotics such as the 
penicillins (primarily ampicillin) are often used alone or in combination to treat 
enterococcal infections. However, their use is limited against E. faecium as 70-95% of 
clinical isolates now exhibit high level resistance due to mutations within the penicillin 
binding protein 5 (PBP5) (Cattoir and Giard, 2014). Although E. faecalis causes the 
majority of enterococcal infections, E. faecium is considerably more difficult to treat due 
to its multidrug resistance. In this regard, glycopeptide antibiotics, such as vancomycin 
or teicoplanin are commonly used to treat serious enterococcal infections, often in 
combination with aminoglycosides due to their synergistic activity.  
 
However, resistance to vancomycin is now increasingly common, as 36.5% of hospital 
acquired E. faecium isolates are vancomycin non-susceptible in Australia (stated above), 
with similar statistics observed within the US (33%) and in Europe (1% - >30% varying 
between regions) (Cattoir and Giard, 2014). This resistance (to vancomycin) is due to the 
acquisition of genes encoding for proteins that alter the terminal residues of peptidoglycan 
amino acid chains from D-Ala-D-Ala to either D-Ala-D-Lac or D-Ala-D-Ser, which have 
significantly reduced affinity for vancomycin. The most common gene operons that drive 
such resistance are the vanA operon, which is common in North America and Europe, and 
the vanB operon which is common in Australia (Cattoir and Giard, 2014). In the case of 
vancomycin resistance, a last resort therapy used to treat multidrug resistant isolates of E. 
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faecium is the cyclic lipopeptide daptomycin, which exhibits potent bactericidal activity 
against gram-positive bacteria. Currently, resistance to daptomycin is relatively 
uncommon in enterococci, although there have been reported cases of therapy failure with 
the sudden onset of high-level resistance (Cattoir and Giard, 2014).  
 
1.4.2 Staphylococcus aureus 
Staphylococci are gram-positive cocci which asymptomatically colonise human epithelia 
and are generally non-pathogenic in healthy individuals. Approximately 20% of 
individuals are persistent carriers of S. aureus within their nasal passages or axillae 
(under-arms), while 60% of individuals are intermittent carriers, playing host to 
fluctuating populations of S. aureus strains (Pendleton et al., 2013). Staphylococci are 
however opportunistic pathogens, often causing both acute and chronic (upon formation 
of biofilms) infections within wounds. The capacity of S. aureus to cause infection is due 
to their ability to produce a variety of toxins and virulence factors (Gould et al., 2012, 
Stefani et al., 2012). Produced by nearly all strains are several extracellular proteins 
including; haemolysins, hyaluronidase, proteases and collagenase, which are all vital in 
breaking down host tissue for nutrients. Additionally, certain strains (often community 
acquired) are able to produce unique toxins which are particularly detrimental to host 
health, such as the exotoxin TSST-1, which is produced by approximately 25% of S. 
aureus strains and can lead to toxic shock syndrome (Pendleton et al., 2013).  
 
In recent years infections caused by MRSA have arisen from within community settings, 
giving rise to community acquired MRSA (CA-MRSA). The majority of CA-MRSA 
(≈90%) infections affect skin and soft tissue, predominantly resulting in cellulitis or 
abscesses. Severe CA-MRSA infections can result in necrotising fasciitis or necrotising 
pneumonia, with substantially higher mortality rates of 20% and 75%, respectively (Skov 
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et al., 2012). Associated with CA-MRSA is an increase in the prevalence and severity of 
virulence factors, most notably Panton-Valentine leukocidin (PVL), which is present 
within the majority of CA-MRSA lineages. 
 
Methicillin resistance within S. aureus was first reported in the 1960s, however it is only 
in the last two decades that MRSA has been considered a significant threat as a 
nosocomial and community acquired pathogen (Pendleton et al., 2013). MRSA strains 
are those which have developed resistance to β-lactam antibiotics through the acquisition 
of the Staphylococcal Cassette Chromosome mec (SCCmec), a mobile genetic element 
which encodes for a low affinity penicillin-binding protein (PBP 2a) (2009).  
 
Presently, severe S. aureus and MRSA infections are treated with the glycopeptide 
antibiotic vancomycin, which has been the treatment of choice for such infections since 
it was introduced in 1958. Of clinical concern, intermediate-resistant strains have been 
observed, with the earliest report being in 1996 (Hiramatsu et al., 1997). In Australia, 
MRSA strains exhibiting vancomycin resistance fall under one of two categories; VISA 
(vancomycin intermediate S. aureus which typically have an MIC of 4-8 µg/mL) and 
hVISA (heterogeneous vancomycin intermediate S. aureus which possess subpopulations 
of cells with increased vancomycin MICs) (Gosbell, 2014). In a clinical setting, studies 
have identified that bacteraemias caused by MRSA with vancomycin MICs of 2 or 3 
µg/mL, result in a much higher mortality rate of 27%, in comparison to 12.5% associated 
with MRSA strains with vancomycin MICs of <1.5 µg/mL (Gosbell, 2014).   
 
Currently, high-level vancomycin resistance in S. aureus is relatively uncommon. In 
2009, only 11 strains had been reported worldwide that displayed high-level resistance to 
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vancomycin through acquisition of the VanA operon (French, 2010). However, no such 
strains have been identified in Australia. Such data may indicate that the longevity of 
vancomycin as the treatment of choice is coming to an end, emphasizing the need for new 
antimicrobials to be developed. 
 
1.4.3 Klebsiella pneumoniae 
K. pneumoniae is a non-fastidious, gram-negative bacillus which belongs to the 
Enterobacteriaceae family, and is a common commensal organism within the human gut 
microbiome. Like S. aureus and E. faecium, K. pneuemoniae is an opportunistic pathogen 
which accounts for one third of all infections caused by gram-negative species, the 
majority of which are healthcare associated, including; urinary tract infections, 
pneumoniae, surgical wound infections and septicaemia. K. pneumoniae is also 
associated with community-acquired infections, including necrotizing pneumonia and 
pyogenic liver abscesses (Harris et al., 2015, Navon-Venezia et al., 2017).  
 
K. pneumoniae is heavily associated with antibiotic resistance, both intrinsically in the 
case of ampicillin (due to the presence of the SHV-1 penicillinase within the 
chromosome), and via the acquisition of antibiotic resistance genes through horizontal 
gene transfer. Remarkably, K. pneumoniae isolates have been identified which possess 
numerous resistance determinants, resulting in pan drug-resistant (PDR) and extensive 
drug-resistant (XDR) clinical isolates (Wyres and Holt, 2018).  
 
The resistome (collection of genes which confer antibiotic resistance) of K. pneumoniae 
is well characterized and is responsible for the observed resistance against the five major 
classes of antibiotics which are used to treat infections caused by the Enterobacteriaceae 
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family. These classes include the β-lactams, aminoglycosides, quinolones, tigecycline 
and polymyxins (Navon-Venezia et al., 2017).  
 
Resistance to β-lactams in K. pneumoniae was first observed in the 1960s following the 
discovery of the β-lactamase genes blaSHV-1 and blaTEM-1. Subsequently, in the 1980s to 
2000s the first extended spectrum β-lactamase (ESBL) gene (blaSHV-2) was identified in 
K. pneumoniae, which conferred resistance to a broad range of β-lactams including third 
generation cephalosporins and monobactams. Multiple ESBL genes have been identified 
within K. pneumoniae including the plasmid/transposon mediated blaTEM-3, blaCTX-M, and 
blaOXA genes. More recently in 2008, the NDM-1 metallo-beta-lactamase was detected 
and has now been identified in multiple plasmids present within the Enterobacteriaceae 
family. Worryingly, K. pneumoniae is now the major ESBL carrying pathogen worldwide 
and continues to increase in prevalence globally, and is considered epidemic in several 
countries (Navon-Venezia et al., 2017, Wyres and Holt, 2018).  
 
Between the 1940s and 1980s, aminoglycosides were the treatment of choice against K. 
pneumoniae, before they were replaced by the third generation cephalosporins, 
carbapenems and fluoroquinolones. During this time K. pneumoniae developed 
significant resistance against aminoglycosides, primarily through the acquisition of drug 
alteration enzymes (carried on plasmids) which function in the acetylation, adenylation 
or phosphorylation of antimicrobial compounds. The major resistance determinant within 
K. pneumoniae is the 16S rRNA methylase, which confers broad spectrum resistance 
against all aminoglycosides as identified in 2003 (Navon-Venezia et al., 2017). 
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Quinolones have been used extensively since the 1960s to treat infections caused by K. 
pneumoniae. Since their introduction, multiple resistance mechanisms against quinolones 
have been identified including; modification of the target site, production of efflux pumps 
and production of drug modifying enzymes. These mechanisms are a combination of 
plasmid mediated and chromosomal routes of resistance, including sequence mutations 
of the cellular target (DNA gyrase and topoisomerase IV) and reduced cell permeability 
through the production of multidrug efflux pumps such as acrAB (Navon-Venezia et al., 
2017).  
 
Polymyxins such as colistin are a class of antibiotics often used in last resort cases against 
infections caused by MDR gram-negative bacteria, including K. pneumoniae. Resistance 
to colistin was first identified in the early 2000s and is chromosomally driven by the 
modification of the target site, which (in this case) is commonly referred to as the LPS 
modification system. This system modifies the structure of LPS by producing a phenotype 
with reduced anionic charge, which severely limits the binding affinity of polymyxins to 
the LPS structure (Navon-Venezia et al., 2017). In recent years, plasmid mediated 
resistance to polymyxins has emerged through the acquisition of the mcr-1 gene, which 
was likely acquired via conjugation from a donor E. coli isolate (Liu et al., 2016).  
 
The final antibiotic commonly used to treat infections caused by K. pneumoniae is 
Tigecycline, which belongs to the glycylcycline class of antimicrobials. Tigecycline has 
been used since 2005 as an effective alternative to circumvent resistance mechanisms 
against tetracyclines. However, resistance to tigecycline is now increasingly reported in 
K. pneumoniae isolates, driven by chromosomal mutations within the drug target (30S 
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and 16S ribosomal subunits) and the acquisition of genes which alter cell permeability 
(Navon-Venezia et al., 2017).  
 
1.4.4 Acinetobacter baumannii  
A. baumannii is a gram-negative, coccobacilli which is found almost exclusively within 
hospital environments, particularly intensive care units. A. baumannii is an opportunistic 
pathogen most often associated with skin/soft tissue infections, urinary tract infections, 
ventilator associated pneumonia and bloodstream infections, and is responsible for 
approximately 2-10% of all gram-negative nosocomial infections worldwide (Antunes et 
al., 2014). A. baumannii is particularly problematic in healthcare settings due to its 
persistence in non-favourable environments, as it remains viable in a range of pH levels, 
temperatures and nutrients levels, which facilitates colonization on inanimate surfaces for 
up to 5 months (Pendleton et al., 2013).  
 
Like other gram-negative pathogens, A. baumannii is intrinsically resistant to several 
antibiotics due to its outer membrane, constitutively expressed efflux pumps and low 
expression of outer membrane porins, all of which result in a reduced permeability to 
antimicrobials (Pendleton et al., 2013). Unsurprisingly, A. baumannii is also capable of 
acquiring resistance through horizontal gene transfer from other gram-negative species, 
including P. aeruginosa and Enterobacteriaceae (Poirel et al., 2011). Resistance to 
antibiotics such as the quinolones/fluoroquinolones, aminoglycosides, polymyxins and β-
lactams is driven by similar resistance mechanisms observed within K. pneumoniae 
(section 1.4.3), including target modification, drug modification and the removal of 
antimicrobials via efflux pumps (Poirel et al., 2011).  
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Multi-drug resistance within A. baumannii isolates has become increasingly common 
within the last two decades in certain regions. For example, in the USA the percentage of 
MDR A. baumannii isolates has increased from 32.1% in 1999 to 51% as reported in 2010 
(Pogue et al., 2013). Unique to MDR A. baumannii are large genomic resistance islands 
capable of carrying tens of resistance genes against antimicrobials and antiseptic agents. 
The first resistance island (AbaR1) was identified in 2006 within the MDR isolate AYE. 
AbaR1 was identified as being 86-kb in length and contained 45 of the 52 resistance genes 
present within the AYE strain.  Analysis of AbaR1 revealed its composition of mobile 
genetic elements, including 82 of its 88 open reading frames which originated from three 
different genera; Pseudomonas, Salmonella and Escherichia (Fournier et al., 2006). 
 
A. baumannii remains a primary concern in healthcare settings, due primarily to its highly 
adaptable genome and rapid acquisition of resistance determinants from other bacteria, 
as well as the lack of novel antimicrobials currently available (or in development) for 
treating MDR A. baumannii infections.  
 
1.4.5 Pseudomonas aeruginosa 
P. aureginosa is a gram-negative rod-shaped bacterium which inhabits a wide range of 
environments including soil, aquatic, plant, and animal habitats. Due to its nutritional 
versatility, P. aeruginosa is one of the most common causes of nosocomial infections, 
especially within immunocompromised patients or those treated within ICUs. P. 
aeruginosa is most commonly associated with chronic lung infections in cystic fibrosis 
(CF) patients, which can often result in complete respiratory failure, lung transplantation 
or death (Folkesson et al., 2012, Pendleton et al., 2013).  
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Like other gram-negative species, P. aeruginosa is intrinsically resistant to a variety of 
antibiotics including aminoglycosides, fluoroquinolones and β-lactams, due to the low 
permeability of its outer membrane, as well as the increased production of efflux pumps 
and antibiotic modification enzymes. Unique to P. aeruginosa is the membrane porin 
OprF which imposes a strict exclusion limit of 500 Da on exogenous substances, severely 
limiting the number of antimicrobials capable of entering the cell. The combination of 
OprF and efflux pumps such as the resistance-nodulation-cell division systems MexAB-
OprM and MexXY-OprM, as well as inducible AmpC (β-lactamase) result in P. 
aeruginosa exhibiting high levels of intrinsic resistance, which plays a significant role in 
associated poor clinical outcomes (Breidenstein et al., 2011, Pendleton et al., 2013).  
 
P. aeruginosa is also capable of acquiring resistance determinants through horizontal 
gene transfer, predominantly those which confer resistance against aminoglycosides and 
β-lactams. Of greatest concern is the documented acquisition of plasmid mediated 
extended-spectrum β-lactamases (ESBLs) and metallo-β-lactamases (MBLs), resulting in 
high level resistance to penicillin/cephalosporins and carbapenems, respectively 
(Breidenstein et al., 2011). Point mutations are also a major contributor to the 
development of antibiotic resistance in P. aeruginosa. For example, mutations within the 
gene mexZ cause an overexpression of the efflux pump MexXY-OprM, resulting in multi-
drug resistance against aminoglycosides, fluoroquinolones and cefepime.  
 
Chronic infections caused by P. aeruginosa pose a unique challenge in treatment, owing 
to the ability of P. aeruginosa to form biofilms under different environmental conditions. 
Biofilms can form on inanimate surfaces such as medical equipment, as well as epithelia, 
such as the lungs of patients with cystic fibrosis (Breidenstein et al., 2011). Biofilms 
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consist of a community of bacterial cells encased in an extracellular polysaccharide (EPS) 
substance, which allows for adhesion to surfaces and severely limits the effectiveness of 
antimicrobial agents and disinfectants (Rasamiravaka et al., 2015). Increased resistance 
within cells growing in a biofilm is due to several factors. Firstly, cells within a biofilm 
possess a unique transcriptome profile that differs substantially from those observed 
within planktonic cells, which often results in the increased expression of efflux pumps 
and enzymes associated with antibiotic resistance. Secondly, cells towards the centre of 
a biofilm have reduced nutrient availability and therefore grow at a slower rate, which 
greatly limits the activity of antibiotics which act on growing cells such as β-lactams. 
Finally, the EPS provides not only a physical barrier for antibiotics, but also creates an 
environment for the accumulation of secreted enzymes such as β-lactamases 
(Breidenstein et al., 2011).  
 
The combination of intrinsic resistance, biofilm formation, and the acquisition of 
resistance determinants makes P. aeruginosa a primary concern within healthcare 
settings. 
 
1.4.6 Enterobacter Species  
The Enterobacter species are non-fastidious, gram-negative rods which are commonly 
associated with urinary and respiratory tract infections, often within 
immunocompromised patients (Pendleton et al., 2013, Santajit and Indrawattana, 2016).  
 
Like the other Enterobacteriaceae, resistance in the Enterobacter species is largely driven 
by plasmid encoded ESBLs and carbapenemases, including both metallo and non-metallo 
β-lactamses such as NDM-1 and KPC, respectively. While treatment options for MDR 
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Enterobacter species vary depending on the isolate, there are often few antibiotics 
currently available besides colistin and tigecycline (Esposito and De Simone, 2017, 
Pendleton et al., 2013).   
 
1.5 Glycopeptide Resistance in E. faecium and S. aureus  
 
Glycopeptide antibiotics are tricyclic or tetracyclic compounds of microbial origin with 
a narrow spectrum of activity against gram-positive bacteria. There are two glycopeptide 
antibiotics that are currently used clinically, namely vancomycin and teicoplanin, as well 
as several semisynthetic derivatives of these compounds, including telavancin and 
oritavancin (derived from vancomycin) as well as dalbavancin (derived from teicoplanin) 
(Figure 1.5) (Henson et al., 2015, Kang and Park, 2015). 
 
Figure 1.5: Chemical structure of Glycopeptide antibiotics. Vancomycin and Teicoplanin are 
natural products while Telavancin and Oritavancin are second generation derivatives of 
vancomycin, and Dalbavancin is a derivative of Teicoplanin. Image adapted from Kang et al 
(Kang and Park, 2015). 
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Vancomycin and teicoplanin share a similar mechanism of action, and act by inhibiting 
peptidoglycan synthesis in dividing bacteria. Inhibition is achieved by forming a 
noncovalent complex with the C-terminal D-Ala-D-Ala of the murein monomer amino 
acid chain, which subsequently blocks glycosyltransferase and the incorporation of 
precursor molecules to growing peptidoglycan. This action prevents further 
transpeptidation and subsequently results in the interruption of cell wall synthesis.  
 
The mechanism of action of the lipoglycopeptides differ slightly, due to the addition of a 
lipophilic side chain. Telavancin is unique as it exhibits a dual mechanism of action by 
inhibiting peptidoglycan synthesis and affecting membrane polarization. Telavancin 
binds to a peptidoglycan precursor called lipid (undecaprenyl)-linked N-
acetylglucosamine-N-muramylpentapeptide at the D-Ala-D-Ala residues, which inhibits 
both the transglycosylation and transpeptidation steps of peptidoglycan synthesis. 
Additionally, the decylaminoethyl hydrophobic side chain interacts with the cell 
membrane which results in an increased affinity for the target site, as well as a 
concentration-dependent reduction in the cell membrane potential and integrity (Kang 
and Park, 2015). 
 
Oritavancin and Dalbavancin exhibit a similar mechanism of action to Vancomycin and 
Teicoplanin, in that they both bind to the D-Ala-D-Ala terminus of a stem pentapeptide 
and inhibit transglycosylation and transpeptidation. However, they differ due to their 
ability to dimerize and anchor to the cell membrane which increases their stability and 
binding affinity for the target site (Kang and Park, 2015).  
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Vancomycin was the first glycopeptide antibiotic discovered in the 1950s and was 
recognised as a potent inhibitor of gram-positive pathogens, notably S. aureus and 
problematic enterococci (E. faecalis and E. faecium). Initially, it was not used extensively 
due to its poor toxicity profile and the concurrent release of safer β-lactam antibiotics 
such as methicillin. However, due to the well documented difficulty in treating 
enterococci due to their high tolerance to β-lactams and widespread resistance to 
aminoglycosides, vancomycin (for a time) was the most reliable option for treating 
enterococcal infections (Cetinkaya et al., 2000). The regular use of vancomycin against 
Enterococci eventually led to the emergence of vancomycin-resistant Enterococci in 
1988, which have continued to spread to endemic levels worldwide (Table 1.1). As of 
2013, the percentage of Enterococci exhibiting resistance to vancomycin within each 
region ranged from 4% in Europe to 35.5% in the United States. Worryingly, the 
percentage of E. faecium isolates which are vancomycin resistant are significantly higher, 
reaching upwards of 79.4% in the United States (Cetinkaya et al., 2000, O’Driscoll and 
Crank, 2015). Vancomycin was not regularly used to treat infections caused by S. aureus 
until the late 1980s, and was generally limited for use against complicated infections 
caused by multi-drug resistant isolates such as MRSA (Henson et al., 2015). 
Unsurprisingly, it was only several years later the first vancomycin-resistant S. aureus 
(VRSA) strain was isolated in 2002 (McGuinness et al., 2017). 
 
Table 1.1: Percentage of enterococci exhibiting Vancomycin resistance based on region. Table 
adapted from O’Driscoll et al (O’Driscoll and Crank, 2015) 
Species Europe 2013 
USA  
2009-2010 
Canada 
2007-2012 
Asia-
Pacific 
2007-2008 
Latin 
America 
2007-2008 
Worldwide 
2007-2012 
E. faecium 8.8 79.4 22.4 14.1 48.1 - 
E. faecalis 1 8.5 0.1 0.01 3.1 10.3 
All 
enterococci 4 35.5 6 11.0 12.9 - 
 
 
 
37 
1.5.1 Vancomycin Resistance in VRE and VRSA 
As stated in section 1.3.1, vancomycin resistance is driven by one of several VanX 
operons encoded on the transposon Tn1546, which originated from a VRE conjugative 
plasmid. Seven VanX operons have been identified (vanA, vanB, vanD, vanE, vanG and 
vanL), of which vanA and remains the most significant in terms of the degree of resistance 
conferred and its prevalence worldwide (Henson et al., 2015, McGuinness et al., 2017). 
The VanA operon is comprised of several genes including vanA, vanX, vanS, vanR, vanY 
and vanZ, and is controlled by a two-component regulatory system encoded by vanS and 
vanR, which sense vancomycin and induce expression of the operon respectively. The 
mechanism of VanA resistance involves altering the C-terminal D-Ala-D-Ala of murein 
monomers to D-Ala-D-Lac, which has a lower binding affinity to vancomycin by 1000-
fold. Resistance to vancomycin in S. aureus is driven solely by the acquisition of the 
VanA operon via conjugation with VRE isolates. In order for vancomycin resistance to 
be maintained, an original copy of the enterococcal operon must be retained, or TN1546 
must be incorporated into a resident staphylococcal plasmid via transposition 
(McGuinness et al., 2017). The VanA cluster confers high levels of resistance to all 
available glycopeptide antibiotics including vancomycin, teicoplanin, dalbavancin and 
telavancin, with only oritavancin retaining efficacy against vanA VRE. The VanB cluster 
is the second most common VanX operon behind VanA, and generally confers resistance 
to vancomycin and (less frequently) teicoplanin, while remaining susceptible to other 
glycopeptides (Henson et al., 2015). 
 
1.5.2 Vancomycin Intermediate Resistance in S. aureus  
While VRSA is still relatively uncommon worldwide, the prevalence of vancomycin 
intermediate resistant S. aureus (VISA) is on the rise. As stated previously (section 1.4.2), 
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VISA isolates are characterized by having a vancomycin MIC of 4-8 μg/mL, and are 
typically associated with persistent infections and prolonged exposure to vancomycin 
(McGuinness et al., 2017). VISA resistance develops in a stepwise manner and is 
generally preceded by the development of a hVISA resistance (see section 1.4.2). There 
are several characteristics associated with the VISA phenotype including; increased cell 
wall thickness, reduced cross-linking of peptidoglycan, decreased autolytic activity, 
altered surface protein profile and disruption of the agr system (McGuinness et al., 2017). 
The genetic basis of the VISA phenotype has been studied extensively, with several 
genes/mutations emerging as being key in the development of VISA resistance. The most 
significant appear to be mutations within genes encoding two-component regulatory 
systems such as walKR and graRS, as well as mutations within the gene rpoB which 
encodes for a DNA-dependent RNA polymerase β-subunit (McGuinness et al., 2017). 
Cell wall thickening is the most common phenotypic characteristic of VISA isolates, 
conferring resistance by reducing the ability of vancomycin to access its active site (C 
terminal D-Ala-D-Ala) and sequestering the molecule within the cell wall (Henson et al., 
2015). 
 
The rapid emergence and continued spread of VRE, VRSA and VISA isolates have 
illuminated major concerns in the reliance on glycopeptide antibiotics as last resort 
antibiotics to treat complicated infections. Alternative, novel compounds are desperately 
needed to combat multi-drug resistant pathogens in the antibiotic resistant era. 
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1.5 Approaches to Combating Antimicrobial Resistance 
 
The reality of antibiotic resistance and its toll on human health has resulted in calls for 
drastic changes in antibiotic stewardship on a global scale. Bacteria developing resistance 
to antibiotics is Darwinian in nature, illustrating the fast- tracked evolution of bacteria to 
adapt to hostile environments. While antibiotic resistance genes and associated mobile 
genetic elements are not new, the intense selective pressures applied to bacteria in both 
healthcare and the environment are. As discussed previously, environments with 
significant anthropogenic pressure such as medical facilities, agriculture/aquiculture 
facilities and wastewater systems are key reservoirs of antibiotic resistant genes due to 
high bacterial load and sub-therapeutic antibiotic use (Berendonk et al., 2015).    
 
A number of methods have been proposed to combat the emergence and spread of 
antibiotic resistance. Firstly, significantly more research (and funding) is required to 
understand the factors involved in the dissemination of antibiotic resistance genes 
throughout bacterial populations, as well as understanding the factors that promote the 
selection and movement of resistant strains from the environment and animals to human 
populations (Bush et al., 2011). Understanding this will allow for the development of 
appropriate methods to monitor, diagnose and intervene against the spread of antibiotic 
resistance. Secondly, the education of the public must be made a priority to raise 
awareness of the dangers associated with antibiotic resistance, the incorrect use of 
antibiotics and its role in selecting for bacterial strains with increased resistance. Thirdly, 
greater attention should be given to developing nations where a number of factors such 
as high population densities, uncontrolled antibiotic use and lack of effective hygiene 
create environments ideal for the proliferation of antibiotic resistance. Interventions need 
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to be made at a governmental level to promote the infrastructure required to combat these 
issues. Fourthly, non-therapeutic antibiotic use such as the addition of antibiotics to 
animal feed as growth promoters should be restricted and monitored on a global scale. 
Finally, and most importantly, significantly more resources should be allocated to 
developing new antibiotics to keep up with the generation of resistant strains (Bush et al., 
2011).    
 
Research and development of novel antibiotics has been a longstanding issue in the past 
number of decades. The World Health Organization (WHO) has regularly reported on the 
ever-growing concern surrounding both the lack of innovation in antimicrobial 
development, as well as the sparse number of antibiotics which are developed each year. 
Most recently in 2017, a report by WHO outlined the lack of antibiotics in development 
capable of effectively combatting antibiotic resistance, identifying that of 51 new 
antibiotics in development, only 8 exhibited a novel mechanism of action, with the 
remainder being derivatives of already available compounds (Kmietowicz, 2017). As of 
2015, 30 new antibiotics and 2 new β-lactam/β-lactamase inhibitor combinations have 
been introduced clinically worldwide. Of the 30 newly introduced antibiotics, all but 5 
were derivatives of already available compounds, and all 5 of the first in class antibiotics 
(linezolid, daptomycin, retapamulin, fidaxomicin and bedaquiline) exhibited activity 
against gram-positive bacteria only. Additionally, the number of pharmaceutical 
companies with antibiotic divisions has declined significantly since the 1990s, decreasing 
from 18 in 1990 to only 4 as of 2015 (Butler et al., 2016).   
 
The lack of innovation in the context of antimicrobial development has also resulted in a 
growing trend towards alternative methods for treating bacterial infections. ‘Non-
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compound’ approaches including the use of antibodies, bacteriophages, vaccines, 
antimicrobial peptides and lysins have been explored to certain degrees in recent years 
(Czaplewski et al., 2016). It is likely that a combination of these approaches must be 
adopted on a global scale to combat antibiotic resistance. 
 
1.6 BDM-I 
 
BDM-I (3,4-methylenedioxy-β-nitropropene; Figure 1.6) is a novel anti-infective 
compound that is currently being developed by the Australian biotechnology company 
Opal Biosciences (Melbourne AUS). It is a yellow crystalline solid that is insoluble in 
water, but soluble in organic solvents such as dimethylsulfoxide (DMSO). BDM-I 
belongs to a class of benzyl nitroalkenes that have been studied since the 1950s for a 
number of therapeutic properties, including as broad-spectrum antibiotics and anti-cancer 
drugs. BDM-I has displayed effectiveness in vitro against a broad range of 
microorganisms including bacteria, fungi and protozoa, and has been tested against a wide 
range of pathogenic organisms, including important clinical strains of bacteria such as 
MRSA and VRE (White et al., 2014). 
 
  
Figure 1.6: Molecular structure of BDM-I 
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Over 31 BDM-I derivative compounds have been developed and assayed against a range 
of bacterial and fungal species; results from these tests concluded that BDM-I itself was 
the most broadly active agent. However, certain derivatives were highly effective against 
a narrow spectrum of organisms such as gram-negative bacteria. Tests on BDM-I have 
also indicated that it has very low toxicity to mammals, with studies conducted on mice 
showing that BDM-I has a high lethal dose (2000 mg/kg), and that a 7-day repeat course 
of the compound (300 mg/kg) resulted in no observable antagonistic effects (White et al., 
2014). Although these findings indicate that the BDM-I target is highly specific to 
microbial organisms, the mechanism of action (MoA) of BDM-I is not fully understood. 
 
In 2014, White et al conducted a study on the BDM-I MoA, which subsequently 
confirmed its classification as a novel compound. Specifically, a series of experiments 
were conducted to examine whether BDM-I had any effect on the most common cellular 
targets for antibiotics including the cell wall and membrane, protein synthesis and RNA 
synthesis. Interestingly, White et al discovered that BDM-I acts intracellularly, most 
likely by inhibiting microbial protein tyrosine phosphatases (PTPs) (White et al., 2014).  
 
Furthermore, a previous study on the mechanism of action of the structurally similar 
benzyl nitrostyrene compounds identified their mechanisms of actions as being inhibitors 
of protein tyrosine phosphatases (Park and Pei, 2004). Additionally, via this study they 
identified that these compounds were inhibited by thiols which are present within 
eukaryotic cells, possibly explaining the specificity of compounds like BDM-I to 
microbial cells. However, this mechanism of action is yet to be shown in the case of 
BDM-I.  
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1.7 Protein Phosphorylation in Bacteria 
 
Post-translational modification of proteins by phosphorylation has been studied 
extensively within eukaryotes over the past century. However, it has only been since the 
1980s that prokaryotic organisms were also shown to utilise phosphorylation as a 
regulatory mechanism (Chao et al., 2014). The most frequently observed phosphorylated 
residues in eukaryotes are Serine (pSer), Threonine (pThr) and Tyrosine (pTyr), with an 
approximate distribution of 86.4%, 11.8% and 1.8% respectively (Cain et al., 2014). 
Initially, protein phosphorylation in bacteria was thought to be limited to histidine and 
aspartate residues as part of two-component regulatory systems. However, in the last 
number of decades, studies have shown that Ser, Thr and Tyr phosphorylation occurs in 
bacteria at a similar distribution to eukaryotes (Cain et al., 2014, Chao et al., 2014). In 
recent years, multiple studies have been published using novel analytical methods to 
identify the phosphoproteome of several bacterial species, including; E. coli (Lin et al., 
2015), B. subtilis (Macek et al., 2007), L. lactis (Soufi et al., 2008), M. tuberculosis (Prisic 
et al., 2010) and S. pneumoniae (Sun et al., 2010). Data from these studies indicate that 
phosphorylation occurs on numerous proteins involved in a broad range of cellular 
processes. In-depth analysis of the E. coli phosphoproteome identified that 30% of the 
proteins encoded by essential genes were phosphorylated, and are involved in a variety 
of cellular functions including central carbon metabolism, DNA metabolism, 
transcription and translation (Lin et al., 2015). 
 
Phosphorylation of tyrosine residues occurs at a significantly lower rate in comparison to 
serine and threonine, typically making up ≤15% of the total phosphoproteome in bacteria. 
Tyrosine phosphorylation has been shown to direct a range of cellular processes which 
appear to be species specific. These processes include; capsule production, growth, 
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proliferation, migration, flagellin export, stress adaptation and synthesis of secondary 
metabolites (Whitmore and Lamont, 2012).  
 
Tyrosine phosphorylation is carried out by the bacterial tyrosine (BY) kinase family, 
composed of a transmembrane domain which functions as a sensor and anchor, as well as 
an intracellular catalytic domain. The catalytic domains of BY kinases contain Walker A 
(P-loop) and B motifs, differing from typical motifs present within eukaryotic tyrosine 
kinases (Whitmore and Lamont, 2012). Initially, BY kinases were thought to be solely 
autophosphorylating enzymes controlling exopolysaccharide production. However, 
recent studies have identified multiple protein substrates which are phosphorylated by 
BY kinases, elucidating additional roles in regulating bacterial physiology (Grangeasse 
et al., 2007). The first proteins identified to be phosphorylated by BY kinases were UDP-
sugar dehydrogenases and glycosyltransferases, which stimulated the formation of 
polysaccharide precursors. Interestingly, some proteins such as UDP-glucose 
dehydrogenases are involved in several metabolic pathways such as Teichuronic acid 
biosynthesis in B. subtilis, which is a key component of peptidoglycan (Soldo et al., 
1999). Additional proteins identified to be phosphorylated by BY kinases include the 
heat-shock sigma factor (σ32) and antisigma factor (σE) of E. coli, and single-stranded 
DNA binding proteins of B. subtilis. These findings indicate that tyrosine phosphorylation 
is directly involved in regulating gene expression in bacteria (Grangeasse et al., 2007).  
 
Conserved sequence motifs encoding for tyrosine phosphatases have also been identified 
in bacteria, which function in the removal of a phosphate molecule resulting in the 
dissemination or inhibition of phospo-mediated signalling (Cain et al., 2014). Bacterial 
tyrosine phosphatases are characterized into three groups; eukaryotic like phosphatases 
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(PTPs) which also dephosphorylate serine and threonine sites, low molecular weight 
protein tyrosine phosphatases (LMW-PTPs) which are also found in eukaryotic cells, and 
polymerase-histidinol phosphatases (PHP) which are commonly found in gram-positive 
bacteria (Whitmore and Lamont, 2012). Eukaryotic like PTPs typically function as 
secreted effector proteins to alter host cells during infection, highlighting their primary 
role in bacterial virulence. However, LMW-PTPs and PHPs have been shown to function 
in regulating the phosphorylation state of bacterial proteins, primarily acting against BY 
kinases encoded upstream of phosphatase genes (Grangeasse et al., 2007). Bacterial 
tyrosine phosphatases have been shown to function in several cellular processes, with 
significant evidence illuminating their roles in polysaccharide production and biofilm 
formation, as well as secreted effector proteins to manipulate host cells during infection 
(Whitmore and Lamont, 2012). 
 
It is important to note that studies on post-translational modifications in bacteria, 
specifically tyrosine phosphorylation, is a relatively new area of research. Therefore, it is 
difficult to hypothesize the effects of the proposed MoA of BDM-I as a (potential) 
tyrosine phosphatase inhibitor on the physiology of bacterial cells.   
 
1.8 Scope of Thesis 
 
Antibiotic resistance continues to be one of the most significant global threats facing 
modern medicine. While major pharmaceutical companies continue to focus on 
developing more financially “safe” drugs for chronic illnesses with long term treatment 
needs, all of the most clinically relevant bacterial pathogens continue to develop and 
spread resistance to (in some cases) every antibiotic which is currently available.  
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BDM-I has been identified as a novel antimicrobial with activity in vitro against several 
clinically important microorganisms. Understanding the pharmacodynamics of novel 
drugs is a major step in its development and is vital to developing appropriate treatment 
regimens in clinical settings. While BDM-I has been studied previously, the MoA remains 
elusive, with evidence suggesting that BDM-I may inhibit tyrosine phosphatases (White 
et al., 2014). Therefore, the aim of the studies presented in this thesis was to gain a deeper 
understanding of the BDM-I MoA, while also investigating the efficacy of BDM-I against 
clinical isolates associated with nosocomial infections. 
 
Previous MoA studies focused on confirming that BDM-I did not affect cellular targets 
typically inhibited by antibiotics (section 1.2), while also relying on predicted targets to 
identify potential binding partners (White et al., 2014). By utilizing an omics approach 
(whole genome sequencing and proteomics), significant pathways and individual proteins 
were identified which are affected by BDM-I. Utilizing this top down approach, pathways 
and proteins of interest can then be studied further to identify how they are affected by 
BDM-I, providing valuable insight into the BDM-I MoA. 
 
Previous efficacy studies with BDM-I have been limited to testing laboratory strains of 
common bacterial species. However, no in-depth studies have been undertaken which 
examine the utility of BDM-I against clinical bacterial isolates associated with persistent 
infections and antibiotic resistance. To address this lack of data, MIC studies were 
conducted on a range of bacterial isolates (ESKAPE pathogens) to assess the useability 
of BDM-I against clinical bacterial pathogens.  
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In combination, the results of these studies have contributed to identifying the BDM-I 
MoA as an inhibitor of ATP Synthesis via the oxidative phosphorylation pathway. 
Furthermore, MIC studies have confirmed that BDM-I is a viable treatment option against 
MRSA both in monotherapy and (potentially) combination therapy with vancomycin.  
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Materials and Methods 
 
2.1 Chemicals, Reagents and Oligonucleotides  
Lysostaphin, lysozyme, ethidium bromide, Triton X-100, dimethylsulfoxide (DMSO), 
pronase, cOmplete™ Mini EDTA-free Protease Inhibitor Cocktail, 4’,6-diamidino-2-
phenylindole (DAPI), SYTOX Green, FM-464, vancomycin, chloramphenicol, 
daptomycin, erythromycin and flucloxacillin were purchased from Sigma. 3,4-
methylenedioxy-β-nitropropene (BDM-I) was supplied by BioDiem. All other chemicals 
were purchased through commercial sources and were of analytical grade. 
Oligonucleotides were designed in CLC Genomics Workbench and purchased from 
Sigma.  
 
Table 2.1: Buffers and Reagents 
Buffer Composition 
Lysis buffer (Genomic Extractions) 
20 mM Tris-Cl 
2 mM EDTA 
1% Triton X‐100 
pH 8 
Electrophoresis running buffer 
45 mM Tris(hydroxymethyl)aminomethane 
45 mM Boric Acid 
1 mM EDTA 
Anode running buffer (10x) 200 mM Tris-Cl pH 8.9 
Cathode running buffer (10x) 
100 mM Tris 
100mM Tricine 
0.1% SDS (w/v) 
Comassie brilliant blue stain 
0.125% Comassie blue R250 (w/v) 
30% Methanol (v/v) 
10% Acetic Acid (v/v) 
Comassie destain solution 30% Methanol (v/v) 10% Acetic Acid (v/v) 
SDS-PAGE loading buffer (5x) 
300 mM Tris-Cl (pH 6.8) 
10% SDS (w/v) 
50% Glycerol (v/v) 
25% 2-mercaptoethanol 
5g/L bromophenol blue 
SDS-PAGE Running Buffer (10x) 
25 mM Tris 
192 mM Glycine 
0.1% SDS (w/v) 
pH 8.3 
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2.2 Bacterial Strains  
 
Bacterial strains used in this study are listed in Table 2.2, along with their relevant genetic 
characteristics and antibiotic phenotype. Clinical strains used are listed in Tables 2.3 to 
2.7 along with relevant clinical information and resistance phenotypes. 
 
2.3 Bacterial media, growth conditions and storage 
 
Media used for bacterial growth as well as their constituent reagents are listed in Table 
2.8. Prior to use, all growth media was sterilised by autoclaving at 121°C and 103 KPa 
for approximately 30 minutes. Solutions which contained heat labile substances were 
filter sterilized using a 0.20 µm pore size Minisart syringe-driven filter unit (Sartorius, 
Goettingen GER). Unless stated otherwise, liquid cultures were grown in Luria-Bertani 
(LB) broth at 37°C with shaking at 250 rpm in a MaxQ 6000 incubator shaker (Thermo 
Scientific, Waltham USA), or an Orbital Mixer Incubator (Ratek, Victoria AUS) for 16-
24 h under aerobic conditions. Growth on solid media was prepared by incubating LB 
Agar (unless stated otherwise) at 37°C for approximately 16-24 h under aerobic 
conditions. Bacterial growth was measured spectrophotometrically by measuring the 
optical density of liquid cultures at 600nm (OD600) using a SpectraMax M2e Plate Reader. 
For long term storage, 1 mL of an overnight culture inoculated from a single colony was 
mixed with 1 mL of sterile 20% glycerol in LB broth (v/v).  Alternatively, colonies were 
stored directly from solid media by inoculating 1 mL of 10% glycerol in LB broth (v/v) 
with a sterile swab before being stored at -80°C. 
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Table 2.2: Bacterial Strains used in this study 
Strain Isolate Number Features Source/Reference 
E. coli IM08B Chloramphenicol Sensitive (Monk et al., 2015) 
S. aureus RN4220 Restrictionless derivative of NCTC 8325-4 (Kreiswirth et al., 1983) 
S. aureus Sa375 MRSA, VISA Liverpool Hospital 
S. aureus Sa0057 MRSA, VSSA Liverpool Hospital 
E. faecium  Efm0003 VRE, VanB Royal Prince Alfred Hospital 
E. faecium Efm0008 VRE, VanA Royal Prince Alfred Hospital 
 
 
 
Table 2.3: Clinical Gram-Negative Isolates Selected for MIC Testing 
P. aeruginosa E. coli K. pneumoniae 
Isolate No. Hospital Isolate No. Hospital Isolate No. Hospital 
Pa0001 RPA Ec0002 - Kp0001 Bankstown 
Pa0005 RPA Ec0003 - Kp0002 Bankstown 
Pa0010 RPA Ec0004 BH Kp0003 RPA 
Pa0015 RPA Ec0005 - Kp0004 BH 
Pa0020 RPA Ec0006 - Kp0005 BH 
Pa0025 RPA Ec0007 - Kp0007 Liverpool 
Pa0030 RPA Ec0008 - - - 
Pa0035 RPA Ec0009 - - - 
 
 
 
Table 2.4: Clinical MRSA Isogenic Isolate Series Selected for MIC Testing 
Series Isolate Number Isolate Type Phenotype 
A 
Sa0048 Initial VSSA 
Sa0049 Persistent VSSA 
Sa0050 Persistent hVISA 
B 
Sa0016 Initial hVISA 
Sa0018 Recurrent hVISA 
Sa0067 Recurrent hVISA 
Sa0020 Persistent hVISA 
Sa0070 Recurrent hVISA 
Sa0054 Recurrent hVISA 
C 
Sa0057 Initial VSSA 
Sa0058 Persistent hVISA 
Sa0059 Persistent VISA 
Sa0060 Persistent hVISA 
Sa0378 Persistent VISA 
Sa0375 Persistent VISA 
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Table 2.5: Clinical MRSA Isogenic Isolate Pairs Selected for MIC Testing 
Pair Isolate Number Isolate Type Phenotype 
A Sa0040 Initial hVISA Sa0012 Recurrent hVISA 
B Sa0227 Initial VSSA Sa0328 Recurrent VSSA 
C Sa0307 Initial VSSA Sa0365 Persistent VSSA 
D Sa0243 Initial VSSA Sa0194 Persistent VSSA 
E Sa0138 Initial VSSA Sa0116 Persistent VSSA 
F Sa0015 Initial hVISA Sa0019 Recurrent hVISA 
G Sa0309 Initial VSSA Sa0238 Persistent VSSA 
H Sa0283 Initial VSSA Sa0284 Persistent VSSA 
I Sa0212 Initial VSSA Sa0214 Recurrent VSSA 
J Sa0158 Initial VSSA Sa0160 Persistent VSSA 
K Sa0343 Initial VSSA Sa0191 Recurrent VSSA 
L Sa0037 Initial hVISA Sa0044 Recurrent hVISA 
M Sa0237 Initial VSSA Sa0285 Persistent VSSA 
N Sa0051 Initial hVISA Sa0052 Persistent hVISA 
O Sa0331 Initial VSSA Sa0332 Persistent VSSA 
P Sa0255 Initial VSSA Sa0256 Persistent VSSA 
Q Sa0294 Initial VSSA Sa0192 Persistent VSSA 
R Sa0014 Initial VSSA Sa0017 Recurrent VISA 
S Sa0228 Initial VSSA Sa0265 Persistent VSSA 
T Sa0055 Initial VSSA Sa0056 Recurrent hVISA 
U Sa0091 Initial VSSA Sa0162 Persistent VSSA 
V Sa0304 Initial VSSA Sa0305 Persistent VSSA 
W Sa0006 Initial VSSA Sa0011 Recurrent hVISA 
X Sa0068 Initial hVISA Sa0047 Persistent VSSA 
Y Sa0329 Initial VSSA Sa0330 Persistent VSSA 
Z Sa0322 Initial VSSA Sa0324 Persistent VSSA 
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Table 2.6: Clinical VRE Isolates Selected for MIC Testing 
Isolate Number Hospital Phenotype 
Efm0092 RPA VSE 
Efm0093 RPA VSE 
Efm0097 RPA VSE 
Efm0100 RPA VSE 
Efm0103 RPA VSE 
Efm0136 RPA VSE 
Efm0138 RPA VSE 
Efm0200 RPA VSE 
Efm0219 RPA VSE 
Efm0222 RPA VSE 
Efm0174 RPA VanB 
Efm0209 RPA VanB 
Efm0202 RPA VanB 
Efm0151 RPA VanB 
Efm0180 RPA VanB 
Efm0218 RPA VanB 
Efm0217 RPA VanB 
Efm0160 RPA VanB 
Efm0128 RPA VanB 
Efm0125 RPA VanB 
Efm0067 QLD VanA 
Efm0072 MH VanA 
Efm0076 MH VanA 
Efm0081 AH VanA 
Efm0087 AH VanA 
Efm0234 Wollongong VanA 
Efm0236 Wollongong VanA 
Efm0315 St George VanA 
SVH193 RPA VanA 
SVH228 RPA VanA 
 
 
 
Table 2.7: Clinical VRE Isogenic Isolate Series Selected for MIC Testing 
Series Isolate Number Isolate Type 
A 
Efm0006 Initial 
Efm0007 Persistent 
Efm0010 Persistent 
Efm0027 Persistent 
Efm0028 Persistent 
Efm0029 Persistent 
Efm0030 Persistent 
Efm0031 Persistent 
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Table 2.8: Media used for Culturing Bacteria 
Media Composition Reference 
Luria-Bertani Broth 
171 mM NaCl 
63.5 mM Tryptone 
0.5 % Yeast Extract 
(Willetts and Finnegan, 1970) 
LB Agar 
171 mM NaCl 
63.5 mM Tryptone 
0.5 % Yeast Extract 
1.2 % Agar 
(Willetts and Finnegan, 1970) 
Mueller Hinton Broth 
2% Beef Extract 
17.5% Casein Hydrolysate 
1.5% Starch 
Becton Dickinson 
(California, USA) 
Mueller Hinton Agar 
2% Beef Extract 
17.5% Casein Hydrolysate 
1.5 % Starch 
1.7% Agar 
Becton Dickinson 
(California, USA) 
Brain Heart Infusion Agar  
0.77% Calf Brains 
0.98% Beef Heart 
1% Proteose Peptone 
0.2% Dextrose 
0.5% Sodium Chloride 
0.25% Disodium Phosphate 
1.5% Agar 
Becton Dickinson 
(California, USA) 
 
B2 Broth 
1% Casein Hydrolysate 
27.8 mM Glucose 
5.7 mM di-Potassium bis 
orthophosphate 
428 mM NaCl 
2.5% Yeast Extract 
(Schenk and Laddaga, 1992) 
Tryptic Soy Broth 
13.9 mM Glucose 
1.7% Peptone 
0.3% Peptone (Soy) 
14.3 mM di-Potassium bis 
orthophosphate 
85.5 mM NaCl 
- 
 
Table 2.9: Stock Concentration and Solvent used for Antibiotics 
Antibiotic Stock Concentration (μg/mL)/Solvent 
BDM-I 10/DMSO 
Vancomycin 10/H2O 
Daptomycin 10/H2O 
Chloramphenicol 10/Methanol 
Ceftaroline dihydrochloride 10/DMSO 
Flucloxacillin 10/H2O 
Erythromycin 10/H2O 
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2.4 Transformation of E. coli 
 
2.4.1 Preparation of Chemically Competent E. coli 
Overnight cultures of the strain of interest were grown from a single, well isolated colony 
in LBB. 200 µL of the O/N culture was then inoculated into 10 mL of sterile LBB and 
grown until an OD600 of 0.5 was reached. Cells were then harvested at 5000 x g for 8 min 
at 4°C, then resusupended in 5 mL of ice-cold 100 mM MgCl2. Cells were then harvested 
again and resuspended in 1 mL of ice-cold 100mM CaCl2 and allowed to sit on ice. 
Glycerol was then added to a final concentration of 16% (v/v) before the cells were 
separated into 100 µL aliquots and stored at -80°C. 
 
2.4.2 Transformation of Chemically Competent E. coli 
100 µL aliquots of chemically competent cells (section 2.4.1) were thawed on ice prior to 
use. Typically, 5 µL of purified plasmid DNA (section 2.5.2) equating to approximately 
1 µg of DNA was added to a 100 µL aliquot and mixed by pipetting before being 
incubated on ice for 30 min. The cells were then heat-shocked by rapidly heating them to 
42°C for 1 min, then allowing them to recover on ice for 10 min. 1 mL of LBB was then 
added to the transformed cells, which were then incubated for 1 h at 37°C with shaking. 
The transformed cells were then plated onto solid LB agar supplemented by an 
appropriate antibiotic, before being incubated at 37 °C for 16-24 h. Single, well isolated 
colonies were then screened for successful transformation using PCR (section 2.6.1) or 
restriction endonuclease digestion (section 2.6.2).   
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2.5 Routine DNA Procedures 
 
2.5.1 Isolation of Genomic DNA for Sequencing and Cloning 
Genomic DNA used for sequencing and cloning reactions was isolated using the 
ISOLATE II Genomic DNA Kit (Bioline) as per the manufacturer’s instructions. For hard 
to lyse bacteria, additional steps were required for cell lysis. Briefly, a single isolated 
colony of the strain of interest was inoculated into 10 mL of LBB and incubated overnight 
at 37°C with shaking. The cells were then harvested from a 1 mL aliquot of the overnight 
culture (5000 x g / 8 min / RT) and resuspended in pre-prepared lysis buffer (20 mM 
Tris/HCl; 2 mM EDTA; 1% Triton X‐100; pH 8) supplemented with lysozyme (20 
mg/mL) or lysostaphin (0.2 mg/mL) before being incubated for 45 min at 37°C. 25 µL of 
Proteinase K (20 mg/mL) was then added and the suspension was incubated at 56°C for 
a further 30 min. Subsequent steps were then completed as per the manufacturer’s 
instructions, with isolated DNA being eluted in 70-100 µL of sterile Milli-Q water. 
Isolated DNA was quantified using either a Nanodrop (ThermoFisher) or Qubit 2.0 
Fluorometer (ThermoFisher).  
 
2.5.2 Isolation of Plasmid DNA for Cloning, Screening and Sequencing 
Plasmid DNA used for downstream molecular reactions was isolated from E. coli using 
the ISOLATE II Plasmid Mini Kit (Bioline) as per the manufacturer’s instructions. For 
isolation of plasmid DNA from S. aureus, a pre-incubation step was required for efficient 
cell lysis. Briefly, a single isolated colony of the strain of interest was inoculated into 10 
mL of LBB supplemented with the appropriate antibiotic, before being incubated for 16h 
at 37°C with shaking. The cells were then harvested with centrifugation (5000x g / 8 min 
/ RT) and resuspended in 250 µL of Resuspension Buffer P1 supplemented with 
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lysostaphin (0.2 mg/mL) and incubated for 45 min at 37°C. Subsequent steps were then 
completed as per the manufacturer’s instructions, with isolated DNA being eluted in 50 
µL of sterile Milli-Q water. 
 
2.5.3 Agarose Gel Electrophoresis 
DNA fragments were separated using electrophoresis through horizontal agarose gels 
following standard biological methods. Typically, 1.5% agarose gels were used to resolve 
DNA fragments ranging in size from 0.2 to 10 Kb using the HyperLadderÔ 1Kb 
molecular weight marker (Bioline). Agarose was dissolved in 0.5X TBE Buffer (45 mM 
Tris(hydroxymethyl)aminomethane; 45 mM Boric Acid; 1 mM EDTA) prior to casting. 
5X DNA loading buffer (Bioline) was then mixed with samples at a ratio of 1:5 before 
the samples were loaded into the gel. Electrophoresis was carried out at 200 V until the 
dye front had reached the final quarter of the length of the gel. Staining was completed 
by immersing the gel in Ethidium bromide (1 mg/L) for approximately 30 min, followed 
by visualization and imaging using a GelDoc-It TS Imaging System (UVP). 
 
2.6 Recombinant DNA Methods 
 
2.6.1 Polymerase Chain Reaction 
Polymerase chain reactions (PCRs) were carried out in 50 µL reactions containing 
approximately 200 ng of DNA, using either AccuzymeÔ DNA Polymerase (Bioline) or 
the 2X MyTaqÔ Mix (Bioline). In the case of the former, DNA was combined with 1 U 
Accuzyme, 0.1 mM dNTP mix and 20 µM of each primer. For the latter, DNA was mixed 
with the 2X MyTaq Mix and 20 µM of each primer. Reactions were carried out in 0.2 mL 
PCR tubes using a C1000 Thermal Cycler (Bio-Rad). Standard cycling conditions 
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included a 5 min denaturation at 95°C, a 30 sec annealing step at 55 to 65°C (depending 
on primers used), and 45 sec extension step which were repeated 35 times, before a final 
extension step for 5 min. PCR products were visualised using Agarose gel electrophoresis 
(section 2.5.3) and purified using the ISOLATE II PCR and Gel Kit (Bioline) as per the 
manufacturer’s instructions. 
 
Table 2.10 Primer Names and Nucleotide Sequence 
Namea Nucleotide sequence (5’-3’) Target 
VRE mutant sequencing primers 
atpD-F CACCTTTCCCAGAAGATG Upstream of atpD gene in E. faecium 
atpD-R GATACTTCAGATCCAGCTTGAG Downstream of atpD gene in E. faecium 
atpD-F2 CATTTGGATGCGACAACC Upstream of atpD gene in E. faecium 
atpC-R GCTGCATGGTGATCATAGAC Downstream of atpC in E.faecium 
atpA-F GACCGTAAAACAGGGAAAACT Upstream of atpA gene in E. faecium 
murA2-R TGACGTCCTTTCTAACGATTG 
Downstream of 
murA2 gene in E. 
faecium 
walK cloning primers 
walK(Bam)-F ATAGGATCCACAACAAGTTGAACGTGAGCG Upstream of G560S mutation in walK 
walK(Xho)-R ATACTCGAGCGCATTCATGTTCAGTACTTGG 
Downstream of 
G560S mutation in 
walK 
aOligonucleotides are grouped under experimental subheadings. 
 
2.6.2 Restriction Endonuclease Digestion and Ligation 
Restriction endonuclease enzymes and associated buffers were acquired from New 
England Biolabs and used according to the manufacturer’s instructions. Double digests 
were completed using the recommended double digest buffer for both enzymes used. 
Following digestion, reactions were purified using the ISOLATE II PCR and Gel Kit 
before ligation experiments. Purified DNA fragments were diluted to a vector:insert ratio 
of 1:7 in a 20 µL volume containing 1 U of T4 DNA Ligase (New England Biolabs) and 
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1X T4 DNA ligase reaction buffer. Ligation reactions were incubated overnight at 4°C 
overnight in a C1000 thermal cycler then heat deactivated at 70°C for 10 min. 
 
2.7 Minimum Inhibitory Concentration (MIC) Determination 
 
2..7.1 Broth Microdilution Method 
Determination of MICs was completed according to the guidelines outlined by the 
Clinical and Laboratory Standards Institute Broth Microdilution Method (CLSI M07-A9, 
2012). Initially the inoculum was prepared using the direct-colony suspension method 
and diluted to obtain a final concentration of 5x105 colony forming units (Cfu/mL) for 
each organism. A series of BDM-I dilutions were then prepared (10-1 μg/mL) in MHB 
and 100 μL was pipetted into a single column of a sterile 96 well plate. Following this, 
10 μL of each bacterial suspension was inoculated in duplicate into the respective rows 
of the 96-well plate and incubated at 37°C for 16-24 h. Results were obtained upon visual 
inspection for growth, and the MIC determined as the concentration of BDM-I at which 
growth was first inhibited. 
 
2..7.2 Agar Dilution Method 
Additional MIC tests were performed using the Agar dilution Method according to the 
Clinical and Laboratory Standards Institute (CLSI M07-A9, 2012). MHA agar plates 
were prepared and supplemented with a range of BDM-I concentrations (5-1 μg/mL). The 
bacterial inoculum was then prepared as described in section 2.7.1, differing in that the 
final concentration required was 1x107 CFU/mL. 2 μL of each inoculum was then 
pippeted onto three isolated areas of agar in triplicate, for each concentration of BDM-I 
as well as MHA with no BDM-I. The plates were then incubated for 16-24 h at 37°C, 
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with MICs being determined as the lowest concentration of BDM-I which inhibited 
growth. 
 
2.8 Synergy Studies using Checkerboard Assays 
 
BDM-I synergism was determined using the checkerboard method as described by the 
literature (Orhan et al., 2005, Sopirala et al., 2010). Antibiotic dilutions were prepared in 
MHB at double the desired concentration and combined in equal volumes (50 μL) into a 
single well of a sterile 96-well plate. The final concentration range for each antibiotic was 
as follows; 5-0.25 μg/mL BDM-I, and two-fold dilutions of vancomycin from 16-0.0625 
μg/mL. 10 μL of the prepared bacterial suspension (diluted to 1x105 Cfu) was then 
inoculated into each well, and the plate then incubated at 37°C for 16-24 h overnight. 
MIC values were then determined as described by the CLSI for broth microdilution 
testing. Determination of the fractional inhibitory concentration index (FICI) was 
calculated with the equation: FICI = FIC A + FIC B, where FIC A is the MIC of drug A 
in combination divided by the MIC of drug A alone, and FIC B is the same for drug B. 
FICI values were then determined as follows: FICI of ≤0.5 indicates synergy, FICI of 
>0.5 to ≤1 indicates additivity, FICI of >1 to ≤4 indicates no interaction and FICI of >4 
indicates antagonism (Sopirala et al., 2010). 
 
2.9 BDM-I Resistance Induction 
 
BDM-I resistance induction experiments were completed on two MRSA isolates, Sa057 
(VSSA) and Sa375 (VISA) and two VRE isolates, Efm003 (VanB) and Efm008 (VanA) 
in triplicate series over a period of approximately 70-110 days. Isolates were passaged 
daily in 10 mL Luria Bertani broth (LBB) supplemented with sub inhibitory 
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concentrations of BDM-I, which was gradually increased as growth was observed. During 
this time, isolates were stored at -80°C and subjected to additional MIC testing in order 
to confirm changes in BDM-I MICs. 
 
2.10 Whole Genome Sequencing of Mutant Isolates 
 
2.10.1 Library Preparation 
DNA libraries were constructed using 1 µg of purified genomic DNA (section 2.5.1) 
extracted from mutant isolates.  Using the NEBNext Fast DNA Fragmentation & Library 
Prep Set for Ion Torrent (New England Biolabs) and the Ion Xpress Plus fragment library 
kit (Life Technologies), 400 bp barcoded libraries were generated as per the 
manufacturer’s instructions. The barcoded libraries were then amplified using a thermal 
cycler and subsequently purified using the Agencourt AMPure XP Reagent (Beckman 
Coulter). The purified libraries were then combined and bound to Ion Sphere™ Particles 
for enrichment and clonal amplification using an Ion OneTouch™ 2 System (Life 
Technologies) as per the manufacturer’s instructions. Quantification of the amplified 
library was completed using a Qubit 2.0 Fluorometer (Life Technologies). The DNA 
samples were loaded onto an Ion 318TM v2 chip (Life Technologies) and sequenced 
according to the manufacturer’s instructions.  
 
2.10.2 Analysis of Sequencing Reads and Confirmation of Mutations 
Whole genome sequencing reads were analysed using CLC Genomics Workbench 
ver.7.0.3 (CLCbio). Briefly, mutant reads were mapped to a reference genome (AUS004 
or JKD6008) before variant detection was completed using a minimum coverage of 10 
and a minimum variant frequency of 95%. Detected variants were then filtered to identify 
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mutations which caused changes to the amino acid sequence. Confirmation of significant 
mutations was carried out through Sanger Sequencing (Macrogen) of PCR fragments 
which amplified regions of interest (section 2.6.1).  
 
2.11 Allelic Exchange of S. aureus Mutant G560S 
 
Allelic exchange experiments were completed using mutant Sa375 isolates produced in 
section 2.9 and sequenced in section 2.11. Allelic exchange was completed using the 
system outlined by Monk et al with the vector pIMAY-Z (Figure 2.1) (Monk et al., 2015). 
pIMAY-Z and the E. coli strain IM08B were supplied by Dr Ian Monk from the Doherty 
Institute in Melbourne, Australia.  
  
Figure 2.1: Plasmid Map of pIMAY-Z 
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2.11.1 Plasmid Vector and PCR Insert Isolation 
Due to the low copy number of pIMAY-Z, 3x cultures of IM08B cells containing pIMAY-
Z were incubated overnight in LBB supplemented with chloramphenicol (10 μg/mL). The 
cells were harvested at 5000xg for 8 min, and pIMAY-Z was then extracted using the 
ISOLATE II Plasmid Mini Kit (section 2.5.2) and stored at 4°C. 
 
Genomic DNA was extracted from a mutant Sa375 isolate using the Isolate II Genomic 
DNA extraction kit (section 2.5.1). PCR was then performed (section 2.6.1) using the 
primers described in Table 2.9 to amplify the region containing the mutation of interest. 
 
2.11.2 Cloning of Insert into pIMAY-Z 
Cloning was performed by digesting 1 μg of pIMAY-Z and PCR product using BamHI 
and XhoI according to the manufacturer’s instructions (section 2.6.2). Ligation was then 
performed (section 2.6.2) prior to the ligation mixture being transformed into chemically 
competent IM08B cells (section 2.4), then plated onto LBA (CML10; XGAL20) and 
incubated overnight at 37°C. Successful plasmid constructs were confirmed using colony 
PCR, restriction digests of isolated plasmid, and sanger sequencing performed by the 
Australian Genome Research Facility (Sydney AUS).  
 
2.11.3 Electroporation of Constructs into the Progenitor Sa375 Isolate 
Electrocompetent cells were prepared from the progenitor Sa375 isolate as described by 
Monk et al (Monk et al., 2012). Briefly, a 10 mL overnight culture of Sa375 was diluted 
to an OD600 of 0.5 into 25 mL of pre-warmed TSB, and incubated at 37°C with shaking 
(250rpm) for 30 min. The culture was then placed on ice for 10 min before the cells were 
harvested at 5000xg for 8 min at 4°C. The cells were then washed twice with ice cold, 
sterile Milli-Q water (20 mL then 15 mL), followed by three washes with ice cold, sterile 
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10% glycerol (10 mL, 5 mL then 2 mL). Following the final wash, the cells were 
resuspended in 1 mL of ice cold 10% glycerol and separated into 50 μL aliquots, before 
being stored at -80°C. 
 
Electrocompetent Sa375 cells were thawed before electroporation, harvested at 5000xg 
for 5 min then resuspended in 50 μL of electroporation buffer (10% glycerol, 200 mM 
sucrose). Up to 20 μL of plasmid construct was then mixed with the cells, before the total 
volume was transferred to a 0.1 cm Gene Pulser Electroporation Cuvette (Bio-Rad). 
Electroporation was then carried out using a Gene Pulser Xcell (Bio-Rad) at 21 kV/cm, 
100 Ω, 25 μF. Immediately after electroporation, 750 μL of pre-warmed (28°C) recovery 
media (TSB with 200 mM sucrose) was added to the cells, then transferred to a 1.5 mL 
Eppendorf tube and incubated for 1 h at 28°C. The cells were then plated on BHIA 
(CML10) and incubated for 48 h at 28°C. 
 
2.11.4 Selection of Recombinant Colonies 
A single colony was then resuspended in 200 μL of TSB, and serial diluted to 10-3 before 
being plated onto BHIA (CML10 XGAL100) and then incubated overnight at 37°C. Blue 
colonies were then streaked onto fresh BHIA (CML10 XGAL100) and incubated 
overnight at 37°C. 10mL of TSB was then inoculated with a single blue colony and grown 
overnight at 28°C without antibiotic to promote plasmid loss. Serial dilutions of the 
overnight culture were then prepared to a final value of 10-6 before being plated onto 
BHIA (XGAL100) and then incubated overnight at 37°C. White colonies were then 
patched onto duplicate plates of BHIA (XGAL100) and BHIA (CML10 XGAL100) and 
incubated overnight at 37°C. White, chloramphenicol sensitive colonies were then 
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selected as potential integrants. Confirmation of the successful integration of G560S into 
the progenitor Sa375 walK gene was carried out by sanger sequencing (Macrogen) 
 
2.12 Transmission Electron Microscopy (Analysis of Cell Wall Thickness) 
 
Transmission electron microscopy (TEM) was completed on Sa375 mutants following 
whole genome sequencing. Overnight cultures of each mutant Sa375 isolate as well as 
the progenitor Sa375 and Sa057 isolates were centrifuged and re-suspended in a 2.5% 
Glutaraldehyde solution in 0.1M cacodylate buffer (pH 7.4). Following fixation for at 
least 4 h, the buffer was exchanged with 2% Osmium tetroxide and rinsed with Sodium 
acetate, and finally stained with Uranyl acetate for 60 min. The samples were then 
dehydrated in alcohol then infiltrated with Spurr resin in acetone (1:1) for 30 min, then 
again in 6:1 resin for 22 h. Polymerisation of samples was then allowed to carry out for 
15 h at 70°C before being cut and imaged using a Morgagni 268D transmission electron 
microscope (FEI, Eindhoven, The Netherlands) at 80 kV and fitted with a Soft Imaging 
Systems MegaView III CCD camera (Munster, Germany). Images were analysed using 
the Olympus Soft Imaging Systems AnalySIS software (Olympus) by measuring the 
thickness of 10 separate cells a total of 10 times. The average thickness and standard 
deviation were then determined for each isolate. 
 
2.13 Proteomic (2D-Gel) Analysis of BDM-I Treated E. faecium 
 
Initially, 2-D Gel Electrophoresis coupled with mass spectrometry was used to examine 
changes to the proteome in BDM-I treated and mutant VRE isolates. All experimental 
work was carried out in collaboration with Professor Jens Coorssen at the Proteomics 
Research Group at Western Sydney University (School of Medicine, WSU).  
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2.13.1 Sample Preparation 
An overnight culture (LBB) was used to inoculate 500 mL of fresh LBB and incubated 
until an OD600 of approximately 0.45 was obtained. The cell pellets were then harvested 
at 16000 x g for 10 min at 4°C. Harvested cells were washed with PBS then homogenised 
using a Mikro-Dismembrator (Sartorius) at 2000 rpm for 90 s and cooled in liquid N2, the 
samples were then stored at -80°C until required. Samples were prepared for protein 
extraction via treatment with 3x volume of 20 mM HEPES (lysis buffer) and 2x cold PBS. 
Subsequently, ultracentrifugation was performed at 124, 436 g for 3 h at 4°C in a 
Beckman Coulter Optima L-100 XP ultracentrifuge. Following centrifugation, the 
supernatant (containing soluble proteins) was collected and snap frozen before being 
stored at -80°C until required. The remaining pellet was washed with cold 20 mM HEPES 
buffer, resuspended and centrifuged at 124, 436 g for 30 min. The supernatant was 
discarded, and the pellet resuspended in 500 µL of total protein extraction buffer (8 M 
urea, 2 M thiourea, 4% CHAPS, 1x protease inhibitors). Samples were then centrifuged 
at 1000 rpm in a bench top centrifuge at 4°C for 2-5 min. The supernatant was then 
collected (containing membrane proteins) and stored at -80°C. Protein estimation was 
then performed using the fluorescent dye method with BSA as a standard.  
 
2.13.2 1st and 2nd Dimension Separation 
Protein samples were diluted to a maximum concentration of 100 µg/mL in preparation 
for isoelectric focusing using 7 cm IPG strips (pH 3-10, Bio-Rad). Initially, diluted 
protein samples were mixed with 58.8 µL total protein extraction buffer, then a further 
58 µL of protein extraction buffer containing 2% ampholytes. Disulfide reduction of 
protein samples using 2.3 µL TBP/DTT disulfide reduction buffer (2.3 mM tributyl 
phosphine and 45 mM DTT) was completed prior to alkylation. Alkylation was 
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performed using 5.1 µL of alkylation buffer (230 mM acrylamide monomer). Each 
reaction was performed at 25°C for 60 min. 125 µL of protein sample was then pipetted 
into a clean rehydration tray (Bio-Rad) before a 7 cm IPG strip was placed over the top 
and subsequently left for 16 h at room temperature (RT). Isoelectric focusing was then 
conducted at 17°C within a Protean IEF Cell (Bio-Rad). Initially, 250 V of current was 
applied for 15 min, which was subsequently increased to 4000 V at 50 µA/gel over the 
course of 2 h, with electrode wicks being changed when the current decreased. IEF was 
then continued at 4000 V for 9 h.  
 
Upon completion of IEF, IPG strips were equilibrated by soaking in 2 mL of equilibration 
buffer #1 (2% DTT) for 10 min at RT, then in 2 mL of equilibration buffer #2 (350 mM 
acrylamide monomer) for 10 min at RT. Equilibrated IPG strips were then transferred to 
a 2nd dimension, 12.5% SDS-PAGE stacking gel (1 mm thick), and overlaid with 0.5% 
agarose containing 0.1% SDS and 375 mM Tris (pH 8.8). Electrophoresis was performed 
at 90 V overnight at 4°C for complete separation. Gels were subsequently washed and 
stained with Sypro Ruby (Bio-Rad) in preparation for imaging and analysis with the 
program Delta2D (Decodon, Greifswald, GER). 
 
2.14 Proteomic (shotgun) Analysis of BDM-I Treated E. faecium and S. aureus 
 
Shotgun proteomics was completed in collaboration with Professor Stuart Cordwell’s 
Laboratory (School of Life and Environmental Sciences, USYD) on BDM-I treated 
Sa057 and Efm008 isolates. 
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2.14.1 Sample Preparation and Peptide Enrichment 
Overnight cultures of each isolate (LBB) were used to inoculate 10 mL of fresh LBB to 
an OD600 of 0.05. The cultures were then treated with BDM-I at MIC50 (1.5 μg/mL for 
Sa057, 4 μg/mL for Efm008) or DMSO (vehicle control) and incubated for approximately 
2.5 h until an OD600 of »0.45-0.5 was reached, indicating the cells were in the mid-
exponential phase. The cells were then harvested at 5000xg at 4°C and washed 2x with 
ice cold PBS, before the pellets were frozen at -80°C. Frozen, washed bacterial cell pellets 
were then lyophilised overnight and kept at -80C until required. Pellets were resuspended 
in tissue lysis buffer containing 150mM Tris-HCl, 125mM NaCl and 0.1mm acid-washed 
glass beads (Sigma). The cells were lysed by four rounds of bead-beating (4 m/s, 1 min) 
with 1 min rest periods on ice. Cell debris was removed by centrifugation for 15 min at 
4oC at 16 000 x g. 250 µL of sample was mixed with ice-cold water/methanol/chloroform 
in a ratio of 3:4:1 to precipitate proteins. Proteins were resuspended in 6 M urea, 2 M 
thiourea and reduced with dithioerythritol (DTT; 10mM) at 37oC for 1 h followed by 
alkylation with iodoacetamide (IAA; 20mM) for 1 h at room temperature in the dark. 
Samples were then diluted 10-fold in 100mM triethylammoniumbicarbonate (TEAB) and 
quantified using the Qubit protocol (Life Technologies). Samples were digested with 
trypsin in a ratio of 1:50 enzyme/sample for 16 h at 37oC. Lipids were precipitated using 
formic acid (FA) to a final concentration of 2% and pellets removed by centrifugation at 
16 000 x g for 15 min at 4oC. 
 
Supernatants were acidified with trifluoroacetic acid (TFA) to a final concentration of 
0.1%, and peptide purification was performed using 60 cm3 hydrophilic lipophilic balance 
(HLB) cartridges (Waters Corp., Bedford, MA). Cartridges were activated with 100% 
methanol (1 volume), followed by 100% acetonitrile (1 volume) and 70% acetonitrile / 
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0.1% TFA (1 volume). The cartridges were equilibrated with 0.1% TFA (2 volumes) and 
loaded with peptide sample. Samples were reapplied three times to ensure sufficient 
binding, washed with 0.1% TFA, and eluted with 70% acetonitrile / 0.1% TFA (1 
volume). Samples were then lyophilised, resuspended in 90% ACN / 0.1% TFA, then 1 
μg was aliquoted and dried in a vacuum centrifuge prior to LC-MS/MS. 
 
2.14.2 LC-MS/MS of Enriched Peptides 
Peptides were resuspended in 0.1% formic acid and separated on a Dionex 3500RS 
coupled to a Q-Exactive Plus with Tune v2.4.1824 in positive polarity mode. Peptides 
were separated using an in-house packed 75 m 55 cm pulled column (1.9 m particle size, 
C18AQ; Dr Maisch, Germany) with a gradient of 2–30% MeCN containing 0.1% formic 
acid over 120 min at 250 nl/min at 55 °C. An MS1 scan was acquired from 350 –1550 
m/z (70,000 resolution, 3e6 AGC1, 100 ms injection time) followed by MS/MS data-
dependent acquisition of the 20 most intense ions with higher collision dissociation 
(HCD) (17,500 resolution, 1e5 AGC, 60 ms injection time, 27 normalized collision 
energy (NCE), 1.2 m/z isolation width). The top 20 most abundant ions were selected for 
MS/MS by higher energy collisional dissociation (HCD). A total of n=3 replicates were 
performed for each treatment group. 
 
2.14.3 Analysis of Proteome Data 
Total proteome data from bacteria were identified and quantified separately with 
MaxQuant (1.6.0.16) against the Uniprot Staphylococcus aureus subsp. aureus str. 
JKD6008 proteome (4/2/17, 2652 proteins) and Uniprot Enterococcus faecium (strain 
Aus0004) proteome (4/2/17, 2826 proteins) with default settings of 20 and 4.5 ppm for 
first and main search precursor tolerance, respectively. The peptides were searched using 
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the MaxQuant LFQ algorithm for normalisation allowing for two full missed tryptic 
cleavages. Oxidation of methionine, protein N-terminal acetylation, 
carbamidomethylation of cysteine were set as variable modifications. The requantify 
option was enabled with a minimum of two unique + razor peptides used for protein 
quantification. All data were searched with both peptide spectral match and protein false 
discovery rate (FDR) set to 1%. Proteins were included for analysis if they contained ≥2 
peptides mapping. Proteins only occurring in only one replicate in either group were 
discarded, and missing values for remaining proteins were imputed from a normal 
distribution using Perseus (v 1.6.07). Multiple t-tests were performed on log2 transformed 
LFQ intensities, with a FDR cutoff of padj <0.05. A log2 difference of ≥2-fold was 
considered differentially expressed between groups for statistically significant results. 
 
2.15 DARTS Analysis of BDM-I Treated Cell Supernatant 
 
Drug Affinity Responsive Target Stability (DARTS) has previously been described as a 
viable method for the identification of small molecule targets. The methodology used was 
adapted from that described by Pai et al for target identification in yeast (Pai et al., 2015).   
 
2.15.1 Cell Lysate Preparation and Drug Treatment 
An overnight culture of Sa057 was diluted into 500 mL of pre-warmed LBB to an OD600 
of 0.05, which was then incubated for approximately 2.5 h at 37°C with shaking (250 
rpm). The cells were then harvested at 5000xg for 10 min at 4°C, then washed twice with 
25 mL of sterile, ice-cold PBS. The cells were then resuspended in 2 mL of lysis buffer 
(20mM Tris-HCl, 2mM EDTA, 1% Triton X-100, pH 8) supplemented with lysostaphin 
and 1X cOmplete protease inhibitors (Roche) before being incubated at 37°C for 45 min 
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in a water bath. The cells were then sonicated using a Q55 Probe Sonicator (Qsonica) at 
an amplitude of 50 in 3x3 sec bursts. The suspension was then centrifuged for 20 min at 
21 000xg at 4°C, before the lysate was transferred to a 1.5 mL Eppendorf and kept on ice. 
The protein lysate was then quantified using the Pierce BCA Protein Assay Kit 
(ThermoFisher), before the lysate was stored at -20°C. 
 
The protein lysate was diluted to a concentration of 4 mg/mL in 1X TNC buffer (100 mM 
Tris-HCl, 500 mM NaCl, 100 mM CaCl, pH 8.0), before 99 μL aliquots were prepared in 
3x separate Eppendorf tubes. In the first tube, 1 μL of DMSO was added as a control, and 
1 μL of BDM-I at MICx1 and MICx5 were added to the two remaining aliquots, which 
were then incubated at 25°C for 30 min with shaking (250 rpm). Pronase (Sigma-Aldrich) 
stocks were prepared at protein:pronase concentrations of 1:50, 1:100, 1:250 and 1:500 
in 1X TNC buffer and kept on ice. Following incubation, each sample was separated into 
4 x 20 μL aliquots and inoculated with 2 μL of each pronase solution, then incubated for 
exactly 30 min at 25°C. Following incubation, protein digestion was stopped with the 
addition of 1.6 μL of 25X protease inhibitors (Roche) followed by incubation on ice for 
10 min.  
 
2.15.2 SDS-PAGE Electrophoresis and Staining 
5X SDS-PAGE buffer was then added to each sample and incubated at 70°C for 10 min. 
13 μL of each sample was then loaded onto a 4-15% Mini-Protean (Bio-Rad) gel and run 
at 100 V for 90 min at RT. The gels were then incubated for 30 min in a fixing solution 
(40% Methanol, 10% Acetic Acid), followed by 40 min in a staining solution (0.025% 
Coomassie Brilliant Blue, 10% Acetic Acid), and finally 15 min (x3) in a wash solution 
(10% Acetic Acid). The gels were then imaged with white light using a GelDoc-It TS 
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Imaging System (UVP) and analyzed for the presence of additional bands within drug 
treated samples. 
 
2.16 Thermal Proteome Profiling of Whole Cells 
 
Thermal proteome profiling was completed in collaboration with Professor Stuart 
Cordwell’s Laboratory (School of Life and Environmental Sciences, USYD) as described 
by Mateus et al (Mateus et al., 2018). 
 
2.16.1 Sample Preparation 
Four 10 mL cultures of LBB were prepared from an overnight broth of Sa057, which was 
diluted to an OD600 of 0.05 and incubated at 37°C for 150 min. Drug (3 µg/mL) or vehicle 
control (DMSO) was then added to 2x cultures and incubated for a further 10 min. Each 
culture was then harvested at 5000 xg for 8 min at RT and washed with sterile PBS 
(containing drug or DMSO). Cells were then resuspended in PBS to an OD600 of 10 and 
heated to 63°C for 3 min, followed by a 3 min incubation at RT. The cells were then snap 
frozen in liquid nitrogen and stored at -80°C until use. 
 
2.16.2 Peptide Preparation 
Frozen, washed bacterial cell pellets were lyophilised overnight and kept at -80C until 
required. Cell pellets were prepared as in Mateus et al (2018) with the following 
modifications. Solubilized, filtered proteins were resuspended in 6 M urea, 2 M thiourea 
and reduced with dithioerythritol (DTT; 10mM) at 37°C for 1 h followed by alkylation 
with iodoacetamide (IAA; 20mM) for 1 h at room temperature in the dark. Samples were 
then diluted 10-fold in 100mM triethylammoniumbicarbonate (TEAB) and quantified 
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using the Qubit protocol (Life Technologies, Carlsbad, CA). Samples were digested with 
trypsin in a ratio of 1:50 enzyme/sample for 16 h at 37°C. Lipids were precipitated using 
formic acid (FA) to a final concentration of 2% and pellets removed by centrifugation at 
16 000xg for 15 min at 4°C. 
 
Supernatants were acidified with trifluoroacetic acid (TFA) to a final concentration of 
0.1%, and peptide purification was performed using 60 cm3 hydrophilic lipophilic 
balance (HLB) cartridges (Waters Corp., Bedford, MA). Cartridges were activated with 
100% methanol (1 volume), followed by 100% acetonitrile (1 volume) and 70% 
acetonitrile / 0.1% TFA (1 volume). The cartridges were equilibrated with 0.1% TFA (2 
volumes) and loaded with peptide sample. Samples were reapplied three times to ensure 
sufficient binding, washed with 0.1% TFA, and eluted with 70% acetonitrile / 0.1% TFA 
(1 volume).  
 
10 μg of each sample of peptides (n=5 each condition) were aliquoted, lyophilised and 
resuspended in 100mM TEAB and labelled with Tandem Mass TagsTM 10-plex 
(TMT10plex) according to the manufacturer’s protocol (Thermo Fisher Scientific, MA). 
Samples were combined and diluted to 1mL in 0.1% TFA and purified by HLB as 
described above. Labelled samples were lyophilized and stored at -80°C until required. 
 
2.16.3 LC-MS/MS of Peptides 
8 µg of TMT-labelled peptides were separated into 8 fractions by hydrophilic interaction 
liquid chromatography (HILIC) using an Agilent 1100 chromatography system. 
Fractionation was performed using a 20 cm, 320 µm i.d column packed with TSK-Amide 
80 HILIC resin, 3 µm particles size. Samples were resuspended in buffer B (90% 
 
 
73 
acetonitrile / 0.1% TFA) and separated using a linear gradient: sample loading for 10 min 
with 100% buffer B at 12 µL/min, sample elution from 90 - 60% B at 6 µL/min for 40 
min. Peptide elution was monitored by an absorbance detector at 280 ± 4. Fractionated 
samples were lyophilised and stored at -20°C until analysis with mass spectrometry. 
 
Fractionated labelled peptides were resuspended in 0.1% formic acid and separated on a 
Thermo Easy-nLC coupled to a Q-Exactive HF-X with Tune v2.4.1824 in positive 
polarity mode. Peptides were separated using an in-house packed 75 m 50 cm pulled 
column (1.9 m particle size, C18AQ; Dr Maisch, Germany). Peptides were eluted with a 
gradient of 2-30% MeCN containing 0.1% formic acid over 150 min at 300 nl/min at 
60°C. An MS1 scan was acquired from 350 –1650 m/z (60,000 resolution, 3e6 AGC1, 50 
ms injection time) followed by MS/MS data-dependent acquisition of the 15 most intense 
ions with higher collision dissociation (HCD) (60,000 resolution, 1e5 AGC, 75 ms 
injection time, 29 normalised collision energy (NCE), 0.7 m/z isolation width). 
 
2.16.4 Proteomic Data Analysis 
Total proteome data from bacteria were identified and quantified separately with 
MaxQuant (1.6.0.16) against the Uniprot Staphylococcus aureus subsp. aureus str. 
JKD6008 proteome (4/2/17, 2652 proteins) with default settings of 20 and 4.5 ppm for 
first and main search precursor tolerance, respectively. Oxidation of methionine, and 
carbamidomethylation of were set as variable modifications, with a maximum of five 
modified amino acids and allowing for two full missed tryptic cleavages. All data were 
searched with both peptide spectral match and protein false discovery rate (FDR) set to 
1%. HCD MS/MS were deisotoped and searched with a tolerance of 0.002 Da for all 
fragment ions and peptides were searched with 10-plex TMT multiplicity. Total reporter 
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ion intensity for each protein was calculated at the protein level, normalised against the 
summed reporter ion intensity for all proteins including contaminants present in that 
channel. 
 
2.17 ATP Assays 
 
ATP assays were conducted on MRSA and VRE isolates following the observation that 
ATP synthase appears to be affected by BDM-I. Assays were completed on two isolates; 
Sa057 and Efm008 in triplicate using the ATP Bioluminescence Assay Kit HS II (Sigma-
Aldrich). Briefly, growth curves were generated for each isolate plotting OD600 values 
against Cfu/mL to be used as standards to determine culture Cfu/mL. Overnight cultures 
of each isolate were diluted to an OD600 of 0.05 in 2x10 mL LBB and incubated at 37°C 
with shaking (250 rpm) for 30 min. Following incubation, one broth was inoculated with 
BDM-I (MIC50) and the other with an identical volume of the vehicle control (DMSO), 
before being incubated for a further 2 h at 37°C with shaking (250 rpm). Following 
incubation, the OD600 was determined for each culture, then cell lysates were prepared 
according to the manufacturer’s instructions and kept on ice until used. 50 μL aliquots 
were then pipetted in triplicate into individual wells of a Nunclon™ Delta Surface opaque 
96-well plate (Thermo Scientific) and mixed with 50 μL of luciferase reagent. 
Immediately after mixing, luminescence was determined in RLU on a SpectraMax M2e 
Plate Reader (Molecular Devices) at 562 nm. ATP concentrations were determined in 
nmoles using a standard curve and normalized to 105 Cfu for both BDM-I treated and 
control samples. 
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2.18 Plasmid Stability Assays 
 
Stability assays were completed using a mini replicon plasmid (pJEG001) to determine 
the effect of BDM-I on plasmid stability. Assays were completed in triplicate using 
pJEG001, pJEG001 BDM-IMIC0.75, pJEG001 BDM-I MIC75 and a known control 
pJEG005. 10 mL overnight cultures were prepared in LBB containing erythromycin (10 
μg/mL) and incubated at 37°C with shaking for 16-24 h. 1 mL of overnight culture was 
then added to 9 mL of fresh LBB containing erythromycin and incubated at 37°C for 4 h 
with shaking. After incubation, serial dilutions were prepared from 10-1 to 10-6 and spread 
plate onto LB agar. 10 μL was then taken from the 10-1 dilution and inoculated into fresh 
LBB containing appropriate concentrations of BDM-I, and incubated for 16-24 h at 37°C 
with shaking. The following day patch plates were prepared using an overnight spread 
plate with at least 100 counted colonies. Using a new toothpick for each colony, 100 
colonies were patched onto LB agar and LB agar containing erythromycin, before being 
incubated for 16-24 h. Simultaneously, serial dilutions were prepared from each overnight 
broth as described previously, with fresh broths being incubated from the 10-1 dilution. 
This process was repeated daily until 0 patched colonies of pJEG5 were cultured on LBA 
containing erythromycin.    
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Assessing the Clinical Utility of BDM-I Against ESKAPE Pathogens 
 
3.1 Introduction 
 
As discussed in Chapter 1, the current state of antibiotic development is very concerning 
when considering both the number of new antimicrobials in clinical trials, as well as the 
fact that no new antimicrobials currently in development display significant activity 
against gram-negative pathogens. Previous BDM-I studies have identified that it displays 
a broad spectrum of activity in vitro against bacteria, fungi and some protozoa. However, 
preliminary MIC testing has indicated that BDM-I displays a greater range of activity 
against gram-positive species than gram-negative ones, with only H. influenzae, P. 
multocida and N. gonorrhoeae exhibiting MIC values of ≤5 μg/mL (White, 2008). 
Understanding the full range of antimicrobial activity for a novel compound is vital during 
its development, therefore we aimed to assess the potential clinical utility of BDM-I in 
more detail. Using the broth microdilution method (BMD), we aimed to determine the 
MIC of BDM-I against a number of clinical isolates from the previously mentioned 
ESKAPE pathogens, including the gram-negative species P. aeruginosa, E. coli and K. 
pneumoniae, as well as the gram-positive species S. aureus and E. faecium. Additionally, 
MIC testing was also performed using the Agar Dilution Method to test the useability of 
this method with BDM-I, given that the BMD method is not a suitable method for MIC 
determination of several bacterial species (for example, N. gonorrhoea). 
 
Furthermore, induction experiments were performed using select MRSA and VRE 
isolates, in order to determine the useability of BDM-I for extended periods. Specifically, 
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these experiments allowed us to assess the ability of each isolate to generate resistance in 
vitro to BDM-I. 
 
3.2 Assessing the Efficacy of BDM-I Against Gram-Negative Isolates 
 
Based on difficulty in obtaining clinical gram-negative isolates, only 22 were selected 
across three species representing the most common causes of nosocomial infections (8 P. 
aeruginosa, 8 E. coli and 6 K. pneumoniae). Due to solubility issues with BDM-I at higher 
concentrations (generally >128 μg/mL), a BDM-I range of 128-0.25 μg/mL was selected 
for BMD testing. The MICs were determined in duplicate for each isolate, with the 
average MICs determined shown in Table 3.1. The MIC data generated reflects similar 
results from previous studies (White, 2008), with BDM-I not exhibiting any activity 
against the gram-negative isolates tested, confirming the limitations of BDM-I against 
these important pathogen types.  
 
 
Table 3.1 Average BDM-I MICs Determined for Selected Gram-Negative Isolates 
P. aeruginosa E. coli K. pneumoniae 
Isolate No. Mean MIC (μg/mL)a Isolate No. 
Mean MIC 
(μg/mL)a Isolate No. 
Mean MIC 
(μg/mL)a 
Pa0001 >128 Ec0002 >128 Kp0001 >128 
Pa0005 >128 Ec0003 >128 Kp0002 >128 
Pa0010 >128 Ec0004 >128 Kp0003 >128 
Pa0015 >128 Ec0005 >128 Kp0004 >128 
Pa0020 >128 Ec0006 >128 Kp0005 >128 
Pa0025 >128 Ec0007 >128 Kp0007 >128 
Pa0030 >128 Ec0008 >128 - - 
Pa0035 >128 Ec0009 >128 - - 
 
  
aMIC testing was completed in duplicate for each isolate and values were determined based 
on visual inspection for growth in a 96-well plate. 
 
aMIC testing was completed in duplicate for each isolate and values were determined based 
on visual inspection for growth in a 96-well plate. 
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3.3 BDM-I has Antimicrobial Activity against S. aureus and E. faecium 
Clinical Isolates 
 
MIC tests were then completed on a range of S. aureus and E. faecium clinical isolates, 
in order to examine the efficacy of BDM-I against clinically important gram-positive 
pathogens. Testing was initially completed using a similar BDM-I range as described in 
section 3.2 (128-0.25 μg/mL), however the results indicated that a lower range was 
needed due to the increased activity of BDM-I against these isolates (<10 μg/mL). 
Therefore, MIC testing was repeated using a range of 10-1 μg/mL, which formed the basis 
for testing all clinical isolates listed in Tables 2.2 and 2.4-2.7 (section 2.1). 
 
The MICs of 26 MRSA isogenic pairs were initially determined as outlined in Table 2.5, 
with each pair consisting of an isolate obtained at the initial stage of infection, and another 
obtained following persistent bacteraemia (and vancomycin therapy, in most cases). 
Studying isogenic pairs allowed us to determine the efficacy of BDM-I against clinical 
isolates associated with persistent infections and treatment failure. The mean MIC was 
determined for each isolate based on duplicate data sets, and is shown in Table 3.2. As 
seen, there were no significant differences in MICs observed between initial and 
recurrent/persistent isolate types, with most MICs being in the range of 3-4 μg/mL. 
 
Further MIC testing was then performed on three clinical MRSA isogenic isolate series, 
with the average MIC values shown in Table 3.3. Examining changes in MIC within a 
persistent series of isolates with previously observed development of vancomycin 
resistance, allows us to identify potential cross-resistance between the two compounds. 
As seen in the case of series A and B, the BDM-I MIC remained unchanged at 5 μg/mL 
 
 
79 
and 3 μg/mL respectively during the course of infection. However, within series C we 
observed a gradual decrease in BDM-I MIC over time, which coincided with a gradual 
increase in vancomycin resistance as observed by the isolate’s vancomycin phenotype. 
This observation is possibly indicative of a “seesaw” effect between BDM-I and 
vancomycin which is discussed in section 3.4.  
 
Additional MIC tests were also performed using the Agar Dilution method to evaluate 
whether BDM-I was capable of diffusing through Agar. Testing was completed using 
four clinical MRSA isolates with known BDM-I MICs (identified through broth 
microdilution testing). Table 3.4 shows the determined MICs for each isolate comparing 
the Agar and Broth Microdilution methods. As seen, there was no difference in the BDM-
I MICs when comparing the two methods, indicating that MIC testing can be performed 
using Agar dilution as an alternative method. 
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Table 3.2 Average BDM-I MICs for MRSA Isogenic Isolate Pairs 
Pair Isolate Number Isolate Type Mean MIC (µg/mL)a 
A Sa0040 Initial 4 Sa0012 Recurrent 4 
B Sa0227 Initial 5 Sa0328 Recurrent 4.5 
C Sa0307 Initial 4 Sa0365 Persistent 4 
D Sa0243 Initial 4 Sa0194 Persistent 4 
E Sa0138 Initial 4 Sa0116 Persistent 4 
F Sa0015 Initial 4 Sa0019 Recurrent 3 
G Sa0309 Initial 3 Sa0238 Persistent 3 
H Sa0283 Initial 3 Sa0284 Persistent 3 
I Sa0212 Initial 3 Sa0214 Recurrent 3 
J Sa0158 Initial 3 Sa0160 Persistent 3.5 
K Sa0343 Initial 3 Sa0191 Recurrent 3 
L Sa0037 Initial 3 Sa0044 Recurrent 3 
M Sa0237 Initial 3 Sa0285 Persistent 3 
N Sa0051 Initial 3 Sa0052 Persistent 3 
O Sa0331 Initial 3 Sa0332 Persistent 3 
P Sa0255 Initial 3 Sa0256 Persistent 3 
Q Sa0294 Initial 4 Sa0192 Persistent 4 
R Sa0014 Initial 3 Sa0017 Recurrent 2 
S Sa0228 Initial 3 Sa0265 Persistent 3 
T Sa0055 Initial 3 Sa0056 Recurrent 3 
U Sa0091 Initial 3 Sa0162 Persistent 3 
V Sa0304 Initial 3 Sa0305 Persistent 3 
W Sa0006 Initial 4 Sa0011 Recurrent 4 
X Sa0068 Initial 3 Sa0047 Persistent 4 
Y Sa0329 Initial 3 Sa0330 Persistent 3 
Z Sa0322 Initial 3 Sa0324 Persistent 3 
 aMIC testing was completed in duplicate for each isolate 
 
aMIC testing was completed in duplicate for each isolate 
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Table 3.3 Average BDM-I MICs for Clinical MRSA Isogenic Isolate Series 
Series Isolate Number Isolate Type 
Vancomycin 
Phenotype 
Mean MIC 
(µg/mL)a 
A 
Sa0048 Initial VSSA 5 
Sa0049 Persistent VSSA 5 
Sa0050 Persistent hVISA 5 
B 
Sa0016 Initial hVISA 3 
Sa0018 Recurrent hVISA 3 
Sa0067 Recurrent hVISA 3 
Sa0020 Persistent hVISA 3 
Sa0070 Recurrent hVISA 3 
Sa0054 Recurrent hVISA 3 
C 
Sa0057 Initial VSSA 4 
Sa0058 Persistent hVISA 3 
Sa0059 Persistent VISA 3 
Sa0060 Persistent hVISA 3 
Sa0378 Persistent VISA 3 
Sa0375 Persistent VISA 2 
 
 
 
 
Table 3.4 Comparison of MICs Determined using the Agar and BMD Methods 
Isolate Phenotype Agar MIC (μg/mL) BMD MIC (μg/mL) 
Sa040 VSSA 4 4 
Sa057 VSSA 4 4 
Sa060 hVISA 3 3 
Sa375 VISA 2 2 
 
In general, the above analysis revealed that BDM-I retains clinical activity and displays 
increased efficacy against MRSA clinical isolates with varying degrees of vancomycin 
susceptibility. Following this, we conducted further MIC studies using 30 clinical E. 
faecium isolates and a single VRE isogenic isolate series, with the determined MICs 
shown in Table 3.5 and 3.6, respectively. Ten isolates were selected representing different 
vancomycin phenotypes, including vancomycin susceptible enterococci (VSE) and 
vancomycin resistant enterococci (VanB and VanA phenotypes). Similar MICs were 
observed between these phenotypes, with most isolates exhibiting a BDM-I MIC between 
6 and 8 μg/mL. Interestingly, a few isolates displayed an increased sensitivity to BDM-I, 
aMIC testing was completed in duplicate for each isolate. No changes in MIC were observed 
within series A and B. However, series C exhibited a gradual decrease in BDM-I MIC in an 
inverse relationship to the generation of vancomycin resistance. 
 
aMIC testing was completed in duplicate for each isolate. No changes in MIC were observed 
within series A and B. However, series C exhibited a gradual decrease in BDM-I MIC in an 
inverse relationship to the generation of vancomycin resistance. 
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notably Efm0174, Efm0002, Efm0072 (Table 3.5) and Efm0007 (Table 3.6), which all 
had an MIC of 3-3.5 μg/mL. 
 
Table 3.5 Average BDM-I MICs for Clinical E. faecium Isolates 
Isolate Number Hospital Phenotype Mean MIC (μg/mL) 
Efm0092 RPA VSE 9 
Efm0093 RPA VSE 7 
Efm0097 RPA VSE 8 
Efm0100 RPA VSE 7 
Efm0103 RPA VSE 8 
Efm0136 RPA VSE 8 
Efm0138 RPA VSE 8 
Efm0200 RPA VSE 8 
Efm0219 RPA VSE 8 
Efm0222 RPA VSE 5 
Efm0174a RPA VanB 3 
Efm0002a Liverpool VanB 3.5 
Efm0202 RPA VanB 7 
Efm0151 RPA VanB 6 
Efm0180 RPA VanB 6 
Efm0218 RPA VanB 6 
Efm0217 RPA VanB 6 
Efm0160 RPA VanB 7 
Efm0128 RPA VanB 8 
Efm0125 RPA VanB 8 
Efm0067 QLD VanA 6 
Efm0072a MH VanA 3 
Efm0076 MH VanA 7 
Efm0081 AH VanA 6 
Efm0087 AH VanA 8 
Efm0234 Wollongong VanA 6 
Efm0236 Wollongong VanA 7 
Efm0315 St George VanA 5 
SVH193 Westmead VanA 7 
SVH228 Westmead VanA 7 
 
 
Table 3.6 Average BDM-I MICs of a Single VRE Isogenic Isolate Series 
Series Isolate Number Isolate Type Mean MIC (µg/mL) 
A 
Efm0006 Initial 6-7 
Efm0007a Persistent 3 
Efm0010 Persistent 6 
Efm0027 Persistent 5 
Efm0028 Persistent 7 
Efm0029 Persistent 7 
Efm0030 Persistent 6 
Efm0031 Persistent 6 
 
 
aIsolates with an atypical E. faecium MIC of 3 µg/mL 
 
Isolates with an atypical E. faecium MIC of 3 µg/mL 
aIsolates with an atypical E. faecium MIC of 3 µg/mL 
 
Figure 3.1 Changes in BDM-I MIC observed for MRSA isolates Sa057 (a) and Sa375 (b) 
following 100 and 110 days of continuous exposure, respectively. Each isolate was 
subcultured in triplicate, and the average MICs for each isolate determined following BMD 
testing at different time points. The horizontal line indicates the progenitor isolates 
MICs.aIsolates with an atypical E. faecium MIC of 3 µg/mL 
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3.4 The Relationship between BDM-I and Vancomycin MICs for MRSA and 
VRE 
 
MIC data for MRSA isolates (section 3.3) suggested a potential “seesaw” effect and 
possible synergism between BDM-I and vancomycin. To explore this further, MIC tests 
were completed on additional MRSA clinical isolates possessing varying degrees of 
vancomycin susceptibility, in order to obtain a large data set for statistical analysis. In 
total, 43 VSSA isolates, 54 hVISA isolates and 6 VISA isolates were subjected to MIC 
testing, with the average MICs determined for each phenotype being 3.42 μg/mL, 3.28 
μg/mL and 2.5 μg/mL, respectively (Table 3.7). Following statistical analysis, a “see-
saw” effect was confirmed as BDM-I MICs are inversely correlated to vancomycin MICs 
(Rho = -0.24; P = 0.0154). This can be observed in Table 3.7, where VSSA isolates have 
a higher average BDM-I MIC when compared to VISA isolates. 
 
Table 3.7 Average BDM-I and Vancomycin MICs for 103 Clinical MRSA Isolates 
 
This confirmed see-saw effect indicated a potential synergistic relationship between 
BDM-I and vancomycin, which was subsequently explored. In this regard, checkerboard 
assays were conducted using three MRSA isolates and three VRE isolates with various 
vancomycin phenotypes, in order to identify potential synergism between the two 
compounds. The isolates selected included Sa057 (VSSA), Sa060 (hVISA), Sa375 
(VISA), Efm201 (vanB located on the chromosome), Efm123 (vanB located on a plasmid) 
and Efm008 (vanA located on a plasmid). The calculated FICI values for each MRSA 
isolate were determined as 1.42 (SD = 0.28) for Sa057, 1.29 (SD = 0.26) for Sa060 and 
Isolate Vancomycin 
Phenotype BDM-I MIC (μg/mL) Vancomycin MIC (μg/mL) 
VSSA (n=43) 3.42 
3.28 
2.5 
1.16 
1.92 
2.2 
hVISA (n=54) 
VISA (n=6) 
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1.14 (SD = 0.09) for Sa375. According to the guidelines described in section 2.3, these 
FICI values indicate there is no in vitro interaction between BDM-I and vancomycin when 
tested in combination against MRSA. However, the raw data showed a significant 
decrease in vancomycin MIC for Sa375 from 4 μg/mL to 0.583 μg/mL (SD = 0.38), when 
combined with BDM-I at MIC50 (1 μg/mL). A similar result was observed for Sa060, 
where at sub-inhibitory BDM-I concentrations the vancomycin MIC decreased from 4 
μg/mL to 0.75 μg/mL (SD = 0.43).  
 
Similar results were observed with the VRE isolates, with the FICI values being 
calculated as 1.06 (SD = 0.2) for Efm008, 0.62 (SD = 0.15) for Efm123 and 0.62 (SD = 
0.01) for Efm201. This data indicates that BDM-I exerts a definite additive effect in 
combination with vancomycin for VRE isolates possessing vanB vancomycin resistance. 
In the case of Efm008, an FICI value of 1.06 places the data in the “no interaction” range, 
however, considering the calculated standard deviation, we are unable to conclude with 
certainty that using BDM-I in combination with vancomycin has no effect on the efficacy 
of vancomycin against VRE possessing vanA resistance. 
 
Additional checkerboard assays were completed using other cell wall active antibiotics 
including flucloxacillin and ceftaroline dihydrochloride combined with BDM-I. 
However, there were no synergistic or additive relationships observed, indicating the 
additive activity observed above is specific to BDM-I and vancomycin.  
 
3.5 In vitro Generation of Mutants with Increased BDM-I MICs 
 
In section 3.3, we identified that there were no observable differences in BDM-I MICs 
between initial and persistent isolates derived from a single patient who had failed 
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antimicrobial therapy, indicating that cross-resistance (to BDM-I) does not emerge in the 
context of extended vancomycin exposure. In order to further explore the clinical utility 
of BDM-I, we then determined if BDM-I MICs increased for MRSA or VRE following 
prolonged periods of exposure against clinically relevant bacteria, in order to identify the 
potential of select isolates to develop increased resistance to BDM-I.  
 
This was achieved through induction experiments as explained in section 2.5, which were 
conducted using four clinical isolates: two MRSA isolates, Sa057 (VSSA) and Sa375 
(VISA), and; two VRE isolates, Efm003 (vanB resistance) and Efm008 (vanA resistance). 
Induction experiments were completed in triplicate for each isolate, and their initial 
BDM-I MICs are shown in Table 3.8.  
 
Table 3.8: Test Isolates Selected for Induction Experiments and Additional MoA Studies 
Isolate Phenotype Mean MIC (µg/mL) 
S.aureus Sa375 MRSA, VISA 2 
S.aureus Sa0057 MRSA, VSSA 4 
E.faecium Efm0003 VRE, VanB 7 
E.faecium Efm0008 VRE, VanA 7 
 
 
3.5.1 MRSA Isolates do not Develop BDM-I Resistance Readily in vitro  
 
MRSA isolates were subcultured for approximately 100 days in triplicate and subjected 
to additional BMD at different time points to identify changes in MICs. Figure 3.1 
illustrates changes in BDM-I MICs for Sa057 (a) and Sa375 (b), determined as an average 
of each triplicate series. Sa057 displayed little ability to adapt to BDM-I, with no 
significant changes in MIC being observed within the 100-day time-period. Interestingly, 
an increased resistance to BDM-I was observed for Sa375 approximately 15 days into the 
experiment, however these changes in MIC were not stable and fluctuated significantly 
until the final days of exposure. Following approximately 100 days of exposure, the 
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Sa375 series developed a stable phenotype with BDM-I MICs of 5 μg/mL which was 
higher than that of the progenitor (2 μg/mL).  
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Figure 3.1 Changes in BDM-I MIC observed for MRSA isolates Sa057 (a) and Sa375 
(b) following 100 and 110 days of continuous exposure, respectively. Each isolate was 
subcultured in triplicate, and the average MICs for each isolate determined following 
BMD testing at different time points. The horizontal line indicates the MIC of the 
progenitor isolates. 
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3.5.2 VRE Readily Develops Increased Resistance to BDM-I in vitro 
 
In contrast to the results observed in section 3.5.1, both VRE isolates were readily capable 
of developing increased resistance to BDM-I. Significant increases in MICs were 
observed over an 80-day period for both Efm003 (a) and Efm008 (b) as shown in Figure 
3.2. Sharp increases in MICs were observed around day 10 for both isolates, increasing 
to approximately 12 μg/mL, which continued to rise until the final time point. As shown 
in Figure 3.2, both strains developed mutants with final MICs more than double that of 
the progenitor strains, indicating that VRE are readily capable of developing increased 
resistance to BDM-I following prolonged periods of exposure. 
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Figure 3.2 Changes in BDM-I MIC observed for VRE isolates Efm003 (a) and Efm008 
(b) following 80 days of continuous exposure. Each isolate was subcultured in triplicate, 
and the average MICs for each isolate determined using BMD testing at different time 
points. The horizontal line indicates the progenitor isolates MICs.   
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3.6 Discussion 
 
It is important to examine the clinical utility of novel compounds against common 
bacterial pathogens, especially those classified as clinically important such as the 
ESKAPE pathogens. In Chapter 3 we examined the activity of BDM-I against a range of 
bacteria including gram negative (E. coli, K. pneumoniae and P. aeruginosa) and gram 
positive (S. aureus and E. faecium) clinical isolates, as well as the activity of BDM-I in 
combination with several antibiotics, particularly the front-line therapeutic vancomycin 
(sections 3.2 to 3.4). In addition, we also examined the ability of S. aureus and E. faecium 
isolates to develop increased resistance to BDM-I following prolonged periods of 
exposure (section 3.5). 
 
Previous work on BDM-I revealed that it is mainly active against gram-positive bacteria 
(White, 2008). Regardless, it was important to conduct further MIC testing with BDM-I 
on common gram-negative pathogens to confirm its spectrum of antimicrobial activity. 
In this regard, several clinical isolates were selected for MIC testing using two-fold 
dilutions of BDM-I with a range of 128-0.5 μg/mL. As expected, BDM-I did not inhibit 
any of the tested isolates tested, confirming that its activity is limited to gram-positive 
pathogens. However, additional MIC testing should be conducted on other gram-negative 
pathogens of interest such as N. gonorrhoeae.  
 
In any case, MIC tests completed on the gram-positive pathogens S. aureus and E. 
faecium (section 3.3) yielded promising results, with BDM-I displaying the best activity 
against MRSA, particularly for clinical isolates with increased resistance to vancomycin 
(i.e., hVISA and VISA). Overall, MRSA is more sensitive to BDM-I with average MICs 
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of 3.42, 3.28 and 2.5 μg/mL for VSSA. hVISA and VISA isolates, respectively, compared 
to average MICs of 7-8 μg/mL for VRE isolates. Furthermore, MIC analysis also 
identified a see-saw effect between BDM-I and vancomycin for MRSA, which formed 
the basis for doing checkerboard assays to identify any potential synergism between the 
two compounds. Checkerboard assays were conducted using MRSA and VRE isolates 
with varying vancomycin phenotypes (section 3.4), with the data acquired suggesting that 
BDM-I does exert an additive effect in combination with vancomycin, primarily for 
hVISA and VISA MRSA isolates as well as VanB VRE. 
 
Extended exposure to an antibiotic in a clinical setting is often associated with the 
emergence of resistance in vivo (van Hal et al., 2013). Therefore, after determining the 
utility of BDM-I against MRSA and VRE, we then aimed to explore the capability of 
these bacteria to develop resistance to BDM-I following prolonged periods of exposure 
(section 3.5). Interestingly, neither of the MRSA isolates tested displayed any significant 
capability to develop increased resistance to BDM-I, with Sa375 developing marginally 
increased resistance with final MICs similar to that of VSSA isolates. Conversely, both 
VRE isolates rapidly developed increased resistance to BDM-I following only several 
days of exposure (section 3.5.2). 
 
In summary, the data outlined in Chapter 3 has illuminated the utility of BDM-I against 
S. aureus in vitro, as both a single compound and in combination with the front-line 
antibiotic vancomycin. Furthermore, the data suggests that the risk of S. aureus 
developing resistance to BDM-I is relatively low, identifying the potential for its use in 
the treatment of chronic infections. While MIC analysis revealed that E. faecium isolates 
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are susceptible to BDM-I at concentrations <10 μg/mL, the rate at which VRE developed 
resistance to BDM-I suggests it is unlikely to be useful in clinical applications. 
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Investigating the Genotype and Phenotype of Mutants with Increased 
Resistance to BDM-I 
 
4.1 Introduction 
 
Determining an antimicrobials mechanism of action (MoA) is often difficult. 
Traditionally, methods utilising radioactively labelled precursors (macromolecular 
synthesis) were used to explore which bacterial synthetic pathway(s) (i.e., synthesis of 
protein, DNA, RNA, lipid or peptidoglycan) was targeted by an antimicrobial compound. 
While this method is still commonly used by the pharmaceutical industry, its application 
in broader settings is limited due to a number of drawbacks, including its ability to only 
identify a narrow range of MoAs. Transcriptional profiling is a commonly used molecular 
method in the research environment and has also been effective in determining the MoA 
of antibiotics (Freiberg et al., 2005, Hutter et al., 2004). 
 
Previous work studying the BDM-I MoA has utilised various molecular techniques, such 
as microarray analysis and targeted assays to study the effect of BDM-I on different 
cellular processes (White et al., 2014). Whole genome sequencing of in vitro or in vivo 
derived resistant mutants has been shown to be a viable method for studying the MoA of 
novel antibiotics. Ioerger et al identified resistance-associated mutations within M. 
tuberculosis against eight novel compounds selected through high throughput screening 
(HTS). Analysis of these mutations identified four likely drug targets and thus such an 
approach represents an unbiased method for target identification that does not rely on 
target-based approaches, which are only effective in a limited number of cases (Ioerger 
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et al., 2013). Similarly, through the sequencing of mutant cell lines with resistance against 
the anti-cancer drug Bortezomib, Wacker et al were able to identify single-point 
mutations within the gene that encodes for the (known) drug targets gene (Wacker et al., 
2012). These studies highlight resistance mutant sequencing as a viable approach to 
identifying a novel drug’s cellular target. The identification of single-point mutation(s) 
associated with increased resistance can give insight into potential resistance 
mechanisms, and by extension may reveal a drugs cellular target and/or MoA. 
 
To date, no mutant isolates with increased BDM-I MICs have been successfully 
generated, which imposes a severe limitation for studying the BDM-I MoA using next-
generation sequencing technologies. However, as part of this study (Chapter 3, section 
3.5), we have successfully generated of E. faecium and S. aureus mutants in vitro with 
increased BDM-I resistance. Utilising these mutant isolates, we therefore conducted 
whole genome sequencing analysis in order to identify any mutations that may contribute 
to our understanding of the BDM-I MoA.    
 
4.2 Whole Genome Sequencing of VRE Mutants  
 
As described in section 3.5, the greatest increase in BDM-I MICs were observed for the 
enterococcal isolates Efm008 and Efm003 (section 3.5.2). Significant increases in MICs 
occurred within 10 days of the initial inoculation for each isolate, which gradually 
increased until the termination of the experiment following approximately 80 days of 
exposure, at which point the final MIC was more than double that of the progenitor isolate 
(final MIC of 16 μg/mL). The capacity for E. faecium to readily develop increased 
resistance to BDM-I makes it an ideal candidate for whole genome sequencing analysis.  
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As such, BDM-I resistance mutants (in addition to the isogenic parents) were selected for 
sequencing from the day 10 and day 60 exposure time-points. In total, 3 colonies were 
selected for sequencing from each of the three replicate series, giving a total of nine data 
sets from each time point (not including the final day Efm003 mutants). Subsequently, 
variant analysis was performed comparing the in vitro derived resistance mutants to the 
Efm003 and Efm008 progenitor isolates. Interestingly, this revealed that the mutants 
analysed commonly had mutations within the coding region of ATP Synthase genes, as 
summarised in Tables 4.1 and 4.2. 
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Table 4.1 Mutations Identified within day 10 Efm008 BDM-I mutants 
Series Colony Region Gene Mutation AA Change Product 
1 
1 2088169 atpE INS - ATP synthase, F0 complex, c-subunit 
2 2085214 atpG INS - ATP synthase, F1 complex, γ-subunit 
3 2083071 atpD DEL Ile456fs ATP synthase, F1 complex, β-subunit 
2 
1 2087896 atpF DEL - ATP synthase, F0 complex, b-subunit 
2 2083526 atpD SNP Tyr304* ATP synthase, F1 complex, β-subunit 
3 2087739 atpF INS - ATP synthase, F0 complex, b-subunit 
3 
1 2088230 atpE INS - ATP synthase, F0 complex, c-subunit 
2 2083847 atpD SNP Tyr107* ATP synthase, F1 complex, β-subunit 
3 2088813 atpB INS - ATP synthase, c-subunit 
 
 
 
 
 
Table 4.2 Common mutations identified within day 60 Efm003 and Efm008 BDM-I mutants 
Isolate Seriesa Region Gene(s) Mutation AA Change Product 
Efm003b 3 2088755 atpB SNP Thr111Lys ATP synthase, c-subunit 
Efm008 
1 2083906 atpD SNP Gly178Cys 
ATP synthase, F1 
complex, β-
subunit 
2 2083213 atpD SNP Gln409Lys 
ATP synthase, F1 
complex, β-
subunit 
3 2082315-2086186 
atpD, 
atpA, 
atpC, 
atpG 
IS1256-
mediated 
deletion 
- 
ATP synthase, F1 
complex, β-, α-, ε- 
and γ-subunits 
aMutant colonies within a series had the same atp gene mutation 
bConamination present within series 1 and 2 
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Mutations identified within the day 10 Efm008 mutants varied between the series and 
colonies sequenced, both in terms of the mutation type identified as well as the ATP 
Synthase gene affected. IS1256-like insertions in different genes, including atpE, atpG, 
atpF and atpB, were identified for 5 of the 9 mutant colonies. Additional deletions and 
single nucleotide polymorphisms (SNPs) were also identified in atpD and atpF for the 
remaining 4 colonies. Similar trends were observed for the day 60 Efm008 mutants, with 
the identification of SNPs (resulting in amino acid changes) within atpD for series 1 and 
2 (Gly178Cys and Gln409Lys, respectively). In the case of series 3, an IS1256-like 
insertion caused the partial deletion of atpA, and the complete deletion of atpC, atpD and 
atpG, all of which encode for constitutive protein subunits of the ATP Synthase F1 
complex.  
 
In the case of Efm003 (and similar to the above), SNPs were identified within the atpB 
gene for the series 3 day 60 mutants. However, there were no mutations identified within 
any ATP synthase genes for the day 10 mutants. Variant analysis did however identify 
SNPs for 6 of the 9 mutant colonies within the gene EFAU004_00165, which encodes for 
an M-protein Trans-acting positive regulator. 
 
While mutations within the ATP synthase operon were present within the majority of the 
mutant Efm003 and Efm008 series mutants, additional mutations were identified in 
individual colonies or series as outlined in Supplementary Tables 1 to 4. In summary, 
mutations identified within Efm003 day 10 isolates mutants appear to affect genes 
functioning in nucleotide and protein synthesis, including guaB and EFAU004_00965, 
which encode for proteins involved in the metabolism of purine and pyrimidine 
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nucleotides, respectively. Interestingly, mutations present within Efm008, day 10 isolates 
are present almost exclusively within genes encoding for subunits of ATP synthase. 
 
Variant analysis also identified a further 8 SNPs within the day 10 mutant series of 
Efm003. 2 SNPs are present within the gene fur, encoding for the Fur family of 
transcriptional regulators responsible for regulating the uptake of ferric iron and defence 
against reactive oxygen species (ROS). Additional SNPs were identified within the genes 
relA (guanosine pentaphosphate synthesis), apt (AMP synthesis), ylov (glycerol 
metabolism), EFAU004_01802 (branched chain amino acid synthesis) and 
EFAU004_02036 (phospholipid synthesis).  
 
In addition to SNPs within atpD, additional mutations were identified within the day 60 
Efm008 mutant isolates, several of which are present within 2 of the 3 series. 
Interestingly, SNPs were identified within the gene EFAU004_02425 encoding a PAS 
domain sensory box histidine kinase within series 1 and 3 (Asp49Tyr and Asp99Tyr 
respectively). EFAU004_02425 is homologous to similar histidine kinases such as walK 
and vicK which are essential for maintaining cell wall homeostasis in gram-positive 
bacteria (Dubrac et al., 2007). Similar to Efm003, SNPs were also identified within relA 
in series 1 and 2.  
 
The majority of the mutations summarised in Supplementary Tables 1 to 4 are specific to 
a single series or colony, and therefore were considered less likely to be important to the 
observed increases in BDM-I MICs. Emphasis has been placed on mutations within the 
ATP synthase operon, as they have been identified in all mutant series except day 10 
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Efm003 mutants. However, further analysis of additional mutations may be required in 
the future. 
 
4.3 Whole Genome Sequencing of MRSA BDM-I Mutants 
 
As outlined in Chapter 3, the MRSA isolates (Sa057 and Sa375) struggled, at least in part, 
to develop increased resistance to BDM-I during the induction experiments, particularly 
Sa057 which showed no significant changes in MIC after 110 days of continuous 
exposure. Interestingly, the greatest increase in BDM-I MICs was observed for the Sa375 
in vitro derived mutants, which increased by >2-fold from 2 to 5 µg/mL in all three 
replicate series following 60 days of exposure. Therefore, whole genome sequencing and 
variant analysis was initially completed using Sa375 BDM-I mutants and the progenitor 
Sa375 VISA isolate. Somewhat unexpectedly, common mutations (amongst the mutants) 
were identified within the walK gene, which encodes a sensor protein kinase. In this 
regards, SNPs resulting in amino acid changes were present in all three-mutant series 
within two domains of WalK, as illustrated in Figure 4.4; the extracellular PAS Domain 
(series 1 and 3) and the Histidine Kinase-like ATPase domain (series 2). 
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The walK gene encodes part of the essential WalKR two-component regulatory system 
which regulates a diverse range of cellular processes, with the most widely studied being 
cell wall homeostasis (see section 4.6.1). Several other mutations were also variously 
identified within genes that play a role in cell wall synthesis. These included SNPs within 
murA and atl (series 2), and mvaA (series 1), which encode for UDP‐GlcNAc enolpyruvyl 
transferase (responsible for the synthesis of UDP-N-acetylmuramic acid during the first 
stage of peptidoglycan synthesis (Blake et al., 2009)), the bifunctional enzyme N-
acetylmuramoyl-L-alanine amidase/endo-beta-N-acetylglucosaminidase (which is the 
major peptidoglycan hydrolase within S. aureus and is essential for maintaining cell wall 
turnover (Grilo et al., 2014)) and 3-hydroxy-3-methylglutaryl coenzyme A reductase 
(plays an indirect role in peptidoglycan synthesis through the production of a lipid carrier 
known as unedecaprenyl pyrophosphate, via the mevalonate pathway (Balibar et al., 
2009)), respectively. 
 
Series 2: 
Gly560Ser 
 
Series 3: 
Gly30Trp 
 
Series 1: 
Leu37Phe 
 
Figure 4.1 Structure of WalK showing protein domains and the position of 
mutations identified within Sa375 BDM-I mutants. Image adapted from Howden 
et al (Howden et al., 2011). 
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A significant number of SNPs (n=21) were identified within the Sa375 mutant series 2, 
compared to those of series 1 and 3, which only contained a total of 3 SNPs each 
(Supplementary Table 5). The pathways affected by these mutations were diverse, and 
included nucleotide synthesis (rpbB and yukA), nutrient transport (potD, 
SAA6008_00647, SAA6008_01966 and nrgA) and capsule synthesis (Cap5A). 
Considering these mutations are unique to series 2, they were considered unlikely to be 
important regarding the BDM-I MoA but may warrant further investigation in the future. 
 
In contrast to the above, Sa057 struggled to develop increased resistance to BDM-I, 
however some colonies (n=4) from the final day mutants series displayed marginally 
higher BDM-I MICs of 1-2 µg/mL (one colony from series 1 and three colonies from 
series 3) following additional MIC testing. Sequencing and variant analysis of these 
colonies revealed several mutations as outlined in Table 4.3, including SNP mutations 
within SAA6008_00679, which encodes a putative phosphate uptake regulator, in all 
sequenced colonies. Series 1 and series 3, colony 1 mutants have an identical amino acid 
change at position 99 (Met99Ile), while colonies 2 and 3 from series 3 possess two amino 
acid changes at positions 166 (Ser166Arg) and 172 (Thr172Ser). SNP mutations were 
also identified within the genes murC and fmtC, which encode for UDP-N-acetylmuramic 
acid (peptidoglycan synthesis) and Phosphatidylglycerol lysltransferase (cell membrane 
synthesis), respectively (series 1 and colony 1 from series 3), Additional SNPs were 
identified within rpoC, whiA and SA6008_01663 (series 3, colonies 2 and 3), which 
function in RNA synthesis, cell division and amino acid transport and metabolism, 
respectively. 
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Table 4.3 Mutations identified within in vitro derived Sa057 BDM-I Mutants 
Isolate Gene Mutation AA Change Product 
1/1 
SAA6008_00679 SNP Met99Ile Putative phosphate uptake regulator 
fmtC SNP Arg784Pro Phosphatidylglycerol lysltransferase 
murC SNP Ser144Arg UDP-N-acetylmuramate-L-alanine-ligase 
3/1 
SAA6008_00679 SNP Met99Ile Putative phosphate uptake regulator 
fmtC SNP Arg784Pro Phosphatidylglycerol lysltransferase 
murC SNP Ser144Arg UDP-N-acetylmuramate-L-alanine-ligase 
3/2 
SAA6008_00679 SNP Ser166Arg Putative phosphate uptake regulator 
SAA6008_00679 SNP Thr172Ser Putative phosphate uptake regulator 
rpoC SNP Leu984Ile DNA directed RNA polymerase beta chain protein 
whiA SNP Asp214Tyr Sporulation regulator 
SA6008_01663 SNP Ser151Phe Amino acid transport and metabolism 
3/3 
SAA6008_00679 SNP Ser166Arg Putative phosphate uptake regulator 
SAA6008_00679 SNP Thr172Ser Putative phosphate uptake regulator 
rpoC SNP Leu984Ile DNA directed RNA polymerase beta chain protein 
whiA SNP Asp214Tyr Sporulation regulator 
SA6008_01663 SNP Ser151Phe Amino acid transport and metabolism 
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4.4 Exploring the Relationship between BDM-I and ATP Synthase 
 
4.4.1 Bacterial ATP Synthase 
Adenosine triphosphate (ATP) is the universal ‘energy currency’ within all living 
organisms, ranging from prokaryotes to higher order eukaryotes. ATP is hydrolysed to 
form adenosine diphosphate (ADP) and an inorganic phosphate molecule (Pi), and can be 
utilized as an energy source for various endergonic metabolic processes (Weber, 2010). 
The primary mechanism by which ATP is synthesized, is during oxidative 
phosphorylation by the F1F0 – ATP synthase complex.  
 
The F0F1 – ATP synthase is a membrane bound protein comprised of two segments; the 
membrane bound F0 complex and the F1 ‘rotor stalk’ portion (Senior et al., 2002). Within 
these two segments are a total of eight subunits; three within the F0 segment with a 
stoichiometry of ab2c10-15, and five within the F1 segment with a stoichiometry of a3β3γδε 
(Figure 4.2) (Deckers-Hebestreit and Altendorf, 1996). ATP synthase utilizes a unique 
rotary mechanism powered by electrochemical energy, which is produced by a proton 
gradient across the F0 segment. Proton flow causes the rotation of the γεc10-15 assembly, 
which in turn alters the catalytic sites within the β-subunits, to synthesize ATP from ADP 
and Pi. Alternatively, under certain conditions bacteria are capable of hydrolysing ATP, 
in order to generate a transmembrane proton gradient that is required for processes such 
as locomotion (Weber, 2010). 
 
In recent years, ATP synthase has been studied as a potential antimicrobial target. The 
first antimicrobial shown to inhibit ATP synthase was a diarylquinoline compound which 
exhibited potent activity against the pathogen Mycobacterium tuberculosis (Andries et 
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al., 2005). More recently in 2012, Balemans et al identified several compounds that 
interacted with subunit c of ATP synthase, and these were shown to have bactericidal 
activity against S. aureus and S. pneumoniae (Balemans et al., 2012). These studies have 
elucidated ATP synthase as a potential target for novel antimicrobial compounds. 
 
In this study, we have identified that ATP synthase is likely affected by BDM-I. In section 
4.2, we identified that all mutant E. faecium isolates (with increased resistance to BDM-
I) possess mutations within the ATP synthase operon, most commonly in the form of 
SNPs within the atpD gene. Based on these results, we hypothesized that BDM-I may be 
inhibiting ATP synthase either directly or indirectly. To explore this, we conducted ATP 
assays on BDM-I treated (MIC50) E. faecium and S. aureus isolates, to identify potential 
changes in intracellular ATP concentrations. 
 
 
  
Figure 4.2 Structure of the bacterial ATP synthase machinery. Illustrated are the locations of 
each protein subunit within the F0 (membrane bound) and F1 segments (intracellular). Image 
obtained from  Weber (Weber, 2010). 
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4.4.2 ATP Assays Utilized to Examine the Effect of BDM-I on ATP Synthase 
ATP assays were performed using the Roche HS II ATP bioluminescence kit with 
Efm008 and Sa057 isolates, treated with sub-inhibitory BDM-I concentrations (MIC50). 
Prior to performing the assay, standard curves were generated for each isolate comparing 
OD600 values and Cfu/mL, which enabled us to normalise intracellular ATP 
concentrations to a desired number of cells (105 Cfu). Cell cultures and ATP readings 
were prepared in triplicate for each isolate and treatment. 
 
Following normalisation of wild type and treated isolates, we identified significant 
decreases in intracellular ATP concentrations within both Efm008 and Sa057. A 2-fold 
change in ATP concentration was observed following BDM-I treatment of Efm008; 
decreased from 2.00 nmols/105 Cfu to 1.03 nmols/105 Cfu, as shown in Figure 4.3. A 
significant decrease was also observed for Sa057; from 1.32 nmols/105 Cfu to 0.86 
nmols/105 Cfu. In any case, this data suggests that BDM-I is likely inhibiting ATP 
synthesis, although it does not elucidate whether this is by direct or indirect inhibition of 
the ATP synthase enzyme. Interestingly, a previous study reported that BDM-I did not 
inhibit ATP synthesis within B. cereus and S. aureus (White et al., 2014). Differences in 
the results are likely due to the methodologies used, as the kits and growth conditions 
were dissimilar between each study. As such, this is the first observation of ATP synthesis 
inhibition due to BDM-I treatment.  
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Figure 4.3 Reduced intracellular ATP concentrations observed within BDM-I treated VRE 
(a) and MRSA (b). Each isolate was treated with BDM-I (MIC50) and incubated for 2 h, 
prior to the intracellular ATP concentrations being quantified using the Roche HS II ATP 
bioluminescence kit. Unknown ATP concentrations were determined using a standard curve, 
and bacterial Cfu were determined based on the OD600 at the time of cell lysis using a 
standard curve. ATP concentrations (nmols) were then normalised to 105 Cfu. Analysis 
revealed a 2-fold decrease in intracellular ATP concentrations within Efm008 (a), as well as 
a significant reduction within Sa057 (b) from 1.32 nmols/105 Cfu to 0.86 nmols/105 Cfu. 
Each experiment was completed in triplicate. 
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4.4.3 Examining Synergism between BDM-I and Polymixin B 
Cationic antimicrobial peptides (CAMPs) are amphipathic antimicrobials which interact 
with the cell membrane, causing the disruption of  membrane integrity and cell death. The 
activity of CAMPs (such as polymyxin B) is generally limited to gram-negative bacteria, 
as gram-positive species such as S. aureus are intrinsically resistant (Vestergaard et al., 
2017). In the context of S. aureus, intrinsic resistance is driven by the reduction of the 
cell surface charge by the incorporation of D-alanine on teichoic acids, or by the 
incorporation of L-lysine to membrane phosphatidylglycerols (Peschel et al., 2001, 
Peschel et al., 1999). Interestingly, Vestergaard et al identified that the inhibition of ATP 
synthase in S. aureus results in hyperpolarization of the membrane, and consequently 
increased sensitivity to polymyxin B (Vestergaard et al., 2017) . 
 
Considering the observed effects of BDM-I on ATP synthase (sections 4.2 and 4.4.2), 
checkerboard assays were utilized to identify changes in polymyxin B sensitivity within 
Sa057, when used in combination with BDM-I. Interestingly, we observed a significant 
increase in the sensitivity of Sa057 to polymyxin B. When used in combination with 
BDM-I at MIC50 (2 µg/mL), the polymyxin B MIC decreased from 256 µg/mL to 64 
µg/mL. The FICI calculated for this interaction (FICI = 0.75) indicates that BDM-I exerts 
an additive effect on polymyxin B, likely through the inhibition of ATP synthase activity 
and the hyperpolarization of the cell membrane. 
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4.5 Examining Phenotypic Changes within BDM-I VISA Mutants 
 
4.5.1 Two-component Regulatory Systems in S. aureus 
Two-component systems (TCS) are regulatory mechanisms employed by bacteria to 
sense and respond to an array of signal types. These systems are comprised of a membrane 
bound histidine kinase with an extracellular sensing loops capable of 
autophosphorylation, and a response regulator protein that functions as a transcriptional 
regulator (Dubrac et al., 2008).  In recent years, several TCS have been identified in 
bacteria as being essential for cell viability. These include the CenKR TCS within 
Caulobacter crescentus, the MtrBA TCS within Mycobacterium tuberculosis, and the 
WalKR TCS, which is commonly found in firmicutes (Dubrac et al., 2008). 
 
Vancomycin intermediate Staphylococcus aureus (VISA) are characterized by a higher 
vancomycin MIC within the range of 4-8 μg/mL (section 1.5). The genetic basis of 
vancomycin resistance within such strains has been linked to mutations within genes 
functioning in cell wall homeostasis, such as walK and clpP (Cui et al., 2003, Shoji et al., 
2011). A previous study by van Hal et al, identified a missense mutation (Q369R) in 
WalK within the progenitor Sa375 isolate, which was likely driving the observed 
intermediate resistance to vancomycin (van Hal et al., 2013). VISA isolates possessing 
mutations within walK are often associated with thickened cell walls, which increase 
resistance to vancomycin by reducing cell wall permeability (Cui et al., 2003, Shoji et al., 
2011).  
 
As discussed in section 4.3, mutations were identified within the walk gene for all Sa375 
mutant isolates. Further analysis revealed that each mutant also retained the previously 
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identified mutation within Sa375 (Q369R), which had been shown to produce a 
phenotype of thickened cell walls (van Hal et al., 2013). Based on the primary function 
of WalK in cell wall homeostasis, and the observed inverse relationship between BDM-I 
and vancomycin MICs, we hypothesized that the newly identified mutations within the 
mutant isolates may be compensatory and result in cell wall thinning. Furthermore, as the 
mutations within walK were consistently observed in all sequenced isolates, it is likely 
they are the primary driver of the observed increases in BDM-I MICs. Previous studies 
have shown that BDM-I does not affect the bacterial cell wall directly (White et al., 2014). 
However, based on our observations it was important to examine potential changes to the 
cell wall phenotype in our mutant isolates.  
 
4.5.2 TEM Used to Identify Changes in Cell Wall Thickness 
Transmission electron microscopy was used to examine the cell wall of Sa375 BDM-I 
mutants (1 colony from each of the 3 series), as well as the progenitor Sa375 isolate 
(VISA control) and Sa057 (VSSA control). The average cell wall thickness was 
determined by examining ten cells from each isolate and is displayed in Figure 4.4. As 
expected, Sa375 was found to have a significantly thicker cell walls compared to Sa057, 
which were measured at 30.1 nm (±2.42) and 21.8 nm (±2.14), respectively. This is 
consistent with previous studies that examined the effect of mutations within walK (Cui 
et al., 2003, Howden et al., 2011, Shoji et al., 2011, van Hal et al., 2013). Interestingly, a 
significant reduction in cell wall thickness was observed in all BDM-I mutants from 30.1 
nm (Sa375 progenitor) to 18.93 nm (±0.72) for Sa375-L37F, 18.37 nm (±1.02) for Sa375-
G560S, and 21.77 nm (±1.26) for Sa375-G30W. 
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Figure 4.4 TEM images identifying changes in the cell wall phenotype within Sa057 (VSSA), Sa375 (progenitor VISA isolate), Sa375 BDM-I mutants 
and Sa375 with an introduced walK mutation (iG560S). Sa057 and Sa375 are derived from the same clinical series associated with chronic bacteraemia 
and the generation of vancomycin intermediate resistance. A mutation within walK (Q369R) is attributed to the thickened cell walls observed in the case 
of Sa375 (30.17 nm) compared to Sa057 (21.8 nm), as well as the increase in vancomycin resistance (4 µg/mL from 2 µg/mL respectively). TEM and MIC 
analysis of BDM-I mutants with novel walK mutations, revealed a significant decrease in cell wall thickness compared to Sa375 (18-21 nm) as well as 
increased susceptibility to vancomycin (4 µg/mL to 0.5-1 µg/mL) and daptomycin (4 µg/mL to 0.5-1 µg/mL). The novel mutation G560S was also 
introduced to the progenitor Sa375 strain (Sa375-iG560S) using allelic exchange, which was shown through TEM and MIC analysis to produce a phenotype 
with thinner walls (24.48 nm) and increased vancomycin susceptibility (1 µg/mL).  
Sa057 
 
Sa375a 
 
Sa375-L37F 
 
Sa375-G560S 
 
Sa375-G30W 
 
21.8 ± 2.14 
Vancb = 2μg/mL 
Dapc = NA 
 
30.17 ± 2.42 
Vanc = 4μg/mL 
Dap = 4μg/mL 
 
18.93 ± 0.72 
Vanc = 0.5μg/mL 
Dap = 0.5μg/mL 
 
18.37 ± 1.02 
Vanc = 0.5μg/mL 
Dap = 1μg/mL 
 
21.77 ± 1.26 
Vanc = 1μg/mL 
Dap = 1μg/mL 
 
Sa375-iG560S 
 
24.48 ± 0.88 
Vanc = 1μg/mL 
Dap = NA 
 aSa375 carries a previously identified walK mutation (Q369R) which is also present within each of the BDM-I mutant series 
bVancomycin 
cDaptomycin 
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4.5.3 Changes in Vancomycin and Daptomycin Sensitivity in Sa375 Mutants  
As stated previously, an increase in cell wall thickness is commonly associated with 
intermediate vancomycin resistance in S. aureus. In section 4.5.2, we observed a 
significant decrease in cell wall thickness for all mutant Sa375 isolates, identified to 
possess novel mutations within walK. Following this, we explored changes in 
vancomycin MICs for these mutants due changes in their cell wall phenotype. In this 
regard, additional BMD MIC tests were completed on isolates from section 4.5.2 using 
vancomycin and daptomycin as described previously. 
 
MIC testing identified significant decreases in vancomycin MICs for all mutant isolates, 
in comparison to the progenitor Sa375. Mutant vancomycin MICs were determined to be 
0.5 μg/mL for Sa375-L37F and Sa375-G560S, and 1 μg/mL for Sa375-G30W (Figure 
4.4), placing each isolate within the susceptible range for vancomycin (≤2 μg/mL). This 
was greater than a two-fold decrease compared to the Sa375 progenitor isolate, with had 
vancomycin MIC of 4 μg/mL. 
 
Cross resistance to the lipopeptide antibiotic daptomycin has previously been observed 
for VISA isolates that possess mutations within walK (Bayer et al., 2013, Chen et al., 
2015, Howden et al., 2011). In a previous study, van Hal et al identified that the Sa375 
progenitor isolate (Q369R) was daptomycin non-susceptible, which was likely due to the 
identified SNP within walK (van Hal et al., 2013). Further MIC testing was then 
completed for the mutant Sa375 isolates with daptomycin, which revealed a significant 
decrease in MIC from 4 μg/mL (Sa375) to 0.5 μg/mL for Sa375-L37F, and 1 μg/mL for 
Sa375-G560S and Sa375-G30W. Similarly, the reduction in MICs places these mutants 
within the susceptible range for daptomycin (≤1 μg/mL). 
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4.5.4 Gly560Ser Alters the Cell Wall Phenotype  
In sections 4.5.2 and 4.5.3, we identified the phenotypic effects of walK mutations on cell 
wall thickness and vancomycin/daptomycin susceptibility, in Sa375 mutant isolates. 
Allelic exchange was then performed to introduce the mutation Gly560Ser from a series 
2 mutant, into the progenitor isolate Sa375, in order to confirm its exclusive role in 
producing the aforementioned phenotype (i.e., decreased cell wall thickness and 
increased sensitivity to vancomycin and daptomycin).  
 
Allelic exchange was successfully performed using the plasmid vector pIMAY-Z, which 
was used to clone a PCR fragment derived from Sa375-G560S (carrying the identified 
walK SNP) prior to transformation into Sa375. Subsequently, the cloned fragment was 
successfully incorporated into the genome of Sa375, producing the genetically modified 
strain Sa375-iG560S which was confirmed with Sanger sequencing. MIC tests were then 
performed on the derived mutant (Sa375-iG560S), which was found to have a 
significantly lower vancomycin MIC and higher BDM-I MIC of 1 μg/mL and 3-4 μg/mL, 
respectively; this is compared to the vancomycin and BDM-I MICs of Sa375, which are 
4 μg/mL and 2 μg/mL respectively. Additionally, TEM was performed on Sa375-iG560S, 
and this revealed a significant decrease in cell wall thickness from 30.1 nm to 24.48 nm 
(Figure 4.4). 
 
As such, based on the observed changes in MICs and cell wall thickness for Sa375-
iG560S, and its phenotypic similarities to Sa375-G560S, it is highly likely that the 
identified compensatory mutations within walK (for the Sa375 mutants generated via the 
induction experiments) are solely driving increased resistance to BDM-I.
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4.6 Discussion 
 
With access to mutants with increased resistance to antimicrobials, as well as their 
progenitor isolates, whole genome sequencing can be utilised to identify mutations that 
are likely relevant to a drugs MoA. In the context of BDM-I, previous studies have failed 
to produce mutant isolates with increased resistance (Denisenko et al., 2010, White et al., 
2014). However, in Chapter 3 we described the generation of mutant VRE and MRSA 
isolates with increased BDM-I resistance (>2x MIC) following prolonged exposure to the 
compound. Derived VRE and MRSA mutant isolates were then subjected to whole 
genome sequencing in order to identify mutations that may be driving increased resistance 
to BDM-I. Mutations were considered significant in relation to the BDM-I MoA if they 
were identified in all (or the majority) of the sequenced mutant isolates from each series. 
In this regard, analysis of the sequencing data revealed two cellular processes that were 
affected by prolonged BDM-I exposure, namely ATP synthesis within VRE and 
peptidoglycan synthesis within MRSA.  
 
Sequencing analysis of Efm003 and Efm008 mutants revealed that mutations within the 
ATP synthase operon were common. Interestingly, the types of mutations identified as 
well as their locations within the operon varied considerably between colonies, series and 
isolates. In the case of Efm003, a SNP was identified within atpB for all three series, 
while SNPs were identified within atpD for series 1 and 2 of Efm008, as well as a large 
IS-mediated deletion of several genes for series 3. Furthermore, mutations were identified 
within 5 atp genes for the day 10 Efm008 mutant series. Considering the unpredictability 
regarding where mutations are present (within the ATP synthase operon), as well as the 
fact that mutant isolates remain susceptible to increased BDM-I concentrations, it is 
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unlikely that ATP synthase is the direct target of BDM-I. Instead, it is likely that altering 
the activity of ATP synthase may be a compensatory mechanism by which VRE can adapt 
to BDM-I exposure. To explore the effect that BDM-I has on the activity of ATP synthase, 
ATP assays were performed to assess intracellular ATP levels within both VRE 
(Efm0008) and MRSA (Sa057) isolates when treated with BDM-I. Interestingly, results 
from these assays revealed that such treatment (with BDM-I MIC50)  significantly reduced 
intracellular ATP concentrations in both isolates (section 4.4.2). While ATP synthesis 
appears to be inhibited by BDM-I within MRSA, no mutations were identified within the 
ATP synthase operon for any of the MRSA mutant isolates. As such, the inability to 
knockout ATP synthase in response to BDM-I exposure may support previous 
observations that is essential for MRSA growth, at least under the conditions tested 
(Balemans et al., 2012).     
 
Additional evidence for the inhibition of ATP synthesis was gathered via checkerboard 
assays combining BDM-I and polymyxin B (section 4.4.3). As discussed in section 4.4.3, 
these assays examined changes in Sa057 sensitivity to polymyxin B (CAMP) when used 
in combination with BDM-I. Results from these studies identified a reduction in the 
intrinsic resistance to CAMPs typically associated with S. aureus. The significance of this 
outcome relates to observations that inhibiting ATP synthase in S. aureus alters the 
membrane potential, which increases the susceptibility of S. aureus to CAMPs 
(Vestergaard et al., 2017).  
 
Therefore, these results in combination strongly indicate that BDM-I treatment affects 
ATP synthase activity, and thus the availability of intracellular ATP. However, 
sequencing analysis of MRSA mutant isolates revealed that they could not circumvent 
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decreased levels of intracellular ATP in the same way (i.e., by knocking out ATP 
synthase), and adapt differently. In this regard, peptidoglycan synthesis was shown to be 
negatively affected by BDM-I exposure, as mutations were identified within genes that 
regulate cell wall maintenance. Specifically, SNPs were identified within the walK gene 
for all Sa375 mutant isolates, while for the Sa057 mutant isolates mutations were 
identified in several genes that function both directly (murA and atlA) and indirectly 
(mvaA) in cell wall synthesis.  
 
As discussed in section 4.5, walK is part of the walKR TCS, which often plays a role in 
the vancomycin and daptomycin resistance displayed by hVISA/VISA isolates. This 
resistance is commonly driven by SNPs within walK that result in a thickened cell wall 
phenotype, as observed for Sa375 (section 4.5.2). By conducting TEM analysis of Sa375 
BDM-I mutants, we revealed that the identified walK mutations produce a phenotype that 
is similar to that of VSSA isolates (i.e., thinner cell walls). Additional MIC studies also 
revealed that these mutant isolates were susceptible to both vancomycin and daptomycin, 
as a result of the cell wall thinning. As such, it appears that in the case of the VISA isolate 
(Sa375), it has reverted to a VSSA phenotype (by acquiring compensatory mutations in 
walK) as an adaptive response to BDM-I exposure. Thus, this implies that the VSSA 
phenotype is less susceptible to BDM-I, which again coincides with the observed 
vancomycin/BDM-I inverse relationship (see section 3.4).  
 
In summary, the data generated in this chapter provides further insight into the BDM-I 
MoA. By examining the genotype and phenotype of mutant isolates with increased 
resistance to BDM-I, we have identified that the compound likely inhibits ATP synthesis 
via the oxidative phosphorylation pathway (i.e., by affecting ATP synthase). The 
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observed reduction in intracellular ATP levels would limit the availability of free ATP 
for various cellular processes and thus favour cell phenotypes that utilize less ATP. This 
is most evident in the case of Sa375 mutants reverting to a VSSA phenotype (upon BDM-
I exposure), which is likely due to the significant amount of energy required to synthesize 
and maintain a thickened cell wall (Jarick et al., 2018).  
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Proteomic Analysis of BDM-I Treated Isolates 
 
5.1 Introduction 
 
Whole genome sequencing was previously utilized to identify mutations that contributed 
to increased BDM-I resistance (see Chapter 4). As discussed, the data generated strongly 
indicated that BDM-I negatively affects the functionality of ATP synthase. However, 
such an approach does not reveal how cells more broadly adapt (to BDM-I exposure) at 
a protein expression level, which would provide a greater understanding of the cellular 
pathways affected and the overall MoA.  
 
To investigate this proteomic studies were carried out using Efm008 and Sa057 treated 
with BDM-I (MIC50), as well as the Efm008 deletion mutant Efm008ΔatpACDG (Chapter 4, 
section 4.2). In this regard, two different methodological approaches were utilized, and 
these were 2-Dimensional Gel Electrophoresis (2-DGE) and shotgun proteomics. 2-DGE 
was initially used for first pass analysis of protein changes in collaboration with the 
proteomics research group from the Western Sydney University School of Medicine. In 
this initial study we analysed both membrane and soluble proteins that displayed greater 
than a 90% change when cells were treated with BDM-I. In this regard, following 
separation by 2-DGE,  proteins with such an expression change were identified (using 
mass spectrometry) based on changes in protein spot intensity as identified using Delta2D 
software. This approach was initially performed using BDM-I treated Efm008, as well as 
the Efm008ΔatpACDG deletion mutant (see section 4.2). 
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Due to the limitations associated with 2-DGE proteomics, a shotgun approach was then 
adopted in collaboration with the Stuart Cordwell laboratory at the University of Sydney 
School of Life and Environmental Sciences. Subsequently, by utilizing shotgun 
proteomics, an in-depth dataset was generated that provided insight into the cellular 
response of BDM-I treated MRSA and VRE. Specifically, common pathways and 
proteins for both bacterial species were identified that are differentially regulated due to 
BDM-I exposure, and these results were then be compared to whole genome sequencing 
data (Chapter 4) in order to gain further insight into the BDM-I MoA.  
 
5.2 2-D Gel Proteomics of BDM-I Treated Efm008 and Efm008ΔatpACDG 
 
Proteome analysis of BDM-I treated Efm008 and the mutant isolate Efm008ΔatpACDG was 
initially performed using 2-DGE. This methodology relies on gel-based protein 
separation according to a proteins isoelectric point (first dimension) and molecular weight 
(second dimension). Each isolate was grown to mid-exponential phase in the presence 
(Efm008) or absence (Efm008DatpACDG) of BDM-I, before the cells were harvested, and 
the protein was extracted for proteomic analysis. Separated proteins were analysed using 
the Delta2D software to detect protein spots with visible changes in intensity. 
Subsequently, spots of interest (i.e., those displaying greater than 90% change) were then 
identified using mass spectrometry.  
 
In this regard, several proteins were identified with altered expression, as shown in Figure 
5.1 (soluble fraction) and Figure 5.2 (membrane fraction). Spots that are circled green 
and red indicate those which are present or absent, respectively, in comparison to the WT 
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Efm0008 isolate.  In total, 17 soluble and 11 membrane bound proteins spots were 
identified with mass spectrometry and are summarised in Tables 5.1 and 5.2, respectively. 
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S6 
 
Figure 5.1 2-DGE of soluble protein fractions from Efm008 (left), Efm008ΔatpACDG (middle) and BDM-I treated Efm008 (MIC50) (right). 
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Figure 5.2 2-DGE of membrane protein fractions from Efm008 (left), Efm008ΔatpACDG (middle) and BDM-I treated Efm008 (MIC50) (right). 
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    Table 5.1 Identification of differentially expressed soluble proteins within Efm008DatpACDG and BDM-I Treated (MIC50) Efm008 
Protein 
Band No. Protein ID Protein Name Score MW (kDa) pI 
Expressiona 
MIC50 ΔatpACDG 
S1 VANA_ENTFC Vancomycin/teicoplainin A-type resistance protein 3566 37.4 5.8 ↓ ↓ 
S2 VANA_ENTFC Vancomycin/teicoplainin A-type resistance protein 3680 37.3 5.2 ↓ ↓ 
S3 VANH_ENTFC D-specific alpha-keto acid dehydrogenase 2263 35.7 6.2 ↓ ↓ 
S4 RL2_ENTFA 50S ribosomal subunit 335 30.2 - = ↓ 
S5 VANX_ENTFC D-alanyl-D-alanine dipeptidase 3371 23.3 5.58 ↓ ↓ 
S6 PTHP_LACSK Phosphocarrier protein 146 9.4 4.9 ↓ = 
S7 L2IW34 Valine tRNA ligase 1847 101.7 4.9 ↑ = 
S8 D0AG92 Asparagine synthetase 1310 72.8 5.4 ↑ ↑ 
S9 
AROB_ENTFA 3-dehydroquinate synthase 148 38.9 5.3 
= ↑ 
KOZN21 3-dehydroquinate synthase 1095 38.4 5.8 
KOZ2V5 Tryptophanyl-tRNA synthetase II 434 37.2 5.7 
K0Z3U9 Fructosamine deglycase 321 38.1 5.6 
K0YZ15 Polyprenyl synthetase 189 37.0 5.9 
D0AGA2 Ferredoxin-NADP reductase 147 36.5 5.7 
S10 
L2MZX4 LPXTG-domain containing protein cell wall anchor domain 
1577 53.1 4.7 
= ↑ 
R2WNK2 Fimbrial isopeptide formation D2 domain-containing protein 
1415 53.0 4.8 
S11 K0Z0H4 Pyruvate dehydrogenase complex, E1 component, beta subunit 
143 35.4 4.6 
= ↑ 
S12 
SYV_ENTFA Valine tRNA ligase 642 101.5 4.8 
↑ = 
MUTS_ENTFA DNA mismatch repair protein 489 96.8 5.0 
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         Table 5.1 continued 
Protein 
Band No. Protein ID Protein Name Score MW (kDa) pI 
Expressiona 
MIC50 ΔatpACDG 
S13 
L2IW34 Valine tRNA ligase 607 101.6 4.9 
↑ = I3U2E8 DNA polymerase 197 100.4 5.3 
C9AHE3 DNA mismatch repair protein 161 99.5 5.2 
K0ZBX1 Sigma-54 factor interaction domain-containing protein 102 102.6 5.2 
S14 D0AG92 Asparagine synthetase 1705 72.8 5.4 ↑ = 
S15&16 
K0Z3Y4 Coenzyme A disulfide reductase 4203 60.3 5.5 ↑ = 
K0Z3H2 Glucan 1,6-alpha gucosidase 239 63.0 5.3 ↑ = 
K0ZR27 Phosphoenolpyruvate-protein phosphotransferase 226 63.2 4.8 ↑ = 
R2CRN4 Uncharacterized protein 206 65.0 5.4 ↑ = 
D0AE22 Proline tRNA ligase 145 64.4 5.0 ↑ = 
K1A8R9 Phosphoglucomutase/mannomutase family protein 142 63.8 5.0 ↑ = 
S17 
K0ZS04 3-ketoacyl-(Acyl carrier protein) reductase 2102 26.1 7.7 ↑ = 
C9APL7 3-oxoacyl-(Acyl carrier protein) reductase 966 26.1 7.7 ↑ = 
L2HFL0 CBS protein 627 24.2 8.3 ↑ = 
        a ↑ signifies upregulated, ↓ signifies downregulated, = signifies no change 
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        Table 5.2 Identification of Differentially Expressed Membrane Bound Proteins within Efm008DatpACDG and BDM-I Treated (MIC50) Efm008  
Protein 
Band No. Protein ID Protein Name Score MW (kDa) pI 
Expression 
MIC50 ΔatpACDG 
M1 
L2IZM7 Dihydrolipoamide S-succinyltransferase 2545 45.9 5.3 
↑ ↓ 
C8NEA0 Dihydrolipoyllysine-residue acetyltransferase 351 55.6 4.9 
M2 ATPB_ENTHA ATP synthase subunit beta 3675 50.9 4.7 = ↓ 
M3 VANA_ENTFC Vancomycin/teicoplanin A-type resistance protein 3121 37.4 5.8 ↓ ↓ 
M4 VANA_ENTFC Vancomycin/teicoplanin A-type resistance protein 2371 37.4 5.8 ↓ ↓ 
M5 RS2_ENTFA 30S ribosomal protein 1383 29.4 5.0 = ↓ 
M6 C9CAX1 50s ribosomal protein 1301 21.9 4.6 ↓ ↓ 
M7 
CLPP_ENTFA ATP dependent Clp protease proteolytic subunit 167 21.6 4.7 
↓ = 
 ATP synthase subunit delta 107 20.6 5.5 
M8 K0Z016 Uncharacterized protein 593 12.8 4.9 ↓ = 
M9 
L2IZM7 Dihydrolipoamide S-succinyltransferase 2767 45.9 5.3 ↑ = 
K0Z094 fusA Elongation factor G 297 76.7 4.8 ↑ = 
L2S531 Penicillin-binding protein transpeptidase 170 73.7 4.9 ↑ = 
M10 
MSMK_STRMU Multiple sugar-binding transport ATP-binding protein 203 41.9 5.9 ↑ = 
D0AGE3 ABC transporter 2022 41.1 6.2 ↑ = 
M11 C2E3E2 Glycerol-3-phosphate-transporting ATPase 144 41.3 5.8 ↑ = 
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Of the 17 soluble protein spots selected for analysis, four (SP1, SP2, SP3 and SP5) were 
identified as being encoded by the vanHAX operon, which functions in facilitating high-
level vancomycin resistance. These four spots were heavily down-regulated in both the 
BDM-I treated and mutant isolates. Two membrane spots (M3 and M4) were also 
identified as one of these proteins (in both isolates) and were similarly down-regulated. 
The downregulation of the vanHAX operon is likely due to the lack of selective pressures 
(imposed by exposure to glycopeptides) and reduced availability of ATP.  
 
In accordance with the whole genome sequencing data generated for the VRE mutants 
described in section 4.2, subunits of ATP synthase were downregulated in the mutant and 
drug treated isolates. Interestingly, several proteins are upregulated that function in the 
metabolism of substrates essential for ATP synthesis via the glycolytic pathway. The E1 
component of the pyruvate dehydrogenase complex (S11) was upregulated within the 
deletion mutant and catalyses the conversion of pyruvate to Acetyl-CoA. Furthermore, 
coenzyme A disulphide reductase (S15 and 16), asparagine synthetase (S8 and 14) and 
Dihydrolipoamide S-succinyltransferase (M1) were upregulated within the BDM-I 
treated isolate. Respectively, these proteins are involved in the production of coenzyme 
A, oxaloacetate (via asparagine) and succinyl-CoA which are all utilized in the TCA 
cycle. 
 
Several transport proteins were also upregulated within BDM-I treated Efm008, including 
MsmK, an ABC transporter (M10) and a Glycerol-3-phosphate-transporting-ATPase 
(M11). Additionally, both the 30S (M5) and 50S (M6) ribosomal proteins were 
downregulated within Efm008DapACDG, possibly indicating a disruption in transcription as 
a result of decreased ATP levels.  
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5.3 Shotgun Proteomics Identifies Several Key Pathways Affected by BDM-I 
Treatment  
 
Due to the limitations associated with 2-DGE proteomics, such as poor resolution and the 
limited amount of data that can be obtained, additional studies were conducted on the 
proteomes of MRSA (Sa057) and VRE (Efm008) isolates treated with BDM-I (MIC50). 
Each isolate was grown to mid-exponential phase in the presence of BDM-I before being 
harvested and utilized for whole proteome analysis using liquid chromatography-mass 
spectrometry (LC/MS) of enriched peptides.  
 
Analysis of the proteome data was completed in collaboration with Stuart Cordwell and 
William Klare at the Charles Perkins Centre, University of Sydney. In short, total 
proteome data was identified and quantified using MaxQuant (ver 1.6.0.16) software and 
the Uniprot Staphylococcus aureus strain JKD6008 (4/2/17, 2652 proteins) and the 
Uniprot Enterococcus faecium strain Aus0004 (4/2/17, 2826 proteins) with the default 
settings of 20 and 4.5 ppm for first and main search precursor tolerance, respectively. 
Peptides were identified using the LFQ algorithm for normalisation allowing for two 
missed tryptic cleavages, while Oxidation of methionine, protein N-terminal acetylation 
and carbamidomethylation of cysteine were set as variable modifications. The quantify 
option was enabled with a minimum of two unique razor peptides used for protein 
quantification. The peptide spectral match and false discovery rate (FDR) were set to 1% 
when all searches were made. 
 
Proteins were selected for analysis if ³2 peptides were successfully mapped, while 
proteins that occurred in only a single replicate were discarded. Missing values for the 
remaining proteins were imputed from a normal distribution using Perseus (ver 1.6.07). 
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Multiple t-tests were performed on log2 transformed LFQ intensities, with a FDR cut-off 
of padj <0.05, with a log2 difference of ≥ 2-fold being considered differentially expressed 
between groups for statistically significant results. 
 
A total of 1589 proteins were identified with >2 peptides mapping to the S. aureus strain 
JKD6008. Of these, 1070 were identified in ³2 replicates within both samples, while 287 
proteins were significantly different (padj <0.05) between the WT and treated isolates. In 
total, 30 proteins met the log2 fold change cut-off as shown in Figure 5.3 (a). In the case 
of Efm0008, 1459 proteins were identified with >2 peptides mapping to the E. faecium 
strain Aus0004. 1068 of these proteins were present in ³2 replicates, while 190 were 
significantly different (padj <0.05) between WT and treated isolates, with 12 proteins 
meeting the final log2 fold cut-off of ³2 (Figure 5.3 (b)). 
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Figure 5.3 Volcano Plots identifying the number of proteins differentially expressed 
within Sa057 (a) and Efm008 (b) following exposure to BDM-I. Data points labelled blue 
indicate proteins with a ³±1-fold change, while green data points indicate proteins with a 
³±2-fold change. Fold change is relative to the untreated isolates. 
a) 
b) 
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Proteins that met the log2 fold change cut-off of ³2 were identified and are shown in 
Supplementary Tables 6 to 9, including the fold change relative to untreated cells. 
Interestingly (and importantly), several proteins were differentially regulated in both 
Sa057 and Efm008 and these are summarised in Table 5.3.  
 
 
Table 5.3 Proteins Differentially Regulated in both Sa057 and Efm008 following BDM-I 
Treatment 
Protein Gene Log2 Fold Change Efm008 Sa057 
Uracil-DNA glycosylase ung +2.06 +2.46 
Nitroredutase family proteins - +6.58 +4.14 
6-phospho-beta-galactosidase lacG -17.69 -13.62 
Primosomal protein N’ priA -11.32 -2.01 
Zinc-containing alcohol dehydrogenase - -3.8 -6.47 
Aspartate carbamoyltransferase pyrB -3.4 -5.34 
Carbamoyl-phosphate synthase pyrA -2.68 -4.96 
ATP Synthase F1, gamma subunit atpG -2.42 -2.13 
Dihydroxyacetone kinase, phosphotransfer subunit - -2.12 -2.07 
Phosphomevalonate kinase mvaK2 -2.12 -2.62 
Acetyltransferase, GNAT family - -2.09 -2.25 
Orotate phosphoribosyltransferase pyrE -2.04 -3.6 
ABC transporter ATP binding protein - -2.02 -3.86 
 
 
The most significant change observed in both isolates was in the expression of 6-phospho-
galactosidase, which was downregulated in Efm008 by 17.69-fold, and in Sa057 by 
13.61-fold. Of note, this protein is involved in the multi-step conversion of lactose to D-
tagatose-6P. Several glycosyl transferases were also downregulated in both isolates, 
including glycosyl transferase family 1 by 32.09-fold in Sa057, and glycosyl transferase 
family 8 by 18.35-fold in Efm008 (Supplementary Tables 6 and 8).  
 
Interestingly, phosphomevalonate kinase (mvaK2), which is indirectly involved in 
peptidoglycan synthesis (via the mevalonate pathway) was downregulated in Sa057 and 
Efm008 by 2.62-fold and 2.12-fold respectively. Furthermore, analysis revealed the 
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downregulation of WalK (see section 4.5) by 9.21-fold in Sa057, as well as several other 
upregulated proteins involved in peptidoglycan hydrolysis including; a transglycosylase 
(sceD) in Sa057 by 34.05-fold, and a LysM containing protein in Efm008 by 7.45-fold.  
 
Several pathways were also found to be differentially regulated following BDM-I 
treatment. Analysis revealed that all proteins involved in de novo Uridine Monophosphate 
(UMP) biosynthesis were downregulated in Sa057 following drug treatment. In total, 7 
proteins are involved in the step-wise production of UMP from carbamoyl phosphate 
(Figure 5.4a). All 7 proteins were downregulated by ³2.5-fold within Sa057, as well as 
several in Efm008; including aspartate carbamoyltransferase (pyrB), carbamoyl-
phosphate synthase (pyrAB) and orotate phosoribosyltransferase (pyrF), by 3.4-fold, 
2.68-fold and 2.04-fold respectively (Figure 5.4b).  
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Figure 5.4 UMP Biosynthesis Pathway (a) and associated proteins downregulated in BDM-
I treated Sa057 and Efm008 (b). Interestingly, all proteins within this pathway were 
downregulated in Sa057, while three were also downregulated in Efm008. 
aIndicates no change in expression following BDM-I treatment compared to WT. 
Product Gene Log2 Fold Change
a 
Sa057 Efm008 
Dihydroorotate dehydrogenase pyrD -6.85 - 
Dihydroorotase pyrC -5.69 - 
Aspartate carbamoyltransferase pyrB -5.33 -3.4 
Carbamoyl phosphate synthase (small chain) pyrAA -4.96 - 
Carbamoyl phosphate synthase (large chain) pyrAB -4.44 -2.68 
Orotate phosphoribosyltransferase pyrE -3.59 -2.04 
Orotidine 5’-phosphate decarboxylase pyrF -2.81 - 
 
a) 
b) 
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Interestingly, proteins involved in pyruvate metabolism also exhibited altered expression, 
including L-lactate oxidase (converts L-lactate to acetate) and Phosphoenolpyruvate 
carboxykinase (converts phosphoenolpyruvate to oxaloacetate), which were 
downregulated by 13.76-fold and 3.04-fold, respectively within Efm008. Furthermore, L-
lactate dehydrogenase (converts pyruvate to L-lactate in a reversible reaction) was 
upregulated by 2.8-fold within Efm008, as well as a Class II Aldolase and Adducin N-
terminal domain protein (upregulated 30.54-fold), which likely functions in the synthesis 
of L-lactaldehyde. Interestingly, L-lactaldehyde is an important precursor for the 
synthesis of L-lactate, possibly indicating that Efm008 is favouring the production of 
pyruvate/L-lactate following drug treatment. Furthermore, the bifunctional 
acetylaldehyde CoA dehydrogenase (converts Acetyl-CoA to acetaldehyde) enzyme and 
formate C-acetyltransferase (converts Acetyl-CoA to CoA and pyruvate using formate) 
were downregulated in Sa057 by 60.93-fold and 10.53-fold, respectively. Interestingly, 
acetyl-coenzyme A synthase (converts acetyladenylate to acetyl-CoA) was upregulated 
by 2.19-fold, suggesting that Sa057 may be responding to drug treatment by increasing 
the production of acetyl-CoA. Interestingly, both pyruvate and acetyl-CoA are essential 
substrates of the TCA cycle. 
 
Furthermore, several proteins were identified which showed drastically altered expression 
profiles, in some cases showing >10-fold changes in expression compared to the WT 
isolates. With regard to Sa057, threonine dehydratase (responsible for the synthesis of 2-
ketobutyrate from L-threonine) was significantly downregulated by 78.33-fold, as well 
as a respiratory nitrate reductase which was downregulated by 52.97-fold. Additionally, 
the osmotically inducible protein OsmC was upregulated by 13.16-fold. Interestingly, 
OsmC is a homologue to hydroperoxide peroxidase and is known to play a role in 
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alleviating oxidative stress. Respective to Efm008, a SIS domain containing protein was 
downregulated 26.65-fold, as well as a mannose/fructose/sorbose-specific IIB component 
of the phosphotransferase system, which was downregulated 10.45-fold. Interestingly, it 
is likely that both of these proteins function in sugar metabolism. Additionally, a D-
alanyl-D-alanine dipeptidase (VanX) was downregulated by 7.54-fold, which 
corresponds to previous proteomic work as described in section 5.2. 
 
STRINGdb analysis was also used to identify protein clusters which were downregulated 
or upregulated following BDM-I exposure. Regarding Sa057, major clusters which were 
downregulated include those associated with virulence factors (EssA, ExsAB), 
metabolism (Ldh1, Ldh2, LdhD) and nucleotide metabolism (Tgt, UvrB, RlmN), as 
shown in Figure 5.5. Clusters which were upregulated include proteins associated with 
the stress response, iron acquisition, urease biosynthesis and capsule biosynthesis (Figure 
5.6). STRINGdb analysis of Efm008 identified two primary protein clusters 
downregulated following exposure to BDM-I, including proteins associated with 
phosphoenolpyruvate-dependent sugar phosphotransferase activity and ATPase activity 
(Figure 5.7a). Protein clusters which were upregulated include those associated with 
nitroreductase activity and cell redox homeostasis (Figure 5.7b). 
  
 
 
133 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 5.5: STRINGdb analysis identifying protein clusters downregulated in BDM-I treated Sa057. Highlighted clusters include proteins associated with virulence (1), metabolism (2) and nucleotide metabolism (3). 
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 Figure 5.6: STRINGdb analysis identifying protein clusters upregulated in BDM-I treated Sa057. Highlighted clusters include proteins 
associated with the stress response (1), iron acquisition (2) and urease metabolism (3). 
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Figure 5.7: STRINGdb analysis identifying protein clusters downregulated (a) and upregulated (b) in BDM-I treated Efm008. Highlighted clusters which were 
downregulated (a) include proteins associated with phosphophenylpyruvate- dependent sugar phosphotransferase activity (1) and ATPase activity (2). Clusters 
which were upregulated (b) include proteins with nitroreductase activity (1) and proteins functioning in cell redox homeostasis (2). 
a) b) 
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5.4 Discussion 
 
Whole proteome analysis of drug treated cells is a well-documented approach to 
understanding the MoA of a compound (Bandow et al., 2003, Thangamani et al., 2016, 
Wang and Chiu, 2008). Following the identification of compensatory mutations within 
mutant isolates with increased resistance to BDM-I, we aimed to utilize proteomics to 
study the cellular response to BDM-I treatment. Two methods were used and discussed 
in Chapter 5, including 2-DGE (section 5.2) as a first pass approach and shotgun 
proteomics (section 5.3), which provided significantly more quantifiable data. 
 
Results discussed in Chapter 4 strongly indicated that BDM-I negatively affects ATP 
synthase, therefore we hypothesized that cellular responses to BDM-I treatment would, 
at least in part, relate to reduced ATP synthesis via the oxidative phosphorylation 
pathway. As shown above, a large number of proteins were found to be differentially 
expressed as a result of BDM-I exposure. Interestingly, a number of these proteins (and 
associated pathways) correlate to data obtained in Chapter 4. For example, multiple 
subunits of ATP synthase were downregulated in drug treated Efm008 (subunits d and g, 
section 5.2 and 5.3, respectively) and Sa057 (subunit g, section 5.3). As a possible 
response to this, several proteins that function in pyruvate and acetyl-CoA metabolism 
exhibited altered expression, as shown in Figure 5.8. 
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Figure 5.8 Proteins associated with the synthesis of pyruvate and acetyl-CoA that are 
differentially regulated following BDM-I treatment. Proteins involved in the synthesis 
of L-Lactaldehyde and L-lactate/pyruvate were upregulated within Efm008 (red), 
while those that convert L-lactate to acetate and phosphoenolpyruvate to oxaloacetate 
were downregulated (blue). Within Sa057, acetyl-CoA synthase was upregulated 
(orange), while acetylaldehyde CoA dehydrogenase and formate C acetyltransferase 
were downregulated (green).  
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In the context of Efm008, shifts in protein expression appear to favour the production of 
L-lactate. This is most evident based on the upregulation of proteins involved in the 
synthesis of L-lactate, and most importantly, the protein L-lactate dehydrogenase, which 
is responsible for the reversible conversion of pyruvate to lactate. Furthermore, proteins 
that convert L-lactate to other substrates (such as L-lactate oxidase) are downregulated 
following BDM-I treatment. This increased production of L-Lactate and pyruvate is likely 
a compensatory mechanism in response to the disruption of ATP synthase activity, and 
the reduced production of ATP via oxidative phosphorylation. Enterococci are capable of 
utilizing multiple pathways to generate ATP (at the substrate level) depending on 
environmental conditions. In the absence of functioning ATP synthase, the up-regulation 
of lactate and pyruvate synthesizing enzymes indicates that BDM-I treated Efm008 may 
be utilizing lactic acid fermentation as an alternative pathway to generate ATP (Ramsey 
M, 2014). Lactate is commonly utilized by lactic acid bacteria as a source of energy and 
can be generated by the reduction of pyruvate, which also produces NAD+. Ensuring a 
continuous supply of NAD+ promotes ATP production via the glycolytic pathway (Jiang 
et al., 2014, Ramsey M, 2014).  
 
Unlike Efm008, several lactate dehydrogenase proteins were downregulated in Sa057. 
Anaerobic growth of S. aureus occurs in the absence of external electron acceptors such 
as oxygen and nitrate. When switching to anaerobic growth, glycolytic enzymes such as 
lactate dehydrogenases, alcohol dehydrogenases, a-acetolactate decarboxylase and 
acetolactate synthase are upregulated, signifying that mixed acid and butanediol 
fermentation is taking place (Fuchs et al., 2007). However, BDM-I treatment resulted in 
the downregulation of all proteins associated with anaerobic growth in S. aureus. 
Furthermore, proteins functioning in the synthesis of acetyl-CoA were upregulated 
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suggesting that ATP synthesis via the TCA cycle and oxidative phosphorylation is still 
favoured. Instead of changes in cellular respiration, the primary pathway affected by 
BDM-I treatment in Sa057 is UMP synthesis, which is the initial step in pyrimidine 
(nucleotide) metabolism (Hammer et al., 2005). Previous results (sections 4.6 and 5.2) 
indicate that changes to cell wall synthesis is the primary mechanism by which S. aureus 
can adapt to BDM-I exposure. Interestingly, proteins involved in pyrimidine metabolism 
have been associated with cell wall homeostasis in other bacteria. Research by Solopova 
et al identified that cell wall rigidity is regulated by aspartate carbamoyltransferase (pyrB) 
in Lactococcus lactis (Solopova et al., 2016). Furthermore, UMP can be phosphorylated 
to uridine diphosphate (UDP), which is required for the production of UDP-N-
acetylglucosamine in the early stages of peptidoglycan synthesis (Jarick et al., 2018). 
WalK was also downregulated (>9-fold) following BDM-I treatment, which correlates 
with results discussed in Chapter 4. The WalKR TCS regulates the expression of a large 
number of proteins, several of which play key roles in peptidoglycan synthesis and 
hydrolysis. Proteomic analysis revealed the up-regulation of a WalKR regulated 
transglycosylase (sceD), with known cell wall degradative functions (Dubrac et al., 
2007). This data suggests that Sa057 is restricting cell wall synthesis and promoting cell 
wall turnover in response to BDM-I treatment.  
 
 In Chapter 3 and 4, it was observed that S. aureus was unable to adapt to BDM-I in the 
same way as E. faecium via mutations within the ATP synthase operon. One possible 
explanation is that ATP synthase may be essential (or more essential) within S. aureus 
under the conditions tested. Balemans et al and Ko et al identified that ATP synthase 
knockout mutants suffered from a severely decreased growth rate, suggesting that ATP 
synthase plays an important role in the growth and survival of S. aureus (Balemans et al., 
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2012, Ko et al., 2006). Therefore, in order to compensate for the decreased levels of 
intracellular ATP, S. aureus may instead downregulate cellular processes that require 
large amounts of ATP, such as cell wall synthesis. The ability of E. faecium to develop 
increased resistance to BDM-I is likely due to its metabolic and physiological 
characteristics as a lactic acid bacteria. Inhibition of ATP synthase promotes anaerobic 
respiration through fermentation and the glycolytic pathway, causing the increased 
production of lactate (Jiang et al., 2014). Unlike enterococci, S. aureus is not capable of 
generating ATP via the same pathway and this likely explains the difficulty experienced 
in generating BDM-I mutants with increased resistance, as well as the alternate 
compensatory mechanisms observed for S. aureus isolates (i.e., decreasing cell wall 
thickness, for example).   
 
In Chapter 5, the effects of BDM-I treatment on exponentially growing Efm008 and 
Sa057 cells were examined in order to gain further insight into its MoA. The data obtained 
provides further evidence that BDM-I negatively affects ATP synthase. Additionally, 
regulation of lactate production within Efm008 explains the ability of E. faecium to 
develop increased resistance to BDM-I, by knocking down ATP synthase activity and 
utilising lactic acid fermentation.  As S. aureus cannot undergo lactic acid fermentation, 
alternate compensatory mechanisms are utilized following BDM-I treatment, relying 
primarily on reducing the activity of pathways that require large amounts of ATP.  
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Identifying the Binding Partner of BDM-I 
 
6.1 Introduction 
 
In previous chapters we have revealed that BDM-I affects ATP Synthase, as well as other 
interconnected cellular processes within both MRSA and VRE cells. However, the 
specific binding partner(s) of BDM-I has not yet been identified as part of the genomic 
and proteomic experiments performed to date. As discussed in Chapter 1, it has been 
proposed that BDM-I  binds to and inhibits bacterial tyrosine phosphatases, although 
there is little data available that directly supports this hypothesis directly (White et al., 
2014). In this chapter, we utilised relatively novel methods of target identification, 
including Drug Affinity Responsive Target Stability (DARTS) analysis and Thermal 
Proteome Profiling (TPP), which have both previously been used to identify binding 
partners of small molecules.  
 
DARTS (Figure 6.1a) is a novel method that has been used successfully to identify the 
binding partner of several drugs that affect eukaryotic cell lines, including; rapamycin, 
resveratrol and ecumicin (Cui et al., 2003, Shoji et al., 2011). DARTS analysis relies on 
the observation that proteins are less susceptible to proteolysis when bound to a small 
molecule. Specifically, protein lysates are compared using SDS-PAGE following 
treatment with a small molecule and a broad-spectrum protease, and this facilitates the 
identification of proteins that exhibit increased stability (in the presence of a small 
molecule drug). DARTS offers several advantages over traditional methods, such as 
affinity chromatography, as it does not rely on chemical modification of the test 
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compound and it facilitates the identification of targets with low binding affinities due to 
the lack of washing steps (Chang et al., 2016).  
 
TPP (Figure 6.1b) is similar in principal to DARTS, however it offers significant 
advantages in terms of the quality and sensitivity of the data generated. TPP combines 
the principals of cellular thermal shift and multiplexed quantitative mass spectrometry to 
identify the binding partner(s) of a compound; identification is based on a target’s relative 
abundance/change in melting temperature following drug treatment and exposure to 
increased temperatures. Specifically, TPP involves the treatment of whole cells or cell 
lysates with a small molecule compound prior to exposing the samples to a range of 
temperatures. Protein-drug interactions have been shown to increase the thermostability 
of bound proteins, and stabilized proteins can be identified using quantitative mass 
spectrometry (Mateus et al., 2018, Mateus et al., 2017). As such, analysis of the resulting 
data allows identification of proteins with higher melting temperatures as a result of drug 
binding.  
 
Due to the relative simplicity of DARTS and TPP analysis, as well as their proven 
accuracy in identifying protein targets (of small molecules), each method was used in an 
attempt to identify the binding partner(s) of BDM-I. DARTS analysis was initially 
performed using whole cell lysates derived from the MRSA isolate Sa057, while TPP was 
completed in collaboration with Professor Stuart Cordwell using Sa057 whole cells 
treated with BDM-I. 
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Figure 6.1: Theory of DARTS (a) and TPP (b) analysis for identifying the targets 
of small molecule drugs. Both methods are based on the same concept that the 
binding of a drug (ligand) will stabilise the target protein against protease activity 
(DARTS) and increase its melting temperature (TPP). The detection methods differ 
for each procedure, with DARTS relying on gel separation of treated lysates coupled 
with MS, while TPP utilizes protein enrichment coupled with LC/MS for greater 
degrees of sensitivity. Figures a and b are derived from Lomenick et al and Mateus 
et al, respectively (Lomenick et al., 2011, Mateus et al., 2017). 
a) 
b) 
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6.2 DARTS Analysis of BDM-I Treated MRSA Protein Lysate 
 
Protein lysates were isolated from Sa057 grown to mid-exponential phase in 500 mL of 
LBB, using lysostaphin digestion and probe sonication, and then quantified using the 
BSA assay and diluted to a concentration of 4 mg/mL. The lysates were then treated with 
DMSO (vehicle control) or BDM-I at working concentrations of 3 μg/mL (MIC) and 15 
μg/mL (MICx5) for 30 min at 25°C. Each sample was then treated with a mixture of 
proteases using Pronase:Protein ratios of 1:50, 1:100, 1:250 and 1:500 for another 30 min 
at 25°C; digestion reactions were stopped using protease inhibitors. The samples were 
then separated on 4-15% Mini-PROTEAN TGX precast gels (Bio-Rad) for 90 min at 100 
V before being stained with Coomassie Brilliant Blue and imaged using white light and 
a UV Gel Dock system. 
 
Subsequently, duplicate Mini-PROTEAN gels were analysed visually in order to identify 
any differences in protein bands between the vehicle control (DMSO) and BDM-I treated 
lysates. Unfortunately, as shown in Figure 6.2, we were unable to identify any proteins 
that were stabilized against Pronase digestion following treatment with BDM-I. Note that 
multiple BDM-I concentrations were tested, including 3 μg/mL (MICx1) and 15 μg/mL 
(MICx5), in an attempt to saturate the sample and increase the chance of BDM-I binding 
to its target(s) under the conditions used.  
 
Based on the results (i.e., no observable difference in banding patterns between the 
samples), it is unlikely that DARTS is a viable method for the elucidation of the BDM-I 
binding partner(s). This could be due to several reasons, including the BDM-I binding 
affinity is weak (under the conditions used) or its target is present in low abundance.
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Figure 6.2 4-15% Mini-Protean Gels loaded with lysate samples derived from Sa057. Samples were treated with DMSO as well as BDM-I at 3 
μg/mL (MIC) and 15 μg/mL (MICx5) before treatment with Pronase.  Wells are grouped based on the Pronase:Protein ratio and treatment type. 
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6.3 TPP of the MRSA Proteome Following Exposure to BDM-I 
 
BDM-I treated Sa057 whole cells were selected for TPP experiments as described by 
Mateus et al (Mateus et al., 2018). As a first pass approach, Sa057 cultures were grown 
to mid-exponential phase before being treated with BDM-I or DMSO and incubated for 
a further 10 min at 37°C. The cells were then harvested and resuspended in sterile PBS 
to an OD600 of 10, prior to heat treatment at 63°C for 3 min. Cell lysates were then 
prepared followed by peptide enrichment and LC/MS for protein identification. 
 
Preliminary data revealed a total of 57 proteins present in higher abundance for drug 
treated Sa057, following treatment at 63°C (Supplementary Table 10); the majority 
(n=51) were 1-fold to 5-fold more abundant relative to the vehicle treated control. 
Interestingly, a significant number of these proteins function in ATP binding (n=7), 
oxidoreductase activity (n=3), DNA binding (n=2) and rRNA binding (n=5).  
 
The greatest difference in relative abundance observed was for a luciferase family 
oxidoreductase and the DNA topoisomerase protein ParC, which were 23.87-fold and 
22.02-fold more abundant, respectively. Interestingly, adenylate cyclase was also 
identified to be present in higher abundance (by 17.24-fold) following BDM-I treatment. 
At this stage, it is difficult to ascertain why ParC and a luciferase family oxidoreductase 
are present in significantly higher abundance without additional studies. In the case of 
adenylate cyclase, it is known to function in the conversion of ATP to 3’,5’cyclic-AMP 
(cAMP), which can be recycled further to adenine monophosphate (AMP).  
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6.4 Discussion 
 
A key step in drug development is exploring protein-drug interactions in order to identify 
the binding partner of a novel compound, and the gold standard methodology often 
utilized is affinity chromatography. However, this method is limited (especially in regards 
to small molecules) due to the need to chemically modify a compound which may affect 
its bioactivity, as well as the potential for high levels of non-specific protein binding to 
matrix columns (Lomenick et al., 2009). Recent methodological approaches have 
attempted to study drug target interactions in situ on a proteome wide scale, removing the 
need to modify a compound prior to target identification. In this regard, the two most 
promising methods that have been used successfully to identify the binding partner(s) of 
small molecule compounds are DARTS and TPP. Both techniques rely on the principal 
that a ligand bound protein is more tolerant to stressors, such as proteolysis and increased 
temperatures (Cui et al., 2003, Mateus et al., 2018, Mateus et al., 2017, Shoji et al., 2011).  
 
DARTS analysis offers a major advantage due to its relative simplicity, as this technique 
utilizes standard laboratory techniques including SDS-PAGE protein separation and mass 
spectrometry. In section 6.2, DARTS analysis was utilized in an attempt to identify the 
BDM-I binding partner(s) within drug treated Sa057 protein lysates. Several BDM-I 
concentrations (MICx1 and MICx5) and Pronase:protein ratios (1:50, 1:100, 1:250 and 
1:500) were utilized, however no observable differences (in banding patterns) were 
observed between BDM-I and control lysates (Figure 6.2) which potentially illustrate the 
limitations of DARTS analysis. In this regard, successful DARTS analysis relies on 
several characteristics that must be associated with the protein target interaction. Firstly, 
the target protein must be sufficiently abundant within the cell to be visible following 
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separation and staining. Secondly, if the target protein comigrates with other proteins of 
similar MW, it may be masked depending on the abundance of these comigrating proteins. 
Finally, the technique relies on a strong binding interaction between the drug and its 
protein target (Lomenick et al., 2011). Based on these limitations, it is likely that the drug-
protein interaction between BDM-I and its target(s) may not be suitable for identification 
using DARTS, although more sensitive stains, such as Sypro Ruby, could be tested.  
 
Following DARTS analysis, an alternative approach was utilized that offers higher 
sensitivity and accuracy when determining the target of a novel compound. TPP combines 
the principal of the cellular thermal shift assay with quantitative mass spectrometry, to 
identify changes in protein abundance following drug and heat treatment. Through TPP, 
the melting behaviour of the proteome can be examined post drug treatment, as protein-
drug interactions typically increase the thermal tolerance of proteins (Mateus et al., 2018). 
Recently, TPP was optimized for usage with bacterial proteomes to identify the (known) 
target of several antibiotics. Mateus et al examined the dynamics of the E. coli proteome 
following treatment with ampicillin and ciprofloxacin in an attempt to identify their 
cellular targets. Using TPP, they observed that the known targets of ampicillin (penicillin-
binding proteins (PBPs)) and ciprofloxacin (DNA Gyrase) were stabilized within cells 
treated with each compound. Furthermore, they noted that TPP can also be used to study 
resistance determinants as well as a compound’s mechanism of action (downstream 
consequences to cellular physiology) (Mateus et al., 2018).  
 
Using this optimized methodology, we collaborated with Stuart Cordwell’s group at the 
University of Sydney to perform TPP on BDM-I treated Sa057. As a first pass approach 
to confirm the validity of TPP, the cells were incubated at 63°C to confirm protein 
 
 
149 
thermostabilization following BDM-I binding. Analysis identified a total of 57 proteins 
that were stabilized by BDM-I treatment relative to the vehicle control. Considering the 
data presented in Chapters 4 to 5, the high abundance of adenylate cyclase within BDM-
I treated Sa057 may be relevant to the observation that BDM-I negatively affects ATP 
synthase. As stated previously, adenylate cyclase converts ATP to cAMP. Interestingly, 
De Rasmo et al identified that depleted intracellular concentrations of cAMP result in 
reduced ATP synthesis and hydrolysis activity by the mammalian ATP synthase (De 
Rasmo et al., 2016). This finding may indicate a possible mechanism by which ATP 
synthase is inhibited by BDM-I treatment, via the inhibition of adenylate cyclase and 
therefore cAMP synthesis.  
 
However, it is critical to note that without additional TPP studies it is not possible to make 
any conclusions based on the available data. Based on work by Mateus et al, TPP analysis 
of drug treated cells yields significantly higher numbers of stabilized proteins compared 
to drug treated cell lysates. In the case of ciprofloxacin, DNA gyrase was only identified 
to be stabilized based on the data generated from TPP of drug treated lysates (Mateus et 
al., 2018). Therefore, additional studies are required to complete TPP on BDM-I treated 
Sa057 protein lysates exposed to a range of temperatures.  
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Discussion 
 
7.1 Introduction 
 
The need for novel antibiotics is becoming increasingly important, as bacteria are masters 
of adaptation and can rapidly become resistant to antimicrobial compounds. In this regard, 
BDM-I represents a novel antimicrobial compound that has good in vitro activity against 
a broad range of microbial organisms, including multi-drug resistant bacteria. Although 
this activity has been demonstrated previously (at least in part), its MoA is not fully 
understood. Currently, the primary target of BDM-I is believed to be protein tyrosine 
phosphatases (PTPs), and this is largely based on a previous study that revealed it inhibits 
the bacterial phosphatases PTP1B and Yop, at rates of 46% and 42% respectively. 
Additionally, virulence factors that rely on PTP activity such as motility in Proteus spp 
and attachment/invasion in Yersinia spp were also shown to be inhibited by BDM-I 
(White et al., 2014). Furthermore, a study by Park et al on structurally similar compounds 
to BDM-I identified the likely binding partner to be PTPs (Park and Pei, 2004). 
 
Although the data from previous studies suggest that BDM-I is likely inhibiting bacterial 
PTPs, the function of these proteins in bacteria is not well understood. This makes it 
difficult to ascertain the mechanism by which BDM-I inhibits microbial growth, 
assuming it is through the inhibition of PTPs. As such, this study aimed to gain further 
insight into the MoA of BDM-I by using an omics approach; whole genome sequencing 
and proteomic analysis of in vitro derived BDM-I mutants, as well as BDM-I treated 
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isolates. Additionally, this study also aimed to determine the efficacy of BDM-I as a 
treatment option for the common bacterial pathogens S. aureus and E. faecium. 
 
7.2 Examining the Utility of BDM-I Against the ESKAPE Pathogens 
 
7.2.1 BDM-I Displays Increased Activity Against MRSA 
As stated previously, BDM-I has been shown to be effective against a broad range of 
microbial organisms. Significant activity has typically been observed against gram-
positive species including, S. pyogenes, C. perfringens and S. aureus (unpublished data). 
As part of this study, we aimed to assess the utility of BDM-I against a library of clinical 
S. aureus and E. faecium isolates with varying degrees of vancomycin susceptibility, in 
order to identify potential cross-resistance in isolates with reduced vancomycin 
susceptibility. As described in section 3.3, MIC analysis was conducted using 103 clinical 
MRSA isolates comprised of 43 VSSA, 54 hVISA, and 6 VISA isolates; this isolate set 
also included 26 isogenic pairs and 3 isogenic series. As observed in Table 3.2, there were 
no significant differences in BDM-I MICs between initial and recurrent/persistent 
isolates, indicating that cross-resistance (to BDM-I) did not develop during prolonged 
periods of exposure to other antibiotics, which can potentially occur (Chen et al., 2015). 
Interestingly, as shown in Table 3.3 we did observe a gradual decrease in BDM-I MICs 
within series C. The initial VSSA isolate Sa057 exhibited an observed MIC of 4 μg/mL, 
which decreased to 3 μg/mL for the persistent hVISA isolates, and finally 2 μg/mL for 
the final VISA isolate. This shift in BDM-I MIC indicated a possible seesaw effect 
between BDM-I and vancomycin MICs.  
 
A seesaw effect refers to an inverse correlation of susceptibility between two types of 
antibiotics. It is a phenomenon that has previously been described for S. aureus, in relation 
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to the in vivo evolution of resistance to glycopeptides and daptomycin, which was shown 
to inversely correlate to β-lactam susceptibility following prolonged treatment periods 
(Vignaroli et al., 2011, Yang et al., 2010). As described in section 3.4, a Spearman’s test 
was used to confirm the potential see saw effect between BDM-I and vancomycin, by 
utilising the average MIC values for each vancomycin phenotype (Table 3.7). Analysis 
revealed a definitive negative correlation between both compounds (Rho = -0.24; P = 
0.0145), with VSSA isolates having a higher BDM-I MIC and lower vancomycin MIC, 
while the opposite was true for VISA isolates.  
 
MIC testing was also completed using 30 clinical E. faecium isolates (10 VSE, 10 vanB 
and 10 vanA) to identify any similar trends to those observed with MRSA isolates. MIC 
results between the three phenotypes were comparable, with the majority of the isolates 
having MICs ranging from 6-8 µg/mL (Table 3.5). Interestingly, several isolates were 
identified to be more susceptible to BDM-I, with MICs of 3-3.5 µg/mL. In the case of the 
vanB isolate Efm0002, previous work had identified it possesses a SNP mutation within 
the gene walK which results in a thickened cell wall (unpublished data). Considering the 
VISA isolates are approximately 2-fold more susceptible to BDM-I than VSSA, it is 
interesting that a VRE isolate with a similar phenotype is also approximately 2-fold more 
susceptible to BDM-I compared to WT E. faecium. The mechanism driving this negative 
correlation between the MICs of WT isolates, and those with thickened cell walls, will be 
discussed further in section 7.3.2. 
 
As described in section 3.4, checkerboard assays were completed using three clinical 
MRSA isolates and three clinical VRE isolates: Sa057 (VSSA), Sa060 (hVISA), Sa375 
(VISA), Efm008 (vanA) and Efm123 (vanB) and Efm201 (vanB). BDM-I was identified 
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to exert an additive effect in combination with vancomycin for Sa060 and Sa375; 
vancomycin MICs decreasing significantly when combined with BDM-I at MIC50. 
However, this relationship was unique to Sa060 and Sa375, as there were no synergistic 
or additive relationships observed for Sa057, Efm008, Efm123 and Efm201.  
 
Combination therapy has been described since the 1950s as a viable method of treatment 
that can significantly reduce the probability of resistance developing (Elek, 1956). 
Currently, there are three categories of combination therapy that are outlined in a review 
by Fischbach (Fischbach, 2011). These categories include drugs that inhibit targets in 
different pathways, drugs that inhibit different nodes in the same pathway, and drugs that 
inhibit the same target in different ways (Fischbach, 2011). An important factor that needs 
to be considered in selecting antibiotics for combination therapy is their synergistic 
relationship. Certain drugs can often be antagonistic to another compound’s MoA, which 
represents the greatest limiting factor in terms of using antibiotics in combination. 
Considering the previously discussed seesaw effect and checkerboard data, BDM-I and 
vancomycin could be used in combination therapy to treat MRSA infections, particularly 
those associated with hVISA/VISA isolates. Additionally, it is important to note that there 
was no antagonism observed between BDM-I and vancomycin, which as described 
previously, is a limiting factor when using compounds in combination. 
 
Upon identifying the additive effect in the case of the hVISA and VISA isolates, 
additional checkerboard assays were completed combining BDM-I with other cell wall 
active antibiotics, specifically the penicillin-binding protein inhibitors Flucloxacillin and 
Ceftaroline Fosamil. However, combination studies with these compounds identified no 
additive or synergistic effects for MRSA or VRE isolates, suggesting that the previously 
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observed additive effect is unique between BDM-I and vancomycin and is likely related 
to cell wall thickness.  
 
7.2.2 E. faecium Readily Develops Increased Resistance to BDM-I  
The data gathered in section 3.3 identifies BDM-I as a viable treatment option for MRSA 
infections, particularly those associated with hVISA and VISA isolates. It is important 
then to determine the potential for bacteria to develop increased resistance to BDM-I in 
vitro, in order to examine its usability during long term treatment, as well as producing 
mutant isolates for use in WGS studies. Section 3.5 described induction experiments 
using two MRSA (VSSA and VISA) and two VRE (vanA and vanB) clinical isolates, 
which were sub-cultured in sub-inhibitory concentrations of BDM-I for ≥70 days. Results 
from these studies indicate that MRSA isolates have a limited capacity to develop 
increased resistance to BDM-I, particularly Sa057 (VSSA), which was unable to adapt 
following an extended period of BDM-I exposure (100 days). However, Sa375 (VISA) 
did appear to generate limited resistance to BDM-I by the final day of treatment, with 
endpoint MICs being determined as 5 μg/mL, higher than that of the progenitor Sa375 
with an MIC of 2 μg/mL (section 3.2.1). In comparison, both VRE isolates were readily 
capable of adapting to BDM-I, with final MIC values for both Efm003 and Efm008 being 
more than double that of the progenitor isolates. Significant increases in BDM-I MICs 
were observed within 10 days of BDM-I exposure, which continued to increase 
throughout the entire duration of the experiment (70 days), which may limit the potential 
utility of BDM-I as a treatment option for E. faecium associated infections. 
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7.3 Developing a Model of the BDM-I Mechanism of Action 
 
7.3.1 BDM-I Affects ATP Synthase Activity 
While the data produced in section Chapter 3 revealed lower activity of BDM-I against 
E. faecium (in comparison to S. aureus), we were able to generate mutant isolates with 
significantly higher MICs compared to the corresponding progenitor isolates. In vitro 
derived VRE and MRSA mutant isolates were then subjected to whole genome 
sequencing, in order to identify mutations driving the increased MICs which can 
potentially provide insight into the BDM-I MoA. Given the ability of both VRE isolates 
to rapidly develop increased BDM-I resistance, they were selected for initial WGS from 
two timepoints (approximately 10 and 60 days of exposure). Three colonies were isolated 
from each of the three series, giving a total of nine data sets from each time point. 
 
Following variant analysis, 15 mutations were identified across the Efm003 day 10 
colonies, and 10 were identified across the final day Efm003 colonies (Supplementary 
Tables 1 and 2). Analysis of the sequencing data identified no common mutation present 
within all day 10 colonies, with the most common mutation identified being a SNP in the 
gene EFAU004_00165, which encodes an M-protein Trans-acting positive regulator. The 
location of these mutations within EFAU004_00165 varied between each colony, ruling 
out a site-specific response to BDM-I exposure. Currently, it is unclear why mutations 
within an M-protein regulator may be advantageous in the presence of BDM-I, given the 
primary role of M-proteins is in bacterial virulence. Interestingly, research on the well-
studied S. pyogenes M-protein has shown that it is regulated by phosphorylation on both 
serine and tyrosine sites, catalysed by the activity of bacterial protein kinases (Chiang et 
 
 
156 
al., 1989). This may be linked to the activity of bacterial tyrosine phosphatases, which are 
the predicted target of BDM-I. 
 
Analysis of the sequencing data for the remaining time points identified common 
mutations within the ATP synthase operon, for both Efm003 and Efm008. Interestingly, 
mutations were not specific to a single gene, but were spread across the entire operon as 
outlined in Tables 4.1 and 4.2. SNP mutations were commonly identified in the final day 
mutant isolates within atpD (Efm008) and atpB (Efm003), which encode the β-subunit of 
the F1 complex and the c-subunit of the F0 complex of ATP synthase, respectively. 
Mutations within the day 10 Efm008 mutants were more varied, and included SNPs and 
IS1256-like insertion sequences (and associated deletions) within atpE, atpD, atpG and 
atpF (see Table 4.1). Considering the presence of mutations within various ATP synthase 
genes for all mutant E. faecium isolates, it is likely that ATP synthase is strongly linked 
to the BDM-I MoA. However, it is unlikely to be its only target due to the fact that day 
60 Efm008 mutant isolates, which have an IS1256-like insertion sequence mediated 
deletion of atpC, atpD, atpG, and partial deletion of atpA, remained sensitive to increased 
concentrations (≥18 μg/mL) of BDM-I. Therefore, it is likely that mutations identified 
within these genes are only partly compensating for the BDM-I MoA; note that this 
compensatory mechanism may only be possible in the case of E. faecium, as ATP 
synthase appears to be more essential for S. aureus growth.  
 
ATP assays were then utilized to confirm that BDM-I is inhibiting ATP synthase within 
both Efm008 and Sa057 (Chapter 4). Subsequently, results revealed a significant decrease 
in intracellular ATP concentrations for both isolates. These results were the first 
indication that ATP synthase was also affected in S. aureus. Interestingly, such an affect 
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was also confirmed via BDM-I and polymyxin B combination studies using Sa057. 
Research by Vestergaard et al identified that inhibition of ATP synthase reduces the 
innate resistance of S. aureus to CAMPS, such as polymyxin B. Specifically, it was 
proposed that ATP synthase inhibition results in the hyperpolarization of the cell 
membrane and (as a result) increased activity of CAMPS (Vestergaard et al., 2017). 
Considering these observations, checkerboard assays revealed that when used in 
combination (BDM-I MIC50), the MIC of polymyxin B decreased from 256 µg/mL to 64 
µg/mL (FICI = 0.75), which is indicative of ATP synthase inhibition. 
 
Additional evidence was obtained regarding the importance of ATP synthase in 
association with the BDM-I MoA, based on the proteomic analysis of BDM-I treated S. 
aureus and E. faecium cells (Chapter 5). Initial analysis was completed using 2-D gel 
electrophoresis of proteins extracted from BDM-I treated Efm008, in order to identify 
changes in expression following drug treatment. Two subunits of ATP synthase (subunit-
b and subunit-d) were downregulated following exposure to BDM-I. Furthermore, a 
pyruvate dehydrogenase complex within the Efm008ΔatpACDG mutant was upregulated, 
possibly indicating a shift to substrate level ATP synthesis due to the inactivity of ATP 
synthase. Due to the limitations associated with gel based proteomic methods (see section 
5.4), additional studies were conducted using shotgun proteomics on BDM-I treated 
Efm008 and Sa057 cells. By using shotgun proteomics, significantly more data was 
obtained which provided a deeper understanding of the cellular response to BDM-I 
treatment. Importantly, analysis revealed that the ATP synthase g-subunit was 
downregulated in both Sa057 and Efm008 by 2.13-fold and 2.42-fold, respectively.  
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Proteomic analysis also revealed the potential mechanism by which E. faecium is able to 
readily adapt to BDM-I. Data revealed that Efm008 is likely utilizing lactic acid 
fermentation to synthesize ATP as a result of BDM-I treatment. Several proteins were 
differentially regulated that promote the production of L-lactate and pyruvate, including 
a lactate dehydrogenase, which was upregulated >2-fold. Enterococci are capable of 
undergoing fermentation in anaerobic environments through the metabolism of glucose. 
During this process, pyruvate and NADH are produced, the latter of which can be further 
oxidised to NAD+ following the conversion of pyruvate to L-lactate (Doi, 2018). This 
continual conversion of pyruvate to L-lactate ensures there is a constant supply of NAD+, 
which is required for the conversion of glyceraldehyde-3-phosphate to 1,3-
bisphosphoglycerate during glycolysis (Figure 7.1) (Ramsey M, 2014, Jiang et al., 2014). 
By utilizing this pathway, Efm008 is able to compensate for the reduced activity of ATP 
synthase by producing ATP at a substrate level.  
 
 
159 
 
 
 
 
Figure 7.1 Glycolysis pathway involved in the stepwise production of Pyruvate from 
Glucose. Through the production of L-lactate from pyruvate, glycolysis can be utilized 
by lactic acid bacteria as an alternative method to produce ATP. Lactate dehydrogenase 
catalyses the reversible conversion of pyruvate to lactate, which releases a continual 
supply of NAD+ which is required for glycolysis to occur. 
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Unlike E. faecium, S. aureus is not capable of using lactic acid fermentation as an 
alternative to oxidative phosphorylation. Proteomic data revealed that BDM-I treated 
Sa057 was still favouring ATP synthesis via oxidative phosphorylation, based on the 
downregulation of all proteins associated with anaerobic respiration (Fuchs et al., 2007), 
as well as the up-regulation of proteins that produce acetyl-CoA which can be used in the 
TCA cycle. Sa057 may be relying on ATP synthase based on its essentiality within S. 
aureus (see section 5.4), which would explain the increased BDM-I sensitivity observed 
for MRSA isolates (relative to VRE), as well as the difficulty in generating MRSA 
mutants with increased resistance to BDM-I (Chapter 3).  
 
Although no mutations were identified within the ATP synthase operon for either MRSA 
isolates, common mutations were identified within the Sa057 gene SAA6008_00679, 
which encodes a putative phosphate uptake regulator (which is distantly related to PhoU). 
PhoU is a negative regulator of Pi uptake in (predominantly) gram-negative bacteria, 
although it has been identified in several gram-positive species (Zheng et al., 2016). The 
mechanisms involved in the transport of inorganic phosphate (Pi) molecules has been 
studied extensively in E. coli, as well as other species (although to a lesser extent) 
including B. subtilis (Qi et al., 1997, Rao and Torriani, 1990, Willsky et al., 1973). 
Acquisition of Pi can be carried out by three classes of importers found within bacteria; 
PstSCAB (phosphate-specific-transport), PitA/PitB (phosphate inorganic transport) and 
the NptA (Na-dependent phosphate transport) systems (Kelliher et al., 2018). PstSCAB 
is a high affinity Pi transporter belonging to the ABC family which is regulated by PhoU 
via the PhoBR two-component regulatory system. In short, when Pi concentrations are 
below or above 0.4 μM, PhoU will initiate the expression or repression of pstA. Therefore, 
Sa057 mutants may be responding to reduced ATP synthase activity by regulating the 
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transport of Pi into the cell. Currently, it is not believed that BDM-I is binding to ATP 
synthase and inhibiting it directly. Mutant VRE isolates bearing mutations within the ATP 
synthase operon still remain susceptible to BDM-I at higher concentrations, including the 
previously discussed deletion mutant (Efm008DatpACDG). Therefore, we hypothesize that 
ATP synthase inhibition is a downstream consequence of the primary BDM-I target.  
 
In the context of the proposed BDM-I MoA as a PTP inhibitor, previous studies have 
identified that ATP synthase is regulated through phosphorylation in eukaryotic cells and 
some prokaryotic cells (e.g. Streptococcus species) (Ge and Shan, 2011, Kane and Van 
Eyk, 2009, Sun et al., 2010). Additional studies of the eukaryotic ATP synthase have 
revealed that it is unable to release ADP efficiently when phosphorylated (Arrell et al., 
2006), possibly indicating that a hyper-phosphorylated form of the enzyme could be 
deleterious to the cell’s metabolism. If bacterial ATP synthase is regulated by a similar 
mechanism, the inhibition of bacterial PTP may be deleterious to the activity of ATP 
synthase. 
 
Alternatively, preliminary TPP data (Chapter 6) identified adenylate cyclase was 
thermostabilized by BDM-I treatment within Sa057. Adenylate cyclase catalyses the 
conversion of ATP to cAMP, which can be converted further to AMP via 
phosphodiesterases (De Rasmo et al., 2016). cAMP has been identified as a regulator of 
ATP synthase activity within mammalian cells, following observations that the depletion 
of cAMP is associated with decreased ATP and hydrolysis by ATP synthase. 
Furthermore, cAMP is also associated with maintaining the expression of ATP synthase 
subunits within mammalian cells (De Rasmo et al., 2016). Currently, it is not possible to 
state with confidence that BDM-I inhibits ATP synthase by depleting the intracellular 
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concentration of cAMP. Significantly more work is required to confirm that both; BDM-
I is binding to and inhibiting adenylate cyclase, and that bacterial ATP synthase activity 
is regulated by cAMP levels.    
 
7.3.2 S. aureus Responds to BDM-I by Regulating Peptidoglycan Synthesis   
As discussed in section 7.3.1, the data generated in this study suggests that the BDM-I 
MoA is (at least in part) inhibition of ATP synthesis.  Sequencing and proteomic analysis 
of mutant/BDM-I treated MRSA and VRE isolates, as well as results from ATP assays, 
strongly support this apparent mechanism. BDM-I treatment of Efm008 resulted in the 
utilization of lactic acid fermentation to compensate for the decreased activity of ATP 
synthase. However, due to the essentiality of ATP synthase in S. aureus, as well as the 
inability for S. aureus to undergo lactic acid fermentation, we observed a unique adaptive 
mechanism within MRSA isolates through the regulation of peptidoglycan synthesis.  
 
Peptidoglycan synthesis is an essential, multi-stage process that is critical in ensuring 
bacterial cell viability and pathogenicity. The gram-positive cell wall is composed of 
cross-linked peptidoglycan, which consists of chains (of repeating disaccharide units) of 
N-acetylglucosamine (GlcNAC) and N-acetylmuramic acid (MurNAc). In S. aureus, 
these polysaccharide chains are cross-linked by interpeptide bridges composed of five 
glycyl residues that protrude from the L-lysine of the stem-peptides (Jarick et al., 2018). 
Briefly, peptidoglycan is synthesized in three stages: first, the nucleotide sugar-linked 
UDP-MurNAc-pentapeptide is formed, second, lipid II is formed by the addition of UDP-
GlcNAc to lipid I, lastly, lipid II is transported across the membrane and added to the 
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growing peptidoglycan sacculus by penicillin binding proteins (see Figure 7.2) (Jarick et 
al., 2018). 
Figure 7.2 Structure and synthesis of Peptidoglycan in S. aureus. Fructose-6-phosphate is initially 
converted to GlcN6P by the aminotransferase GlmS, before being processed to N-acetylglucosamine-6-
phsphate (UDP-GlcNAc) by GlmM and GlmU. UDP-GlcNAc is then converted to N-acetylmuramic acid 
(UDP-MurNAc) by MurA and MurB, followed by the sequential addition of the amino acids L-Ala, D-
Glu and L-Lys as well as the dipeptide D-Ala-D-Ala which is catalysed by MurC-F. The resulting product, 
UDP-MurNAc-L-Ala-D-Glu-L-Lys-D-Ala-D-Ala is then linked to the lipid carrier undecaprenyl-
diphosphate by the translocase MraY, which produces the membrane bound Lipid I. UDP-GlcNAc is then 
linked to the Lipid I molecule by the glycosyltransferase MurG, forming Lipid II. Lipid II is then modified 
by the addition of five glycine residues by the FemX/A/B proteins, which use glycyl tRNAs to transfer 
glycine to the PGN-lysl side chain of Lipid II. Following several modifications including the deamination 
of D-Glu of the stem peptide by MurT/GatD, the pentaglycine-Lipid II molecule is translocated to the outer 
side of the membrane. Here, penicillin binding proteins incorporate extracellular Lipid II to the growing 
PGN through transglycosylation and transpeptidation. Image and caption derived from Jarick et al, 2018 
(Jarick et al., 2018). 
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As discussed in Chapter 3, VISA isolates are more sensitive to BDM-I in comparison to 
hVISA and VSSA isolates, as they have a lower average MIC of 2.5 μg/mL. Additionally, 
Efm0002, which also has a thickened cell wall like VISA isoaltes, was also more sensitive 
to BDM-I compared to WT E. faecium. Interestingly, Sa375 (VISA) exhibited the greatest 
capacity to generate increased (and stable) resistance to BDM-I following prolonged 
periods of exposure in comparison to Sa057 (VSSA). WGS of Sa375 mutants identified 
SNPs within the gene walK for all sequenced mutant colonies. As mentioned previously, 
walK belongs to the essential WalKR two-component regulatory system, which is 
associated with controlling cell wall homeostasis and cell viability (Delauné et al., 2012). 
In context of the VISA phenotype, mutations within walK have been attributed to reduced 
vancomycin susceptibility via the production of thickened cell walls with reduced 
permeability, which can also be associated with daptomycin cross-resistance (Bayer et 
al., 2013, Howden et al., 2010, Howden et al., 2011, Kelley et al., 2011, Shoji et al., 2011). 
Regarding Sa375, its VISA phenotype is driven by a SNP within walK (Q369R) that 
results in thickened cell walls. Interestingly, this mutation is still present within BDM-I 
mutants (van Hal et al., 2013) 
 
Given the well-established role of walK in maintaining cell wall homeostasis, as well as 
the presence of novel mutations in walK within all BDM-I mutants, it was hypothesized 
that these mutations were driving increased BDM-I resistance by altering the phenotype 
of the cell wall. Electron microscopy (section 4.5.2) of Sa375 mutants revealed significant 
reductions in cell wall thickness which were also associated with increased sensitivity to 
both vancomycin and daptomycin (Figure 4.4). The SNP within mutant series 2 (G560S) 
was then introduced into Sa375-WT, which exhibited similar sensitivity profiles to the 
mutant isolate (increased BDM-I resistance, increased vancomycin sensitivity, increased 
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daptomycin sensitivity, decreased cell wall thickness), confirming that the walK 
mutations identified within mutant Sa375 isolates are driving the observed phenotype, as 
well as the increased resistance to BDM-I.  
 
Furthermore, the importance of cell wall regulation as an adaptive mechanism against 
BDM-I was further illustrated following proteomic analysis of BDM-I treated Sa057 cells 
(section 5.3). Analysis revealed the downregulation of walK by 9.21-fold following drug 
treatment, which corresponds with previous sequencing data. Transcriptome profiling of 
the WalKR regulon has revealed its role in regulating the expression of a large number of 
proteins involved in cell wall metabolism, regulatory pathways, the stress response, 
transport and metabolism. Regarding cell wall metabolism, inhibition of WalKR activity 
is associated with reduced peptidoglycan synthesis and cell wall turnover, as well as 
increased autolytic activity (Delauné et al., 2012, Dubrac et al., 2007). Interestingly, 
WalKR is essential in regulating the expression of proteins responsible for cell wall 
degradation, namely lytM, atlA, isaA, sceD and ssaA. Proteomic analysis of BDM-I 
treated Sa057 revealed the upregulation of sceD by >30-fold as a result of WalKR 
inactivation. As shown in Figure 7.3, the increased expression of sceD is likely due to the 
repression of isaA, which is positively regulated by walR under optimal conditions 
(Stapleton et al., 2007).  
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Additionally, it is worth noting that mutations were identified within the gene murC in 
50% of Sa057 BDM-I mutants (Table 4.3). murC encodes UDP-N-acetylmuramic acid 
L-alanine ligase, which plays an essential role in peptidoglycan synthesis in S. aureus by 
catalysing the ligation of L-Ala to UDP-MurNAc in the early stages of peptidoglycan 
synthesis (Figure 7.2) (Kurokawa et al., 2008). Furthermore, proteomic analysis of BDM-
I treated Efm008 identified the upregulation of a LysM domain containing protein by 
7.45-fold. While the majority of evidence suggesting that BDM-I affects cell wall 
synthesis has been observed in S. aureus, the identification of a cell wall hydrolase being 
Figure 7.3 WalKR regulates the expression of several genes with known autolytic activities. 
Several genes including atlA, lytM and isaA have been identified to be positively regulated 
by walK. Evidence also suggests that sceD is positively expressed when isaA is repressed, 
which occurs when walK activity is reduced. 
 
Figure 7.2: Expression pathway of the walKR TCS, regulating genes which function in cell 
wall maintenance. Several genes including atlA, lytM and isaA have been identified to be 
positively regulated by walK. Evidence also suggests that sceD is positively expressed when 
isaA is repressed, which occurs when walK activity is reduced. 
 
Figure 7.3: Expression pathway of the walKR TCS, regulating genes which function in cell 
wall maintenance. Several genes including atlA, lytM and isaA have been identified to be 
positively regulated by walK. Evidence also suggests that sceD is positively expressed when 
isaA is repressed, which occurs when walK activity is reduced. 
 
Figure 7.4: Expression pathway of the walKR TCS, regulating genes which function in cell 
wall maintenance. Several genes including atlA, lytM and isaA have been identified to be 
positively regulated by walK. Evidence also suggests that sceD is positively expressed when 
isaA is repressed, which occurs when walK activity is reduced. 
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upregulated (similar to sceD) in E. faecium is notable and may be worth further 
investigation (Buist et al., 2008). Furthermore, the downregulation of all proteins 
involved in UMP biosynthesis following BDM-I treatment may be another mechanism to 
limit cell wall synthesis, considering that UMP is a precuroor to UDP, which is a major 
component of precursors utilized in peptidoglycan synthesis. 
 
Through whole genome sequencing, proteomics and electron microscopy, we have 
identified that S. aureus responds to BDM-I treatment through the regulation of 
peptidoglycan synthesis. This observation provides further evidence for the apparent 
MoA of BDM-I as an (in)direct inhibitor of ATP synthesis. Peptidoglycan synthesis is an 
essential process that requires significant amounts of energy, more so in the case of VISA 
isolates such as Sa375 (and Efm0002), as they have significantly thicker cell walls. This 
phenomenon would explain the observed alterations to the phenotype of mutant Sa375 
isolates with increased resistance to BDM-I. By reverting to a VSSA cell wall phenotype, 
ATP that would have been required for peptidoglycan synthesis can be utilised in other 
essential cellular pathways, which may also explain why VISA isolates have lower BDM-
I MICs compared to VSSA isolates.  
 
7.4 Proposed Model of the BDM-I MoA 
 
Considering the results presented in this study, which are discussed in detail above, we 
propose that the key BDM-I MoA is inhibition of ATP synthesis via ATP synthase and 
oxidative phosphorylation (outlined in Figure 7.4).
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S. aureus E. faecium 
 
 
Lactic Acid 
Fermentation (synthesize 
ATP) 
Peptidoglycan Synthesis 
(conserve ATP) 
ATP Synthase 
Cell Membrane 
Adenylate cyclase 
cAMP 
Figure 7.4 Proposed BDM-I MoA is inhibition of ATP synthase. ATP assays indicate that BDM-I treatment reduces the 
intracellular concentration of ATP within S. aureus and E. faecium. Proteomic and sequencing data indicates that E. faecium 
responds (and adapts) to BDM-I treatment by knocking down the activity of ATP synthase in favour of lactic acid fermentation.  
As S. aureus cannot utilize this pathway, it compensates for reduced ATP availability by repressing cellular pathways (such as 
peptidoglycan synthesis) that require large amounts of ATP. Red lines connecting adenylate cyclase to BDM-I and ATP synthase 
inhibition represent theoretical interactions which have not yet been proven experimentally. 
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Briefly, BDM-I inhibits ATP synthase indirectly (or possibly directly) by a currently 
unknown mechanism. One possible explanation could be that BDM-I negatively affects 
adenylate cyclase, which would result in cAMP depletion within a cell and potential 
repression of ATP synthase activity. In any case, how bacteria respond to this appears to 
be species specific, as E. faecium appears to utilize lactic acid fermentation as an 
alternative pathway to produce ATP, while S. aureus, which cannot utilize lactic acid 
fermentation, downregulates cellular processes (such as cell wall synthesis) that require 
large amounts of ATP. This inhibitory mechanism explains why S. aureus is more 
susceptible to BDM-I than E. faecium (particularly VISA isolates that need to synthesize 
significantly thicker cell walls) and the observed difficulty for S. aureus to develop 
increased resistance to BDM-I (compared to E. faecium).  
 
7.5 Future Directions 
 
Currently, we are unable to confidently identify the binding partner of BDM-I. While 
TPP analysis did identify a potential binding partner that corresponds with other results 
outlined in this study, the data is preliminary and requires significantly more work before 
conclusions can be made regarding the BDM-I target. As such, future experiments are 
required to optimise the TPP protocol for S. aureus, and to repeat the experiment on drug 
treated protein lysates to improve data resolution and narrow the pool of potential binding 
partners (Mateus et al., 2018). Additionally, TPP analysis should also be completed using 
E. faecium to confirm the BDM-I target across species, which would increase reliability 
of the results and proposed MoA. 
 
It is also important to conduct further studies examining the relationship between BDM-
I and cell wall synthesis in S. aureus. While we have confirmed that BDM-I exposure 
 
 
170 
drives mutations that favour a thinner cell wall phenotype and increased sensitivity to 
glycopeptide antibiotics, it is also important to study associated changes in peptidoglycan 
morphology and structure. Following proteomic analysis of S. aureus, we identified 
significant downregulation (³3-fold) of all proteins involved in UMP metabolism. In this 
regard, previous research has identified a correlation between pyrimidine metabolism and 
peptidoglycan morphology in L. lactis (Solopova et al., 2016). Therefore, additional steps 
should be taken to analyse the peptidoglycan morphology within BDM-I treated MRSA. 
 
Considering the poor success rate associated with clinical drug development, additional 
research could also be undertaken to identify alternative uses for BDM-I. Considering it 
negatively affects ATP synthase, BDM-I could potentially be used as a component of 
industrial antiseptics and cleaning agents to inhibit the spread of plasmids carrying 
multiple antibiotic resistance determinants. Plasmid partitioning (Par) systems in bacteria 
ensure the stable transmission of low-copy plasmids to daughter cells during cell division. 
These systems consist of two proteins called ParA and ParB, as well as a centromere like 
parS partition site. During cell division, ParB binds to the parS site forming the partition 
complex, and this is followed by DNA segregation which is driven by the hydrolysis of 
either ATP or GTP by ParA (Funnell, 2016, Brooks and Hwang, 2017). There are three 
well characterized partitioning systems and these are classified based on their ATPase 
activity; Walker-type ATPase (type I), Actin-like ATPase (type II) and Tubulin-like 
GTPase (type III) (Brooks and Hwang, 2017). Walker-type ATPase (type I) systems 
represent the most commonly observed Par systems in bacteria, and can be further divided 
into type Ia and type Ib subgroups (Yin et al., 2006).  
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Considering that ATP is required for these systems to function effectively, BDM-I could 
be explored as a potential inhibitor of plasmid (and therefore resistance) segregation. 
Preliminary work was undertaken to examine the stability of a Type 1b plasmid (pJEG1) 
in the presence of sub-inhibitory concentrations of BDM-I, with results finding that 
BDM-I treatment resulted in the rapid loss of pJEG1 in the absence of selective pressures 
(erythromycin) (Figure 7.5). While promising, further studies are required to confirm the 
potential use of BDM-I to inhibit plasmid segregation and spread amongst bacteria, 
particularly in a hospital environment.  
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Figure 7.5 Reduced plasmid stability following treatment with BDM-I. Stability assays were 
performed using the S. aureus strain RN4220 containing pJEG001 treated with BDM-I (0.15 
and 1.5 µg/mL) and pJEG005 as a control. Assays determined that following treatment with 
BDM-I and in the absence of antibiotic selection (erythromycin), the percentage of cells 
retaining pJEG001 decreasd to <10% within 10 generations. This trend was comparable to the 
pJEG005 control, which carries in inactive parA gene. 
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Finally, recent research (unpublished) has also revealed that BDM-I displays activity in 
vitro against the clinically important species N. gonorrhoea. N. gonorrhoea causes the 
sexually transmitted infection (STI) gonorrhoea, which is highly prevalent worldwide and 
increasingly difficult to treat due to a high incidence of multi-drug resistance (Unemo and 
Shafer, 2014). Additional MIC studies should be undertaken to examine the efficacy of 
BDM-I against reference N. gonorrhoea strains using the agar dilution method (see 
section 3.3). 
 
7.6 Concluding Remarks 
 
In order to combat the now global threat that antibiotic resistance represents, a significant 
shift in prioritization back to the research and development of novel antimicrobials is 
required by large pharmaceutical companies. Such a shift also requires strong support 
from relevant government bodies. However, until this happens,  the primary responsibility 
of developing new and novel antibiotics will remain with smaller biotechnology 
companies and within academia, often in partnership with each other.  
 
When developing any potential therapeutic it is critically important to broadly examine 
its efficacy and understand its MoA. 3,4-methylenedioxy-β-nitropropene (BDM-I) is a 
small molecule compound that is currently being developed at Opal Biosciences, and has 
emerged as a potential antimicrobial that could be used for the treatment of complicated 
infections caused by important hospital bacterial pathogens. One aspect of BDM-I which 
is not currently understood is its MoA.  
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A previous study by White et al confirmed that BDM-I does not target typical cellular 
processes associated with antibiotics, such as cell wall synthesis, nucleotide synthesis, or 
protein synthesis, but likely acts intracellularly by inhibiting protein tyrosine 
phosphatases. As part of this study, it was observed that BDM-I is readily capable of 
permeating the cell membrane and inhibit several bacterial virulence factors that are 
associated with PTP activity (White et al., 2014). In any case, while these results are 
interesting, the roles of PTPs in bacterial physiology are not well understood outside of 
their roles as secreted virulence factors. Therefore, through further studies we aimed to 
examine the BDM-I MoA within bacteria, as well as study its activity against the 
ESKAPE pathogens, which are most often associated with antibiotic resistance and 
nosocomial infections.  
 
Initial studies included large scale BDM-I MIC screening using several different bacterial 
species, including P. aureginosa, K. pneumoniae, E. coli, E. faecium and S. aureus. MIC 
data gathered revealed that BDM-I displays no antimicrobial activity against gram-
negative bacteria (of the ESKAPE pathogen group), limiting its utility to gram-positive 
species members. In this regard, BDM-I displayed the greatest activity against S. aureus, 
particuarly MRSA isolates with reduced susceptibility to vancomycin (hVISA and 
VISA). Additional checkerboard studies also revealed a synergistic relationship between 
BDM-I and vancomycin when used in combination against such isolates, illuminating a 
potential treatment option for problematic/persistent staphylococcal infections. Induction 
experiments also revealed the limited capacity for S. aureus isolates to develop increased 
resistance to BDM-I during prolonged periods of exposure.  
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Combined, these results indicate that BDM-I is a potential treatment option for MRSA, 
either as monotherapy or in combination with vancomycin for difficult to treat VISA 
isolates. While BDM-I did display activity against VRE isolates, the higher average MICs 
and the rapid rate at which VRE is able to develop resistance against BDM-I severely 
limits its usability for this pathogen in a clinical setting. 
 
Unlike previous studies, a broader omics approach was taken to studying the BDM-I 
MoA, using techniques such as whole genome sequencing and proteomics. The ability to 
generate BDM-I mutants allowed us to explore novel mutations that are associated with 
increased BDM-I resistance. The discovery of mutations within ATP synthase genes (for 
all mutant VRE isolates) revealed an important connection between ATP synthesis and 
the BDM-I MoA. This was reinforced through proteomic analysis of BDM-I treated 
MRSA and VRE cells using 2-D gel electrophoresis and shotgun proteomics, which 
revealed downregulation of several subunits of ATP synthase, as well as the regulation 
of proteins involved in lactic acid fermentation (in the case of VRE). To study the 
relationship between BDM-I and ATP synthesis further, ATP assays were performed in 
order to identify changes in intracellular ATP concentrations following treatment with 
BDM-I. Subsequently, results from these assays confirmed a significant reduction in 
intracellular ATP levels, strongly supporting the idea that BDM-I inhibits ATP synthesis. 
However, without further research it is difficult to confirm whether this occurs by direct 
inhibition, or more likely, is occurring as a downstream consequence of BDM-I inhibiting 
another cellular target, the latter of which is more likely.  
 
In any case, we propose that the primary MoA of BDM-I is the disruption of ATP 
synthesis by ATP synthase, which subsequently limits the availability of ATP for various 
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cellular processes. Additionally, we have confirmed the potential utility of BDM-I (via in 
vitro testing) as a treatment option for MRSA infections, either as monotherapy, in 
combination with vancomycin, or as salvage therapy in the context of vancomycin 
treatment failure. 
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Appendix 
 
Supplementary Table 1: Mutations Identified within day 8 Efm003 Mutant Isolates  
Series Colony Mutation AA Change Gene Product 
1 
1 G→T Gly235Val EFAU004_00433 SPFH Domain/Band 7 family protein 
2 
C→T Gln171* EFAU004_00165 M-protein Trans-acting positive regulator 
C→A Leu7Ile EFAU004_02233 Transcriptional regulator, Fis family 
C→T Gly366Arg guaB Inosine-5-monophosphate dehydrogenase 
3 C→T Gln57* EFAU004_00165 M-protein Trans-acting positive regulator C→A Arg254Leu EFAU004_01140 Helix-turn-helix protein 
2 
1 G→T Glu134* EFAU004_00165 M-protein Trans-acting positive regulator G→A Ala869Val EFAU004_02606 Transcription repair coupling factor 
2 C→A Thr443Lys EFAU004_00165 M-protein Trans-acting positive regulator C→A Gln184Lys EFAU004_1360 Beta-lactamase 
3** - - - - 
3 
1 
G→A Asp51Asn EFAU004_00117 Translation initiation factor, IF-1 
G→T Ala230Asp EFAU004_00162 Glycerol uptake facilitator protein 
G→A Thr159Ile EFAU004_00965 Dihydroorotate dehydrogenase, electron transfer subunit 
2 G→T Glu275* EFAU004_00165 M-protein Trans-acting positive regulator 
3 DEL Gly173fs EFAU004_00165 M-protein Trans-acting positive regulator 
**No mutations identified within colony 3 
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Supplementary Table 2: Mutations identified within final day Efm003 Mutant Isolates  
Series Colony(s) Mutation AA Change Gene Product 
1 
1-3 C→A Thr172Asn ylov DAK2 domain fusion protein YIoV 
1-3 C→T Met27Ile apt adenine phosphoribosyltransferase 
1-3 C→A Glu* fur transcriptional regulator, FUR family 
1-3 G→A Trp104* EFAU004_01238 hypothetical protein 
1-3 C→G Ser214Thr EFAU004_01286 Transcriptional regulator, FUR family 
1-3 C→A Glu* EFAU004_01802 acetolactate synthase 
1-3 C→A Asp138Tyr EFAU004_02036 cardiolipin synthetase 
1-3 G→T Thr111Lys atpB ATP synthase subunit C 
1-3 T→C Ile316Val relA GTP diphosphokinase 
 
Supplementary Table 3: Mutations identified within day 8 Efm008 Mutant Isolates 
Series Colony Mutation AA Change Gene Product 
1 
1 INS - atpE ATP Synthase F0 subunit c 
2 INS - atpG ATP synthase F1 gamma subunit 
3 DEL Ile456fs atpD ATP synthase F1 beta subunit 
2 
1 C→A Val323Leu EFAU004_00970 Uracil permease DEL Gly38fs atpF ATP synthase F0 B subunit 
2 
A→C Tyr304* atpD ATP synthase F1 beta subunit 
G→T Phe3Leu yycH YycH protein 
C→A Gly228Val aspS Aspartyl-tRNA synthetase 
3 INS - atpF ATP synthase F0 subunit b 
3 
1 INS - atpE ATP synthase F0 subunit c 
2 
T→C Phe348Leu EFAU004_00143 Bifunctional glutamate-cysteine ligase/glutathione synthetase 
A→C Tyr197* atpD ATP synthase F1 beta subunit 
C→A Pro197His mleA Malic enzyme NAD binding domain protein 
C→A Ala180Ser EFAU004_02132 Phage portal protein HK97 family 
3 INS - atpB ATP synthase F0 subunit a 
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Supplementary Table 4: Mutations identified within day 58 Efm008 Mutant Isolates 
Series Colony(s) Mutation AA Change Gene Product 
1 
1-3 C→A Ala257Asp EFAU004_00083 ABC transporter permease protein 
1-3 G→A Trp201* EFAU004_00165 M protein trans acting positive regulator 
1-3 C→A Asn392Lys recN DNA repair protein RecN 
1-3 A→G Ile231Thr EFAU004_01257 PTS system, galactitol specific IIC component 
1-3 C→A Gly178Cys atpD ATP synthase F1, beta subunit 
1-3 C→A Asp49Tyr EFAU004_02425 PAS domain sensory box histidine kinase 
1-3 C→A Ser181Ile relA GTP diphosphokinase 
2 
1-3 G→T Glu227* pip Phage binding protein 
1-3 C→A Ser76Ile EFAU004_01744 UDP-glucose-4-epimerase 
1-3 G→T Gln409Lys atpD ATP synthase F1 beta subunit 
1-3 C→A Asp31Tyr EFAU004_02349 Extracellular solute binding protein 
1-3 G→A Pro48Leu EFAU004_02477 GTP diphosphokinase 
1-3 C→A Arg810Leu EFAU004_02487 snf2 family protein 
1-3 G→T Ala24Glu EFAU004_02618 Serine/threonine protein-kinase 
3 
1-3 C→A Ala198Glu EFAU004_00177 DNA mismatch repair protein 
1-3 G→T Glu186Asp EFAU004_00284 Hypothetical protein 
1-3 C→A Phe161Leu EFAU004_00640 Hypothetical protein 
1-3 G→T Ser144Tyr EFAU004_01007 N-acetylmuramoyl-L-alanine-amidase 
1-3 C→A Trp363Cys gnd 6-phosphogluconoate dehydrogenase, decarboxylating 
1-3 C→A Met338Ile EFAU004_01883 Cation transporter E1-E2 family ATPase 
1-3 C→A Ala576Ser ntpl V-type ATP synthase subunit I 
1-3 C→A Asp99Tyr EFAU004_02425 Pas domain sensory box histidine kinase 
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Supplementary Table 5: Mutations identified within final day Sa375 Mutant Isolates 
Series Colony(s) Mutation AA Change Gene Product 
1 
1-3 C→T Leu37Phe walK Mutli-sensor signal transduction histidine kinase 
1-3 C→T Pro45Leu rpoC DNA directed RNA polymerase beta chain protein 
1-3 G→T Pro82His mvaA Hydroxymethylglutaryl-CoA reductase 
2 
1-3 G→A Gly560Ser walK Multi-sensor signal transduction histidine kinase 
1-3 G→A Gly36Arg SAA6008_00223 oxidoreductase, zinc-binding dehydrogenase family 
1-3 C→A Thr331Lys SAA6008_00647 sodium/hydrogen exchanger family protein 
1-3 G→A Ala814Val atl bifunctional N-acetylmuramoyl-L-alanine amidase/endo-beta-N-acetylglucosaminidase 
1-3 C→T Ala210Val potD spermidine/putrescine ABC superfamily ATP binding cassette transporter, binding protein 
1-3 C→T Trp124* SAA6008_01077 conserved hypothetical protein 
1-3 C→T Arg154* efb fibrinogen-binding protein precursor 
1-3 T→A Phe790Leu fmtC (mprF) oxacillin resistance-related FmtC protein 
1-3 C→T Ala109Thr SAA6008_01543 SigmaW regulon antibacterial protein 
1-3 C→T Thr73Ile SAA6008_01966 ABC-2 type transport system permease protein 
1-3 G→A Leu146Phe nrgA AMT family ammonium or ammonia transporter 
1-3 G→A Pro231Ser rpbB 50S ribosomal protein L2 
1-3 C→A Glu154* SAA6008_02318 acetyltransferase (GNAT) family protein 
1-3 C→T Gly97Arg SAA6008_02767 transcriptional regulator, Cro/Cl family 
1-3 G→A Met365Ile ileS isoleucyl-tRNA synthetase 
1-3 G→A Pro116Ser murA putative UDP-N-acetylglucosamine 1-carboxyvinyltransferase 
1-3 G→A Gln131* SAA6008_01768 prolyl oligopeptidase 
1-3 G→A Gly206Arg pabB anthranilate synthase component I and chorismate binding protein 
1-3 T→G Phe88Val rsgA ribosome small subunit-dependent GTPase A 
1-3 T→C Leu1461Ser yukA DNA segregation ATPase like protein 
1-3 A→G Thr4Ala Cap5A capsular polysaccharide biosynthesis protein 
3 
1-3 G→T Gly30Trp walK Multi-sensor signal transduction histidine kinase 
1-3 G→A Ala29Thr mvaK2 phosphomevalonate kinase 
1-3 C→T Arg207Cys SAA6008_00647 sodium/hydrogen exchanger family protein 
1-3 G→T Gly113* trkA NAD+ binding potassium transporter 
1-3 C→T Ser42Leu SAA6008_00679 putative phosphate uptake regulator 
1-3 G→A Val103Met SAA6008_00851 phage protein 
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Supplementary Table 6: Proteins downregulated within Sa057 (³2-fold) following exposure to BDM-I  
Protein ID Annotation Log2 Fold Change (Treated vs WT) Peptide Count 
ADL65445.1 threonine dehydratase  -78.3386864 13 
ADL64206.1 bifunctional acetaldehyde-CoA/alcohol dehydrogenase  -60.93074444 55 
ADL66445.1 respiratory nitrate reductase, alpha subunit  -52.9772531 59 
ADL64332.1 putative membrane protein  -47.25758378 36 
ADL65037.1 glycosyl transferase, group 1 family protein  -32.0913884 24 
ADL64308.1 cell division and morphogenesis-related protein scdA -17.49459732 12 
ADL64355.1 secreted acid phosphatase  -14.53853543 12 
ADL66244.1 6-phospho-beta-galactosidase  -13.61714621 18 
ADL64271.1 formate C-acetyltransferase  -10.53505692 68 
ADL64107.1 multi-sensor signal transduction histidine kinase, WalK  -9.21419286 15 
ADL64288.1 L-lactate dehydrogenase  -8.748175592 15 
ADL66644.1 putative dihydroorotate dehydrogenase  -6.855137534 25 
ADL66495.1 glycine betaine/choline ABC superfamily ATP binding cassette transporter, ABC protein  -6.841772152 11 
ADL64682.1 zinc-binding alcohol dehydrogenase  -6.470065085 19 
ADL64301.1 Putative polyribitolphosphotransferase  -6.438815694 24 
ADL65200.1 putative dihydroorotase  -5.694503817 25 
ADL66097.1 autoinducer sensor protein response regulator protein  -5.674180422 10 
ADL65199.1 aspartate carbamoyltransferase catalytic subunit  -5.338100128 14 
ADL66344.1 staphylococcal accessory regulator R, SarR  -5.313715031 5 
ADL64170.1 immunoglobulin G binding protein A  -5.248837005 5 
ADL65201.1 putative carbamoyl-phosphate synthase, pyrimidine-specific, small chain  -4.968032867 14 
ADL64335.1 putative secretion system component EssB  -4.76814551 8 
ADL65202.1 putative carbamoyl-phosphate synthase, pyrimidine-specific, large chain  -4.449515778 55 
ADL65964.1 nitric-oxide synthase, oxygenase subunit  -4.263064876 12 
ADL64290.1 inosine/uridine-preferring nucleoside hydrolase  -4.154048896 3 
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Supplementary Table 6 continued  
Protein ID Annotation Log2 Fold Change (Treated vs WT) Peptide Count 
ADL65082.1 putative SAM-dependent methyltransferase  -4.078166283 12 
ADL66357.1 molybdopterin oxidoreductase  -4.067159972 40 
ADL64171.1 staphylococcal accessory regulator A, SarH2  -4.062007357 12 
ADL64113.1 rRNA large subunit methyltransferase  -4.008504358 10 
ADL64287.1 nitric oxide dioxygenase  -3.954988289 26 
ADL66105.1 putative ABC transporter ATP-binding protein  -3.859808138 17 
ADL66561.1 D-lactate dehydrogenase  -3.790363083 32 
ADL64341.1 conserved hypothetical protein  -3.613467058 3 
ADL65204.1 putative orotate phosphoribosyltransferase  -3.599849446 8 
ADL64972.1 ATP-dependent nuclease subunit A  -3.553605213 20 
ADL65014.1 putative permease  -3.528115076 5 
ADL66568.1 L-serine dehydratase, iron-sulfur-dependent, beta subunit  -3.500429185 7 
ADL65218.1 Ribosomal RNA large subunit methyltransferase N, Rlmn  -3.497626429 19 
ADL64250.1 type-I restriction-modification system restriction endonuclease subunit  -3.483128459 23 
ADL66356.1 conserved hypothetical protein  -3.449172577 6 
ADL64331.1 ESAT-6/WXG100 family secreted protein EsxA/YukE  -3.328987043 7 
ADL66262.1 putative acetolactate synthase  -3.322187076 18 
ADL64938.1 D-alanine membrane transfer protein  -3.18006715 2 
ADL66655.1 L-lactate dehydrogenase 2  -3.153587563 17 
ADL66692.1 immunodominant antigen B  -3.142508865 9 
ADL65108.1 inositol monophosphatase  -3.128015277 7 
ADL65643.1 Sec family Type I general secretory pathway preprotein translocase subunit YajC  -3.084574195 3 
ADL66528.1 DEAD/H helicase / Type III restriction enzyme, res subunit  -2.82182902 30 
ADL65203.1 putative orotidine 5'-phosphate decarboxylase  -2.818874378 10 
ADL65364.1 amino acid carrier protein (sodium/alanine symporter) -2.716251467 7 
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Supplementary Table 6 continued  
Protein ID Annotation Log2 Fold Change (Treated vs WT) Peptide Count 
ADL64774.1 fructose 1-phosphate kinase  -2.687885938 5 
ADL64727.1 dihydroxyacetone kinase, phosphotransfer subunit  -2.628047446 4 
ADL64686.1 iron (Fe3+) ABC superfamily ATP binding cassette transporter, binding protein  -2.53994924 13 
ADL66529.1 NUDIX hydrolase  -2.511587694 10 
ADL66401.1 multidrug resistance protein A, drug resistance transporter  -2.495911693 11 
ADL64563.1 pur operon repressor  -2.46218884 11 
ADL66654.1 alpha-acetolactate decarboxylase  -2.426411658 5 
ADL66233.1 aerobactin biosynthesis protein, IucA/IucC family  -2.393765324 12 
ADL64632.1 poly (glycerol-phosphate) alpha-glucosyltransferase  -2.363133898 6 
ADL65149.1 putative succinate dehydrogenase iron-sulfur protein  -2.361213793 19 
ADL64542.1 alpha, alpha-phosphotrehalase  -2.340916978 23 
ADL64481.1 recombinational DNA repair ATPase, RecF_1  -2.286391655 25 
ADL66305.1 acetyltransferase (GNAT) family protein  -2.245055566 8 
ADL66431.1 conserved hypothetical protein  -2.236593347 13 
ADL65847.1 transcriptional regulator Fur family protein  -2.226509728 2 
ADL64772.1 putative prolyl-tRNA synthetase  -2.218619038 4 
ADL65646.1 crossover junction endodeoxyribonuclease  -2.218522277 12 
ADL66390.1 ABC superfamily ATP binding cassette transporter, ABC protein  -2.206746157 14 
ADL66567.1 L-serine dehydratase, iron-sulfur-dependent, alpha subunit  -2.202348394 12 
ADL64747.1 conserved hypothetical protein  -2.195095231 3 
ADL65583.1 radical SAM domain protein  -2.144928234 17 
ADL66162.1 ATP synthase subunit gamma, AtpG  -2.134067086 14 
ADL64663.1 conserved hypothetical protein  -2.125674099 8 
ADL66129.1 alanine racemase 1  -2.093932952 10 
ADL64791.1 allophanate hydrolase subunit 1  -2.085491982 12 
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Supplementary Table 6 continued  
Protein ID Annotation Log2 Fold Change (Treated vs WT) Peptide Count 
ADL65958.1 adenylosuccinate lyase  -2.077549751 24 
ADL64659.1 phosphomevalonate kinase  -2.074897261 18 
ADL64715.1 teichoic acid biosynthesis protein B  -2.032342007 7 
ADL65975.1 acyl-coenzyme A:6-aminopenicillanic acid acyl-transferase  -2.022737258 7 
ADL65501.1 two component transcriptional regulator, winged helix family  -2.019039521 14 
ADL64228.1 conserved hypothetical protein  -2.016422082 9 
ADL65212.1 primosomal protein N prime  -2.01424942 9 
ADL65917.1 conserved hypothetical protein  -2.013212855 5 
ADL65063.1 putative quinol oxidase polypeptide II precursor  -2.00312755 29 
ADL66301.1 30S ribosomal protein S10  -2.000056663 10 
ADL65958.1 adenylosuccinate lyase  -2.077549751 24 
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Supplementary Table 7: Proteins upregulated within Sa057 (³2-fold) following exposure to BDM-I 
Protein ID Annotation Log2 Fold Change (Treated vs WT) Peptide Count 
ADL66154.1 transglycosylase  34.50375643 6 
ADL64875.1 osmotically inducible protein OsmC  13.16270146 7 
ADL65629.1 luciferase family oxidoreductase  6.433228181 12 
ADL66559.1 glyoxalase/bleomycin resistance protein/dioxygenase superfamily protein  5.437865627 10 
ADL65585.1 ribosomal protein L11 methyltransferase  4.910310404 10 
ADL64551.1 DNA polymerase III, delta prime subunit  4.227090545 7 
ADL66091.1 nitroreductase family protein  4.147105225 9 
ADL66741.1 rhodanese domain sulfurtransferase  4.100034435 17 
ADL65852.1 Lipid A export ATP-binding/permease protein MsbA  3.949098196 11 
ADL64635.1 GlcNAc-PI de-N-acetylase  3.93037638 7 
ADL64592.1 D-isomer specific 2-hydroxyacid dehydrogenase family protein  3.810606402 15 
ADL66340.1 urease accessory protein UreE  3.737455131 6 
ADL65518.1 glyoxalase/bleomycin resistance protein/dioxygenase superfamily protein  3.689545107 7 
ADL65343.1 catalase  3.454203144 25 
ADL64979.1 ATPase subunit of an ATP-dependent protease, ClpB  3.406325523 54 
ADL66074.1 conserved hypothetical protein  3.364733779 2 
ADL65282.1 putative CDP-diacylglycerol--glycerol-3-phosphate 3-phosphatidyltransferase  3.212117942 3 
ADL64586.1 putative transcriptional regulator, GntR family  3.065023048 4 
ADL66739.1 base-induced perplasmic lipid-binding protein  3.05423771 11 
ADL64451.1 Nitroreductase family protein  2.970383107 8 
ADL65861.1 intracellular protease  2.925664068 10 
ADL64397.1 putative bacteriophage envelope protein  2.923949773 2 
ADL65531.1 putative exodeoxyribonuclease VII small subunit  2.911255911 3 
ADL64257.1 FMN-dependent NADH-azoreductase, AzoR  2.897438876 7 
ADL66625.1 beta-lactamase regulatory protein  2.817311488 14 
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Supplementary Table 7 continued 
 
Protein ID Annotation Log2 Fold Change (Treated vs WT) Peptide Count 
ADL64590.1 Firmicute transcriptional repressor of class III stress genes  2.79416438 7 
ADL66087.1 co-chaperonin GroEL  2.788330614 35 
ADL64593.1 Clp protease ATP binding subunit  2.767540333 79 
ADL65515.1 AraC family transcriptional regulator  2.694627491 7 
ADL65286.1 conserved hypothetical protein  2.670937981 10 
ADL64588.1 pyridoxine biosynthesis amidotransferase  2.664503624 10 
ADL66080.1 succinyl-diaminopimelate desuccinylase  2.662257767 10 
ADL64961.1 NADH:flavin oxidoreductase / NADH oxidase family protein  2.638600371 24 
ADL66210.1 PTS system mannitol-specific IIBC component  2.629936417 8 
ADL64921.1 SUF system FeS assembly protein  2.619284294 7 
ADL65586.1 chaperone protein DnaJ  2.591884162 14 
ADL66339.1 urease, alpha subunit  2.567173323 15 
ADL65188.1 alanine racemase  2.54684881 13 
ADL65371.1 4-oxalocrotonate tautomerase  2.540961098 2 
ADL65716.1 thiol peroxidase  2.515635858 13 
ADL65177.1 conserved hypothetical protein  2.51527679 26 
ADL64208.1 capsular polysaccharide biosynthesis protein Cap5B  2.504169227 5 
ADL65588.1 heat shock molecular chaperone protein  2.470605208 25 
ADL64648.1 putative uracil-DNA glycosylase  2.456007626 9 
ADL64225.1 putative aldehyde dehydrogenase  2.450589659 29 
ADL66650.1 low molecular weight phosphotyrosine protein phosphatase  2.436743015 3 
ADL64639.1 putative 6-phospho-3-hexuloisomerase  2.436707181 9 
ADL65000.1 transcriptional regulator Spx  2.412416046 7 
ADL66615.1 short chain dehydrogenase  2.382488134 8 
ADL66088.1 co-chaperonin GroES  2.373084031 7 
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Supplementary Table 7 continued 
 
Protein ID Annotation Log2 Fold Change (Treated vs WT) Peptide Count 
ADL64842.1 putative ATP-dependent Clp protease proteolytic subunit  2.368380809 13 
ADL65778.1 arsenate reductase (glutaredoxin)  2.364841024 5 
ADL64580.1 redox regulated Hsp33-like chaperonin  2.364639974 14 
ADL64578.1 hypoxanthine-guanine phosphoribosyltransferase  2.357999056 11 
ADL66464.1 2,3-bisphosphoglycerate-dependent phosphoglycerate mutase  2.28507014 10 
ADL66560.1 nitroreductase family protein  2.283796937 15 
ADL65587.1 molecular chaperone DnaK  2.282979795 60 
ADL65577.1 putative metalloprotease  2.279382837 5 
ADL66617.1 putative hydrolase/acyltransferase  2.278951875 23 
ADL64722.1 iron (Fe3+) ABC superfamily ATP binding cassette transporter, ABC protein  2.269510151 12 
ADL64932.1 conserved hypothetical protein  2.254961682 3 
ADL66647.1 3-demethylubiquinone-9 3-methyltransferase  2.248803828 13 
ADL65019.1 UDP-glucose diacylglycerol glucosyltransferase  2.246684013 7 
ADL64691.1 conserved hypothetical protein  2.243634022 3 
ADL65690.1 glyceraldehyde-3-phosphate dehydrogenase (phosphorylating)  2.239396544 14 
ADL65620.1 caffeoyl-CoA O-methyltransferase  2.232089552 9 
ADL64877.1 nitroreductase family protein  2.230423906 5 
ADL65561.1 superoxide dismutase Mn/Fe family protein  2.211703299 17 
ADL64223.1 heme-degrading monooxygenase IsdI  2.2001967 4 
ADL65437.1 Scaffold protein Nfu/NifU N terminal  2.199657712 7 
ADL65735.1 acetyl-coenzyme A synthetase  2.191851199 7 
ADL66213.1 putative mannitol-1-phosphate 5-dehydrogenase  2.187265028 20 
ADL65715.1 Adenine-specific DNA methylase-like protein  2.1832174 11 
ADL65426.1 acetyltransferase, GNAT family protein  2.177895593 4 
ADL65209.1 putative guanylate kinase  2.177670498 9 
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Supplementary Table 7 continued 
 
Protein ID Annotation Log2 Fold Change (Treated vs WT) Peptide Count 
ADL65224.1 50S ribosomal protein L28  2.164712451 5 
ADL64544.1 acetyltransferase (GNAT) family protein  2.137555556 5 
ADL66229.1 iron-dicitrate transporter substrate-binding subunit, FecB  2.128032793 29 
ADL65005.1 adenylate cyclase  2.118276879 10 
ADL66212.1 phosphoenolpyruvate-dependent sugar phosphotransferase system, EIIA 2, MtlA_1  2.11782364 10 
ADL64316.1 glycoside hydrolase, family 1  2.095924561 16 
ADL66225.1 conserved hypothetical protein  2.091357282 6 
ADL65743.1 UDP-N-acetylmuramate--L-alanine ligase murC 2.090310744 25 
ADL66595.1 MerTP family mercury (Hg2+) permease, binding protein MerP  2.070150033 4 
ADL65299.1 DNA-directed DNA polymerase III gamma and tau subunits  2.039124622 45 
ADL66104.1 redox-sensing transcriptional repressor rex  2.034930665 17 
ADL66334.1 iron (Fe+3) ABC superfamily ATP binding cassette transporter, binding protein  2.028436455 27 
ADL64939.1 D-alanine-activating enzyme/D-alanine-D-alanyl, dltC protein  2.026606349 2 
ADL65681.1 MutT/Nudix hydrolase family protein  2.006159589 14 
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Supplementary Table 8: Proteins downregulated within Efm008 (³2-fold) following exposure to BDM-I 
Protein ID Annotation Log2 Fold Change (Treated vs WT) Peptide Count 
AFC64337.1 SIS domain protein  -26.65753425 14 
AFC63565.1 glycosyl transferase family 8  -18.34897994 14 
AFC62125.1 6-phospho-beta-galactosidase  -17.69985836 15 
AFC64206.1 L-lactate oxidase  -13.76819181 17 
AFC64703.1 Primosomal protein N'  -11.32424812 13 
AFC64341.1 PTS system, mannose/fructose/sorbose-specific IIB component  -10.45982677 8 
AFC64854.1 D-alanyl-D-alanine dipeptidase  -7.641660784 2 
AFC64656.1 PTS system, cellobiose-specific IIB component  -7.6310165 5 
AFC64187.1 fructose-1,6-bisphosphatase  -5.212541395 24 
AFC63020.1 oxidoreductase family, NAD-binding Rossmann fold protein  -5.117372394 9 
AFC62972.1 bacterial extracellular solute-binding protein  -4.931218253 11 
AFC62876.1 acetyltransferase  -4.22286793 13 
AFC62979.1 amidase  -4.12809139 26 
AFC62871.1 PTS system, lactose/cellobiose-specific IIA component  -4.015847339 5 
AFC62417.1 zinc-containing alcohol dehydrogenase  -3.803904902 13 
AFC62763.1 PTS system, mannose/fructose/sorbose-specific IIB component  -3.755647764 11 
AFC62870.1 PTS system, lactose/cellobiose-specific IIB component  -3.742572944 4 
AFC63023.1 PTS system, ascorbate-specific IIB component  -3.573722893 3 
AFC63024.1 PTS system, ascorbate-specific IIC component  -3.572409326 3 
AFC64648.1 16S rRNA pseudouridylate synthase A  -3.534789793 5 
AFC62980.1 bacterial extracellular solute-binding protein, family 3  -3.534028866 16 
AFC63054.1 Aspartate carbamoyltransferase  -3.400024803 14 
AFC62412.1 PTS system, lactose/cellobiose-specific IIB component  -3.205072675 5 
AFC62580.1 phosphoenolpyruvate carboxykinase  -3.047501988 28 
AFC63240.1 pyridine nucleotide-disulfide oxidoreductase  -3.045390499 16 
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Supplementary Table 8 continued 
  
Protein ID Annotation Log2 Fold Change (Treated vs WT) Peptide Count 
AFC62165.1 cytidine deaminase  -2.985996965 7 
AFC62968.1 peroxiredoxin, Ohr family protein  -2.983057004 9 
AFC63751.1 hypothetical protein  -2.84221956 6 
AFC63850.1 choloylglycine hydrolase family protein  -2.793723077 4 
AFC62515.1 transcriptional regulator, PadR family  -2.719153564 4 
AFC63052.1 carbamoyl-phosphate synthase, small subunit  -2.686446011 8 
AFC63562.1 oxidoreductase, short chain dehydrogenase/reductase family protein  -2.679993499 14 
AFC64706.1 hypothetical protein  -2.649911504 3 
AFC62598.1 Manganese containing catalase  -2.64033264 17 
AFC64752.1 mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase  -2.63634943 15 
AFC64195.1 ribonuclease HIII  -2.51457448 8 
AFC63566.1 glycosyl transferase family 8  -2.49900728 6 
AFC64142.1 ATP synthase F1, gamma subunit  -2.419258373 10 
AFC64761.1 Bacterial transcription activator  -2.349567171 8 
AFC62461.1 pyridine nucleotide-disulfide oxidoreductase  -2.316142089 8 
AFC64381.1 alpha/beta hydrolase fold protein  -2.312429104 11 
AFC63143.1 universal stress protein UspA  -2.27554741 9 
AFC64111.1 hypothetical protein  -2.263393819 54 
AFC63413.1 glycosyl transferase  -2.262510629 2 
AFC62528.1 ribokinase  -2.215064147 5 
AFC62548.1 cystathionine gamma-synthase  -2.20862705 8 
AFC64437.1 hypothetical protein  -2.199606041 8 
AFC63006.1 site-specific tyrosine recombinase XerC-family  -2.175168307 8 
AFC64522.1 glutaredoxin  -2.152388994 3 
AFC64509.1 DNA-binding response regulator  -2.127355247 16 
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Supplementary Table 8 continued 
 
Protein ID Annotation Log2 Fold Change (Treated vs WT) Peptide Count 
AFC62478.1 dihydroxyacetone kinase, phosphotransfer subunit  -2.116424722 6 
AFC62344.1 phosphomevalonate kinase  -2.115003575 13 
AFC62546.1 glutathione peroxidase  -2.10446904 4 
AFC62747.1 Acetyltransferase, GNAT family  -2.092021596 4 
AFC62488.1 tyrosine decarboxylase  -2.091990875 28 
AFC64739.1 DNA repair protein RadA  -2.089862645 13 
AFC62983.1 hypothetical protein  -2.070057016 7 
AFC62480.1 dihydroxyacetone kinase, DhaL subunit  -2.058653369 9 
AFC62712.1 hypothetical protein  -2.052891436 8 
AFC63047.1 orotate phosphoribosyltransferase  -2.045554142 6 
AFC62723.1 ABC transporter ATP-binding protein  -2.020137511 4 
AFC62594.1 toxin-antitoxin system, antitoxin component, AbrB family  -2.007049054 3 
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Supplementary Table 9: Proteins upregulated within Efm008 (³2-fold) following exposure to BDM-I 
Protein ID Annotation Log2 Fold Change (Treated vs WT) Peptide Count 
AFC63340.1 Class II Aldolase and Adducin N-terminal domain protein  30.54215653 10 
AFC62472.1 coenzyme A disulfide reductase  7.454184564 27 
AFC63235.1 LysM domain-containing protein  7.454097246 4 
AFC64602.1 adenine deaminase  7.108953144 9 
AFC64750.1 nitroreductase family protein  6.581129344 13 
AFC63131.1 nitroreductase family protein  4.923962658 18 
AFC64516.1 Substrate binding domain of ABC-type glycine betaine transport system  3.869457152 8 
AFC63338.1 glyoxalase family protein  3.48252801 9 
AFC64005.1 cadmium-translocating P-type ATPase  3.463106231 14 
AFC64926.1 Glutathione reductase  3.413432185 27 
AFC62308.1 30S ribosomal protein S14  3.223476172 4;1 
AFC62693.1 deoxynucleoside kinase  3.115803123 9 
AFC63575.1 major cold shock protein CspA  2.962165782 4 
AFC64768.1 zinc-binding alcohol dehydrogenase family protein  2.919130909 14 
AFC64349.1 ABC transporter, ATP-binding protein  2.819601738 25 
AFC64281.1 hypothetical protein  2.77449745 3 
AFC63030.1 L-lactate dehydrogenase  2.769151037 16 
AFC63645.1 sodium/dicarboxylate symporter family protein  2.762107504 9 
AFC63873.1 sulfatase  2.477181745 10 
AFC64365.1 oligopeptide ABC superfamily ATP binding cassette transporter, binding protein  2.393125324 10 
AFC64569.1 HAD superfamily hydrolase  2.300032418 9 
AFC63980.1 hypothetical protein  2.224204534 5 
AFC62627.1 tRNA-specific 2-thiouridylase MnmA  2.212 22 
AFC64941.1 tRNA modification GTPase MnmE  2.154207069 23 
AFC62720.1 putative flavoprotein NrdI  2.142066795 2 
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Supplementary Table 9 continued 
 
Protein ID Annotation Log2 Fold Change (Treated vs WT) Peptide Count 
AFC64409.1 ABC transporter, ATP-binding protein/permease  2.123501098 12 
AFC63886.1 acetolactate synthase  2.079857935 26 
AFC63794.1 riboflavin biosynthesis protein RibF  2.059165154 11 
AFC62623.1 Putative cysteine desulfurase  2.058215674 11 
AFC62736.1 uracil-DNA glycosylase  2.056703901 8 
AFC62553.1 dihydrodipicolinate synthase  2.044401286 6 
AFC63118.1 ABC transporter, permease protein  2.043657765 3 
AFC63110.1 (3R)-hydroxymyristoyl- 2.00862528 13 
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Supplementary Table 10: TPP Raw Data  
Protein ID Annotationa vehiclelogFCheated treatedlogFCheated Peptide Count 
ADL65759.1 putative flavoprotein -1.9234386 -0.1826861 2 
ADL66624.1 transcriptional repressor  -2.3438984 -0.9501199 2 
ADL65633.1 DNA-directed DNA polymerase III gamma and tau subunits  -3.6683702 -1.0059938 3 
ADL65578.1 phosphate starvation-inducible ATPase  -3.725101 -0.7705093 4 
ADL65793.1 aldo/keto reductase  -1.4047512 -0.6590122 12 
ADL65179.1 S-adenosyl-methyltransferase MraW -1.1105394 -0.3852162 8 
ADL64305.1 ribitol-5-phosphate dehydrogenase  -1.589581 -0.5765594 9 
ADL64542.1 alpha, alpha-phosphotrehalase  -4.5103661 -2.283215249 7 
ADL66181.1 putative transcriptional regulator  -0.9870488 -0.302047412 6 
ADL64626.1 deoxynucleoside kinase -1.6474427 -0.572427227 2 
ADL65625.1 exodeoxyribonuclease V alpha chain -1.0850242 -0.578700808 2 
ADL64609.1 methyltransferase small domain protein  -1.8537793 -0.71497432 9 
ADL66298.1 50S ribosomal protein L23  -1.4430294 -0.364077475 12 
ADL66299.1 50S ribosomal protein L4  -1.1960211 -0.528465019 18 
ADL66207.1 haloacid dehalogenase-like hydrolase  -1.8853719 -0.926597717 5 
ADL64560.1 dimethyladenosine transferase  -1.1609899 -0.291207266 10 
ADL65528.1 putative DNA repair protein -1.7296668 -0.556939062 13 
ADL65629.1 luciferase family oxidoreductase  -1.724091 -0.0722193 7 
ADL65511.1 pyrroline-5-carboxylate reductase  -1.9719112 -0.9132596 6 
ADL65005.1 adenylate cyclase  -1.8791887 -0.1089413 5 
ADL65744.1 FtsK/SpoIIIE (DNA translocase stage III) family protein  -1.2085907 -0.3590943 20 
ADL66318.1 molybdenum cofactor biosynthesis protein A -1.39003 -0.6014978 6 
ADL65924.1 phage protein  -2.1239442 -0.3870147 6 
ADL65055.1 acetyltransferase, GNAT family  -2.1829768 -0.7389112 4 
ADL66712.1 putative flavin reductase -1.380061 -0.484067 2 
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Supplementary Table 10 continued 
Protein ID Annotation vehiclelogFCheated treatedlogFCheated Peptide Count 
ADL64404.1 putative cyclase enzyme 1.94042584 0.88777655 3 
ADL64718.1 Serine-type D-Ala-D-Ala carboxypeptidase 2.57674405 1.02454728 2 
ADL65267.1 conserved hypothetical protein 2.11247141 0.92036414 6 
ADL66358.1 cell envelope-related function transcriptional attenuator, LytR/CpsA family 2.74549852 1.27519418 10 
ADL65731.1 Trypsin-like serine endoprotease 2.21904052 0.85659023 5 
ADL66329.1 molybdenum (Mo2+) ABC superfamily ATP binding cassette transporter, binding protein 2.30828856 0.84278013 8 
ADL64125.1 penicillin-binding protein 2 prime 2.1608036 0.6394437 19 
ADL66462.1 amino acid ABC superfamily ATP binding cassette transporter, binding protein 3.03769188 0.86112219 23 
ADL65093.1 putative cell-wall binding lipoprotein, YkyA 2.75358204 1.41299675 19 
ADL64810.1 ABC-type siderophore binding protein 2.86063992 1.27903032 4 
ADL64442.1 putative secreted protease inhibitor 2.36382903 0.42493416 11 
ADL65827.1 peptidylprolyl isomerase, PrsA 2.5901633 0.79515768 23 
ADL65363.1 DNA topoisomerase (ATP-hydrolyzing) ParC 2.26323987 0.10277375 3 
ADL64550.1 conserved hypothetical protein 2.91443879 1.02375092 4 
ADL65833.1 transcriptional regulator 0.40793007 0.17115798 9 
ADL65931.1 conserved hypothetical protein 1.16678002 0.89471604 8 
ADL65592.1 putative 30S ribosomal protein S20 0.61007039 0.09721033 9 
ADL64762.1 MarR family transcriptional regulator 1.7521588 0.4372054 11 
ADL66123.1 RNA polymerase sigma factor SigB 0.97850859 0.41281521 5 
ADL66394.1 isopentenyl-diphosphate delta-isomerase 0.79677979 0.22570414 15 
ADL65543.1 glycine dehydrogenase (decarboxylating) subunit 2 1.17451036 0.82575423 21 
ADL64411.1 conserved hypothetical protein 0.65849023 0.15664664 3 
ADL65918.1 phage protein 1.03567352 0.54949669 3 
ADL64798.1 histidinol-phosphate aminotransferase 1.6010087 0.3330248 2 
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Supplementary table 10 continued 
Protein ID Annotation vehiclelogFCheated treatedlogFCheated Peptide Count 
ADL66229.1 iron-dicitrate transporter substrate-binding subunit, FecB 1.4163958 0.31233554 7 
ADL64513.1 conserved hypothetical protein  0.74036251 0.17797913 2 
ADL64284.1 ABC superfamily ATP binding cassette transporter, binding protein  2.42020463 1.477065 7 
ADL65953.1 pheromone lipoprotein CamS 3.28015977 1.69404819 9 
ADL65390.1 conserved NfeD-like membrane protein 3.39683607 1.60268756 2 
ADL65560.1 penicillin-binding protein 3  5.0114709 2.81975724 2 
ADL64447.1 conserved hypothetical protein  3.60485327 1.51560631 5 
ADL64802.1 NADPH-dependent 7-cyano-7-deazaguanine reductase 2.49451755 1.29771647 4 
aAnnotation derived from Staphylococcus aureus strain JKD6008 
 
